



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2629461 C 2016/01/12

(11)(21) **2 629 461**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) **Date de dépôt PCT/PCT Filing Date:** 2006/11/13
(87) **Date publication PCT/PCT Publication Date:** 2007/05/24
(45) **Date de délivrance/Issue Date:** 2016/01/12
(85) **Entrée phase nationale/National Entry:** 2008/05/12
(86) **N° demande PCT/PCT Application No.:** US 2006/044149
(87) **N° publication PCT/PCT Publication No.:** 2007/059108
(30) **Priorité/Priority:** 2005/11/10 (US60/735,692)

(51) **Cl.Int./Int.Cl. C07D 401/06** (2006.01),
A61K 31/395 (2006.01), **C07D 215/233** (2006.01),
C07D 413/06 (2006.01), **C07D 413/14** (2006.01),
C07D 417/06 (2006.01), **C07D 471/04** (2006.01),
C07D 491/056 (2006.01)

(72) **Inventeurs/Inventors:**
MELIKIAN, ANITA, US;
WRIGHT, JOHN JESSEN, US;
KRASINSKI, ANTONI, US;
HU, CHENG, US;
NOVACK, AARON, US

(73) **Propriétaire/Owner:**
CHEMOCENTRYX, INC., US


(74) **Agent:** FETHERSTONHAUGH & CO.

(54) **Titre : QUINOLONES SUBSTITUEES ET PROCEDES D'UTILISATION**

(54) **Title: SUBSTITUTED QUINOLONES AND METHODS OF USE**

(57) **Abrégé/Abstract:**

Substituted quinolone compounds and compositions are provided along with methods for the use of those compounds in the treatment of diseases and disorders such as cancer.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 May 2007 (24.05.2007)

PCT

(10) International Publication Number
WO 2007/059108 A3

(51) International Patent Classification:
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/US2006/044149

(22) International Filing Date:
13 November 2006 (13.11.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/735,692 10 November 2005 (10.11.2005) US

(71) Applicant (*for all designated States except US*): **CHEMO-CENTRYX, INC.** [US/US]; 850 Maude Avenue, Mountain View, California 94043 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MELIKIAN, Anita** [FR/US]; 4150 17th Street, #25, San Francisco, California 94114 (US). **WRIGHT, John Jessen** [AU/US]; 720 Bair Island Road, Apt. 107, Redwood City, California 94063 (US). **KRASINSKI, Antoni** [PL/US]; 777 West Middlefield Road, #192, Mountain View, California 94043 (US). **HU, Cheng** [CN/US]; 250 Waverley Street, #6, Menlo Park, California 94025 (US). **NOVACK, Aaron** [US/US]; 92 Mirabelli Circle, San Jose, California 95134 (US).

(74) Agents: **KEZER, William, B.** et al.; Townsend And Townsend And Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, California 94111 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
— with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:
13 December 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED QUINOLONES AND METHODS OF USE

(57) Abstract: Substituted quinolone compounds and compositions are provided along with methods for the use of those compounds in the treatment of diseases and disorders such as cancer.



WO 2007/059108 A3

SUBSTITUTED QUINOLONES AND METHODS OF USE

[0001] <deleted>

**STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY
SPONSORED RESEARCH AND DEVELOPMENT**

5 [0002] NOT APPLICABLE

REFERENCE TO A "SEQUENCE LISTING"

[0003] This description contains a sequence listing in electronic form in ASCII text format. A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office.

10

BACKGROUND OF THE INVENTION

[0004] The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-I chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CCXCKR2. These compounds are useful in preventing tumor cell proliferation, tumor formation,
15 metastasis, inflammatory diseases, treatment of HIV infectivity, and treatment of stem cell differentiation and mobilization disorders (see also US2005/0074826 and US2005/0214287).

[0005] Chemokines are a superfamily of small, cytokine-like proteins that induce cytoskeletal rearrangement, firm adhesion to endothelial cells, and directional migration and may also effect cell activation and proliferation. Chemokines act in a coordinated fashion
20 with cell surface proteins to direct the specific homing of various subsets of cells to specific anatomical sites.

[0006] Early research efforts by a number of groups have indicated a role for the chemokine receptor CXCR4 in metastasis and tumor growth. Muller, et al., "Involvement of Chemokine Receptors in Breast Cancer Metastasis," Nature, 410:50-56 (2001) demonstrated

that breast tumor cells use chemokine-mediated mechanisms, such as those regulating leukocyte trafficking, during the process of metastasis. Tumor cells express a distinct, non-random pattern of functionally active chemokine receptors. Signaling through CXCR4 mediates actin polymerization and pseudopodia formation in breast cancer cells, and induces chemotactic and invasive responses. Additionally, the organs representing the main sites of breast cancer metastasis (such as lymph nodes, bone marrow, and lungs) are the most abundant sources of ligand for the CXCR4 receptor.

[0007] Using immunodeficient mice, Muller and colleagues succeeded in reducing the metastasis of injected human breast cancer cells by treating mice with an antibody known to bind CXCR4. Their finding suggests that breast cancer metastasis could be reduced by treating a patient with a CXCR4 antagonist.

[0008] Bertolini, et al., "CXCR4 Neutralization, a Novel Therapeutic Approach for Non-Hodgkin's Lymphoma," Cancer Research, 62:3106-3112 (2002) demonstrated a reduction of tumor volume as well as prolonged survival of immunodeficient mice injected with human lymphoma cells treated with anti-CXCR4 antibodies. They interpreted their finding to mean that tumor volume could be reduced by treating a patient with a CXCR4 antagonist.

[0009] More recent studies suggest that another chemokine receptor, CCXCKR2, may also be a potential candidate in the treatment of cancer. CCXCKR2 is preferentially expressed in transformed cells over normal cells, with detectable expression in a number of human cancers. In vitro studies indicate that proliferation of CCXCKR2 expressing cells can be inhibited by an antagonist of CCXCKR2. In vivo studies in mice indicate that CCXCKR2 antagonists can inhibit tumor formation and tumor growth.

[0010] The potential importance of CCXCKR2 is illustrated by an alternative interpretation of the reduction in tumor volume seen by Bertolini and colleagues. This reduction could clearly be the result of an antibody-mediated clearance, and not the result of the anti-CXCR4 antibody as originally believed. In an antibody-mediated clearance, any antibody that recognized a protein on the cell surface of the lymphoma cells would have had the same effect as that attributed to the anti-CXCR4 antibody. Unfortunately, Bertolini and colleagues studies are inconclusive as to whether the observed tumor response was due to antibody-mediated clearance or interaction with CXCR4.

[0011] However it is now known that the lymphoma cells used by Bertolini and colleagues express both CXCR4 and CCXCKR2. SDF-1 is the only ligand for CXCR4. SDF-1 and I-

TAC both bind CCXCKR2. Using anti-SDF-1 antibody, it has now been shown that antagonists of CCXCKR2 are responsible for the reduction in tumor load and increased survival rate. Because SDF-1 is the only ligand for CXCR4, one would expect neutralization of SDF-1 with anti-SDF-1 antibody would be equivalent to the neutralization of CXCR4 with anti-CXCR4 antibody. However, experiments using an anti-SDF-1 antibody demonstrated only a partial reduction in tumor load and an increased survival rate. As a result, CCXCKR2 is the likely target, as the continued activity appears due to the interactions of the second ligand, I-TAC, with CCXCKR2.

[0012] Until recently, the possible importance of CCXCKR2 in tumor cell proliferation, tumor growth, and metastasis was unknown. Now, with recent evidence pointing to the ability of certain CCXCKR2 antagonists to prevent the growth and spread of cancer, and expression patterns indicating a limited tissue distribution for the CCXCKR2 receptor.

[0013] Moreover, recently it has been discovered that CCXCKR2 can serve as a co-receptor for certain genetically divergent human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV), in particular for the HIV-2-ROD, an X4-tropic isolate (Shimizu, N. *et al.*, *J. Virol.*, (2000) 74: 619-626; Balabanian, K., *et al.*, *J. Biol. Chem.*, [2005], 280:35760-66).


[0014] Still further, SDF-1, has been described to have a role in the mobilization of hematopoietic progenitor cells and stem cells, and in particular of those cells bearing the CXCR4 receptor, to specific hematopoietic tissues including bone marrow has been described (Hattori, K., *et al.*, *Blood*, (2000) 97:3354-3360; WO 2005/000333, the disclosure of which are incorporated herein by reference). For example, it is known that CD34+ progenitor cells express CXCR4 and require SDF-1 produced by bone marrow stromal cells for chemoattraction and engraftment, and that in vitro, SDF-1 is chemotactic for both CD34+ cells and for progenitor /stem cells. SDF-1 is also an important chemoattractant, signaling via the CXCR4 receptor, for several other more committed progenitors and mature blood cells including T-lymphocytes and monocytes, pro- and pre-B lymphocytes, and megakaryocytes. As mentioned above, SDF-1 is the only ligand for the CXCR4 receptor. SDF-1 and I-TAC are both ligands for CCXCKR2 receptor. More recent studies suggest that the CCXCKR2 receptor may also play a part in stem cell mobilization processes.

[0015] In view of the above, it is apparent that compounds that are able to bind specifically to CCXCKR2 receptors may be useful to treating diseases and other biological conditions

that may benefit from such interactions. The present invention provides such compounds along with pharmaceutical compositions and related methods for treatment.


BRIEF SUMMARY OF THE INVENTION

5 [0016] The present invention provides, in one aspect, compounds having formula I,



or pharmaceutically acceptable salts and N-oxides thereof. The various groups (e.g., R¹, R², R³, L¹, A, a, b, c and d) are described in the Detailed Description of the Invention.

10 [0016A] Various embodiments of this invention provide a compound having formula I



and pharmaceutically acceptable salts and N-oxides thereof; wherein == is a double bond; A is N or CH; R¹ is absent; L¹ is -C(O)-; R² is -R^e; R³ is -CH₂-R^e; R^e in R² is a 5-6 membered aryl or heteroaryl group that is optionally substituted with 1-5 substituents selected from the group

15 consisting of halogen, -CN, -NO₂, -CO₂R^t, -OC(O)R^t, -C(O)NR^tR^s, -C(O)R^t, -S(O)R^t, -S(O)₂R^t, -R^t, -C(NOR^t)R^s, -NR^t-C(O)NR^tR^s, -NH-C(NH₂)=NH, -NR^tC(NH₂)=NH, -NH-C(NH₂)=NR^t, -NH-C(NHR^t)=NH, -NR^tS(O)₂R^t, -NR^tS(O)₂R^t, -NR^tS(O)₂NR^tR^s, -N₃, -C(NR^tV)=NV, -N(V)C(R^t)=NV, -X²C(NOR^t)R^s, -X²C(NR^tV)=NV, -X²N(V)C(R^t)=NV, -X²NR^tR^s, -X²SR^t, -X²CN, -X²NO₂, -X²CO₂R^t, -X²OC(O)R^t, -X²CONR^tR^s, -X²C(O)R^t, -X²OC(O)NR^tR^s,
20 -X²NR^sC(O)R^t, -X²NR^sC(O)₂R^t, -X²NR^tC(O)NR^tR^s, -X²NH-C(NH₂)=NH, -X²NR^tC(NH₂)=NH, -X²NH-C(NH₂)=NR^t, -X²NH-C(NHR^t)=NH, -X²S(O)R^t, -X²S(O)₂R^t, -X²NR^tS(O)₂R^t, -X²S(O)₂NR^tR^s, -X²N₃, -OR^t, -SR^t, -NR^tR^s, -NR^sC(O)R^t, -NR^sC(O)₂R^t, -S(O)₂R^t, -S(O)₂NR^tR^s, -X²OR^t, -O-X²OR^t, -X²NR^tR^s, -O-X²NR^tR^s and -NR^s-X²CO₂R^t,

wherein any two substituents located on adjacent atoms in R^e are optionally combined to form a 5- to 7- membered ring optionally having from 1-3 heteroatoms selected from N, O and S; X^2 is C_{1-8} alkylene, C_{1-8} heteroalkylene, C_{2-8} alkenylene, C_{2-8} alkynylene, arylene or heteroarylene; and each R^f and R^s is independently selected from hydrogen, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl and heteroaryl, or optionally, R^f and R^s when attached to the same nitrogen atom are combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O and S, and wherein each R^t is independently selected from the group consisting of C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl and heteroaryl, V is independently selected from the group consisting of $-R^t$, $-CN$, $-CO_2R^f$ and $-NO_2$, and each of X^2 , R^f , R^s and R^t is optionally further substituted with from one to three members selected from the group consisting of $-OH$, $-OR^u$, $-OC(O)NHR^u$, $-OC(O)N(R^u)_2$, $-SH$, $-SR^u$, $-S(O)R^u$, $-S(O)_2R^u$, $-SO_2NH_2$, $-S(O)_2NHR^u$, $-S(O)_2N(R^u)_2$, $-NHS(O)_2R^u$, $-NR^uS(O)_2R^u$, $-C(O)NH_2$, $-C(O)NHR^u$, $-C(O)N(R^u)_2$, $-C(O)R^u$, $-NHC(O)R^u$, $-NR^uC(O)R^u$, $-NHC(O)NH_2$, $-NR^uC(O)NH_2$, $-NR^uC(O)NHR^u$, $-NHC(O)NHR^u$, $-NR^uC(O)N(R^u)_2$, $-NHC(O)N(R^u)_2$, $-CO_2H$, $-CO_2R^u$, $-NHCO_2R^u$, $-NR^uCO_2R^u$, $-CN$, $-NO_2$, $-NH_2$, $-NHR^u$, $-N(R^u)_2$, $-NR^uS(O)NH_2$ and $-NR^uS(O)_2NHR^u$, wherein each R^u is independently an unsubstituted C_{1-6} alkyl; R^e in R^3 is a 5-6 membered heteroaryl group that is optionally substituted with 1-5 substituents selected from the group consisting of halogen, $-CN$, $-NO_2$, $-CO_2R^f$, $-OC(O)R^f$, $-C(O)NR^fR^s$, $-C(O)R^f$, $-S(O)R^t$, $-S(O)_2R^t$, $-R^t$, $-C(NOR^f)R^s$, $-NR^f-C(O)NR^fR^s$, $-NH-C(NH_2)=NH$, $-NR^tC(NH_2)=NH$, $-NH-C(NH_2)=NR^t$, $-NH-C(NHR^t)=NH$, $-NR^fS(O)_2R^t$, $-NR^fS(O)_2R^t$, $-NR^fS(O)_2NR^fR^s$, $-N_3$, $-C(NR^fV)=NV$, $-N(V)C(R^f)=NV$, $-X^2C(NOR^f)R^s$, $-X^2C(NR^fV)=NV$, $-X^2N(V)C(R^f)=NV$, $-X^2NR^fR^s$, $-X^2SR^f$, $-X^2CN$, $-X^2NO_2$, $-X^2CO_2R^f$, $-X^2OC(O)R^f$, $-X^2CONR^fR^s$, $-X^2C(O)R^f$, $-X^2OC(O)NR^fR^s$, $-X^2NR^sC(O)R^f$, $-X^2NR^sC(O)_2R^t$, $-X^2NR^fC(O)NR^fR^s$, $-X^2NH-C(NH_2)=NH$, $-X^2NR^tC(NH_2)=NH$, $-X^2NH-C(NH_2)=NR^t$, $-X^2NH-C(NHR^t)=NH$, $-X^2S(O)R^t$, $-X^2S(O)_2R^t$, $-X^2NR^fS(O)_2R^t$, $-X^2S(O)_2NR^fR^s$, $-X^2N_3$, $-OR^f$, $-SR^f$, $-NR^fR^s$, $-NR^sC(O)R^f$, $-NR^sC(O)_2R^t$, $-S(O)_2R^t$, $-S(O)_2NR^fR^s$, $-X^2OR^f$, $-O-X^2OR^f$, $-X^2NR^fR^s$, $-O-X^2NR^fR^s$ and $-NR^s-X^2CO_2R^f$, wherein any two substituents located on adjacent atoms in R^e are optionally combined to form a 5- to 7- membered ring optionally having from 1-3 heteroatoms selected from N, O and S; X^2 is C_{1-8} alkylene, C_{1-8} heteroalkylene, C_{2-8} alkenylene, C_{2-8}

alkynylene, arylene or heteroarylene; and each R^f and R^s is independently selected from hydrogen, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl and heteroaryl, or optionally, R^f and R^s when attached to the same nitrogen atom are combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional

5 heteroatoms as ring members selected from N, O and S, and wherein each R^t is independently selected from the group consisting of C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl and heteroaryl, V is independently selected from the group consisting of $-R^t$, $-CN$, $-CO_2R^f$ and $-NO_2$, and each of X^2 , R^f , R^s and R^t is optionally further substituted with from one to three members selected from the group consisting of $-OH$, $-OR^u$, $-OC(O)NHR^u$,

10 $-OC(O)N(R^u)_2$, $-SH$, $-SR^u$, $-S(O)R^u$, $-S(O)_2R^u$, $-SO_2NH_2$, $-S(O)_2NHR^u$, $-S(O)_2N(R^u)_2$, $-NHS(O)_2R^u$, $-NR^uS(O)_2R^u$, $-C(O)NH_2$, $-C(O)NHR^u$, $-C(O)N(R^u)_2$, $-C(O)R^u$, $-NHC(O)R^u$, $-NR^uC(O)R^u$, $-NHC(O)NH_2$, $-NR^uC(O)NH_2$, $-NR^uC(O)NHR^u$, $-NHC(O)NHR^u$, $-NR^uC(O)N(R^u)_2$, $-NHC(O)N(R^u)_2$, $-CO_2H$, $-CO_2R^u$, $-NHCO_2R^u$, $-NR^uCO_2R^u$, $-CN$, $-NO_2$, $-NH_2$, $-NHR^u$, $-N(R^u)_2$, $-NR^uS(O)NH_2$ and $-NR^uS(O)_2NHR^u$, wherein each R^u is independently

15 an unsubstituted C_{1-6} alkyl; and each of the ring vertices a, b, c and d in formula I is N, C(H) or $C(R^4)$, wherein R^4 at each occurrence is independently selected from the group consisting of halogen, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{1-8} alkoxy and C_{1-8} haloalkoxy, and optionally any two R^4 substituents located on adjacent ring vertices are combined to form a 5- to 6-membered ring having from 0 to 2 heteroatom ring members selected from the group consisting of N, O and S.

20 Also provided are compositions comprising a compound of this invention and a pharmaceutically acceptable salt or N-oxide thereof, as well as use of such a compound, salt, N-oxide, or composition for treating a disease or disorder in a mammal as defined herein. Also provided is use of a compound, N-oxide, salt, or a composition of this invention for inhibiting binding of chemokine I-TAC or SDF-1 to a CCXCKR2 receptor. The inhibition of binding

25 may be in a cell that expresses the CCXCKR2 receptor.

[0017] The compounds provided herein are useful for binding to CCXCKR2 (also referred to as CXCR7), and in some cases, treating diseases that are dependent, at least in part, on CCXCKR2 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a

30 pharmaceutically acceptable excipient.

[0018] In still another aspect, the present invention provides methods for treating various diseases, discussed further herein, comprising administering to a subject in need to such treatment a therapeutically effective amount of a compound of the above formula for a period of time sufficient to treat the disease.

5

BRIEF DESCRIPTION OF THE DRAWINGS

[0019] None

DETAILED DESCRIPTION OF THE INVENTION

10 I. Abbreviation and Definitions

[0020] The term "alkyl", by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon radical, having the number of carbon atoms designated (*i.e.* C₁₋₈ means one to eight carbons). Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl,
15 n-hexyl, n-heptyl, n-octyl, and the like. For brevity, the term alkyl also includes haloalkyl group. The term

"alkenyl" refers to an unsaturated alkyl group having one or more double bonds. Similarly, the term "alkynyl" refers to an unsaturated alkyl group having one or more triple bonds.

Examples of such unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butylnyl,

and the higher homologs and isomers. The term "cycloalkyl" refers to hydrocarbon rings having the indicated number of ring atoms (e.g., C₃₋₆cycloalkyl) and being fully saturated or having no more than one double bond between ring vertices. "Cycloalkyl" is also meant to refer to bicyclic and polycyclic hydrocarbon rings such as, for example,


bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, etc. The term "heterocycloalkyl" refers to a


cycloalkyl group that contain from one to five heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. The heterocycloalkyl may be a monocyclic, a bicyclic or a polycyclic ring system. Non limiting examples of heterocycloalkyl groups include pyrrolidine, piperidiny, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide, piperidine, 1,4-dioxane, morpholine, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S,S-oxide, piperazine, pyran, pyridone, 3-pyrroline, thiopyran, pyrone, tetrahydrofuran, tetrahydrothiophene, quinuclidine, and the like. A heterocycloalkyl group can be attached to the remainder of the molecule through a ring carbon or a heteroatom.

[0021] The term "alkylene" by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified by -CH₂CH₂CH₂CH₂-. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having four or fewer carbon atoms.

Similarly, "alkenylene" and "alkynylene" refer to the unsaturated forms of "alkylene" having double or triple bonds, respectively.

[0022] The term "arylene" by itself or as part of another substituent means a divalent

radical derived from an aryl group, as exemplified by . Typically, an arylene group is derived from a 6-12 membered aryl group (can be monocyclic, fused bicyclic or a covalently linked bicyclic such as a biphenyl group, for example). Similarly, heteroarylene

refers to a divalent radical derived from a heteroaryl group, e.g., , and the like.

[0023] As used herein, a wavy line, "~~~", that intersects a single, double or triple bond in any chemical structure depicted herein, represent the point attachment of the single, double, or triple bond to the remainder of the molecule.

[0024] The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group. The heteroatom Si may be placed at any position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule. Examples include -CH₂-CH₂-O-CH₃, -CH₂-CH₂-NH-CH₃, -CH₂-CH₂-N(CH₃)-CH₃, -CH₂-S-CH₂-CH₃, -CH₂-CH₂-S(O)-CH₃, -CH₂-CH₂-S(O)₂-CH₃, -CH=CH-O-CH₃, -Si(CH₃)₃, -CH₂-CH=N-OCH₃, and -CH=CH-N(CH₃)-CH₃. Up to two heteroatoms may be consecutive, such as, for example, -CH₂-NH-OCH₃ and -CH₂-O-Si(CH₃)₃. Similarly, the terms "heteroalkenyl" and "heteroalkynyl" by itself or in combination with another term, means, unless otherwise stated, an alkenyl group or alkynyl group, respectively, that contains the stated number of carbons and having from one to three heteroatoms selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group.

[0025] The term "heteroalkylene" by itself or as part of another substituent means a divalent radical, saturated or unsaturated or polyunsaturated, derived from heteroalkyl, as exemplified by -CH₂-CH₂-S-CH₂CH₂- and -CH₂-S-CH₂-CH₂-NH-CH₂-, -O-CH₂-CH=CH-, -CH₂-CH=C(H)CH₂-O-CH₂- and -S-CH₂-C≡C-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (*e.g.*, alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like).

[0026] The terms "alkoxy," "alkylamino" and "alkylthio" (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively. Additionally, for dialkylamino groups, the alkyl portions can be the same or different and can also be combined to form a 3-7 membered ring with the nitrogen atom to which each is attached.

Accordingly, a group represented as $-NR^aR^b$ is meant to include piperidinyl, pyrrolidinyl, morpholinyl, azetidiny and the like.

[0027] The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl," are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "C₁₋₄ haloalkyl" is mean to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0028] The term "aryl" means, unless otherwise stated, a polyunsaturated, typically aromatic, hydrocarbon group which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently. The term "heteroaryl" refers to aryl groups (or rings) that contain from one to five heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of aryl groups include phenyl, naphthyl and biphenyl, while non-limiting examples of heteroaryl groups include pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indoliziny, benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridines, benzothiazolyl, benzofuranyl, benzothienyl, indolyl, quinolyl, isoquinolyl, isothiazolyl, pyrazolyl, indazolyl, pteridinyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiadiazolyl, pyrrolyl, thiazolyl, furyl, thienyl and the like. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.

[0029] For brevity, the term "aryl" when used in combination with other terms (*e.g.*, aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the term "arylalkyl" is meant to include those radicals in which an aryl group is attached to an alkyl group (*e.g.*, benzyl, phenethyl, pyridylmethyl and the like).

[0030] The above terms (*e.g.*, "alkyl," "aryl" and "heteroaryl"), in some embodiments, will include both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below. For brevity, the terms aryl and heteroaryl will refer to substituted or unsubstituted versions as provided below, while the

term "alkyl" and related aliphatic radicals is meant to refer to unsubstituted version, unless indicated to be substituted.

[0031] Substituents for the alkyl radicals (including those groups often referred to as alkylene, alkenyl, alkynyl and cycloalkyl) can be a variety of groups selected from: -halogen, -OR', -NR'R'', -SR', -SiR'R''R''', -OC(O)R', -C(O)R', -CO₂R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R''', -NR''C(O)₂R', -NH-C(NH₂)=NH, -NR'C(NH₂)=NH, -NH-C(NH₂)=NR', -S(O)R', -S(O)₂R', -S(O)₂NR'R'', -NR'S(O)₂R'', -CN and -NO₂ in a number ranging from zero to (2 m'+1), where m' is the total number of carbon atoms in such radical. R', R'' and R''' each independently refer to hydrogen, unsubstituted C₁₋₈ alkyl, unsubstituted heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted C₁₋₈ alkyl, C₁₋₈ alkoxy or C₁₋₈ thioalkoxy groups, or unsubstituted aryl-C₁₋₄ alkyl groups. When R' and R'' are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring. For example, -NR'R'' is meant to include 1-pyrrolidinyl and 4-morpholinyl. The term "acyl" as used by itself or as part of another group refers to an alkyl radical wherein two substituents on the carbon that is closest to the point of attachment for the radical is replaced with the substituent =O (e.g., -C(O)CH₃, -C(O)CH₂CH₂OR' and the like).

[0032] Similarly, substituents for the aryl and heteroaryl groups are varied and are generally selected from: -halogen, -OR', -OC(O)R', -NR'R'', -SR', -R', -CN, -NO₂, -CO₂R', -CONR'R'', -C(O)R', -OC(O)NR'R'', -NR''C(O)R', -NR''C(O)₂R', -NR'-C(O)NR''R''', -NH-C(NH₂)=NH, -NR'C(NH₂)=NH, -NH-C(NH₂)=NR', -S(O)R', -S(O)₂R', -S(O)₂NR'R'', -NR'S(O)₂R'', -N₃, perfluoro(C₁-C₄)alkoxy, and perfluoro(C₁-C₄)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R'' and R''' are independently selected from hydrogen, C₁₋₈ alkyl, C₃₋₆ cycloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, unsubstituted aryl and heteroaryl, (unsubstituted aryl)-C₁₋₄ alkyl, and unsubstituted aryloxy-C₁₋₄ alkyl. Other suitable substituents include each of the above aryl substituents attached to a ring atom by an alkylene tether of from 1-4 carbon atoms.

[0033] Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CH₂)_q-U-, wherein T and U are independently -NH-, -O-, -CH₂- or a single bond, and q is an integer of from 0 to 2. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH₂)_r-B-, wherein A and B are

independently -CH₂-, -O-, -NH-, -S-, -S(O)-, -S(O)₂-, -S(O)₂NR'- or a single bond, and r is an integer of from 1 to 3. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -(CH₂)_s-X-(CH₂)_t-, where s and t are independently integers of from 0 to 3, and X is -O-, -NR'-, -S-, -S(O)-, -S(O)₂-, or -S(O)₂NR'-. The substituent R' in -NR'- and -S(O)₂NR'- is selected from hydrogen or unsubstituted C₁₋₆ alkyl.

[0034] As used herein, the term "heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).

[0035] As used herein, the term "progenitor cells" refers to cells that, in response to certain stimuli, can form differentiated hematopoietic or myeloid cells. The presence of progenitor cells can be assessed by the ability of the cells in a sample to form colony-forming units of various types, including, for example, CFU-GM (colony-forming units, granulocyte-macrophage); CFU-GEMM (colony-forming units, multipotential); BFU-E (burst-forming units, erythroid); HPP-CFC (high proliferative potential colony-forming cells); or other types of differentiated colonies which can be obtained in culture using known protocols.

[0036] As used herein, the term "stem cells" refer to cells that are less differentiated forms of progenitor cells. Typically, such cells are often positive for CD34. Some stem cells do not contain this marker, however. These CD34+ cells can be assayed using fluorescence activated cell sorting (FACS) and thus their presence can be assessed in a sample using this technique.

[0037] In general, CD34+ cells are present only in low levels in the blood, but are present in large numbers in bone marrow. While other types of cells such as endothelial cells and mast cells also may exhibit this marker, CD34 is considered an index of stem cell presence.

[0038] The term "pharmaceutically acceptable salts" is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of salts derived from pharmaceutically-acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the

like. Salts derived from pharmaceutically-acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, 5 ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by 10 contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and 15 the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S.M., et al, 20 "Pharmaceutical Salts", *Journal of Pharmaceutical Science*, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

[0039] The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent 25 form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.

[0040] In addition to salt forms, the present invention provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily 30 undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an *ex vivo* environment. For example,

prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.

[0041] Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

[0042] Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers, regioisomers and individual isomers (e.g., separate enantiomers) are all intended to be encompassed within the scope of the present invention. The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (^3H), iodine-125 (^{125}I) or carbon-14 (^{14}C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

[0043] "CCXCKR2" also referred to as "RDC1" or "CXCR7" refers to a seven-transmembrane domain presumed G-protein coupled receptor (GPCR). The CCXCKR2 dog ortholog was originally identified in 1991. *See, Libert et al. Science* 244:569-572 (1989). The dog sequence is described in Libert *et al.*, *Nuc. Acids Res.* 18(7):1917 (1990). The mouse sequence is described in, e.g., Heesen *et al.*, *Immunogenetics* 47:364-370 (1998). The human sequence is described in, e.g., Sreedharan *et al.*, *Proc. Natl. Acad. Sci. USA* 88:4986-4990 (1991), which mistakenly described the protein as a receptor of vasoactive intestinal peptide. "CCXCKR2" includes sequences that are substantially similar to or conservatively modified variants of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.

II. General


[0044] Compounds of the present invention can inhibit the binding of ligands to the CCXCKR2 receptor and are useful in the treatment of various diseases, including cancer, particularly solid tumor cancers and lymphomas. More recently, the inhibition of ligand

binding to CCXCKR2 was noted to reduce the severity of rheumatoid arthritis in an animal model.

III. Embodiments of the Invention

A. Compounds

5 [0045] The present invention provides, in one aspect, compounds having formula I,



or pharmaceutically acceptable salts and N-oxides thereof; wherein
 --- represents a single or double bond.

10 [0046] In formula I, the symbol A is -N(H)-, -N(R^a)-, -CH₂-, -CH(R^a)-, or -C(R^a)₂-, wherein R^a is absent or is C₁₋₄ alkyl.

[0047] In formula I, the substituent R¹ is absent; or alternatively is hydrogen or C₁₋₆ alkyl. The linker L¹ is -C(O)-. The substituent R² is -R^e, and the substituent R³ is selected from -X¹-R^e and -R^e, wherein the linker X¹ is a C₁₋₂ alkylene.

15 [0048] For the substituents R² and R³, the symbol R^e represents a 5- or 6-membered aryl or heteroaryl group that is optionally substituted with 1-5 substituents selected from the group consisting of halogen, -CN, -NO₂, -CO₂R^r, -OC(O)R^r, -C(O)NR^rR^s, -C(O)R^r, -S(O)R^t, -S(O)₂R^t, -R^t, -C(NOR^r)R^s, -NR^r-C(O)NR^rR^s, -NH-C(NH₂)=NH, -NR^tC(NH₂)=NH, -NH-C(NH₂)=NR^t, -NH-C(NHR^t)=NH, -NR^rS(O)₂R^t, -NR^rS(O)₂R^t, -NR^rS(O)₂NR^rR^s, -N₃, -C(NR^rV)=NV, -N(V)C(R^t)=NV, -X²C(NOR^r)R^s, -X²C(NR^rV)=NV, -X²N(V)C(R^t)=NV, -X²NR^rR^s, -X²SR^r, -X²CN, -X²NO₂, -X²CO₂R^r, -X²OC(O)R^r, -X²CONR^rR^s, -X²C(O)R^r, -X²OC(O)NR^rR^s, -X²NR^sC(O)R^r, -X²NR^sC(O)₂R^t, -X²NR^rC(O)NR^rR^s, -X²NH-C(NH₂)=NH, -X²NR^tC(NH₂)=NH, -X²NH-C(NH₂)=NR^t, -X²NH-C(NHR^t)=NH, -X²S(O)R^t, -X²S(O)₂R^t, -X²NR^rS(O)₂R^t, -X²S(O)₂NR^rR^s, -X²N₃, -OR^r, -SR^r, -NR^rR^s, -NR^sC(O)R^r, -NR^sC(O)₂R^t, -S(O)₂R^t, -S(O)₂NR^rR^s, -X²OR^r, -O-X²OR^r, -X²NR^rR^s, -O-X²NR^rR^s and -NR^s-X²CO₂R^r,
 20
 25 wherein any two substituents located on adjacent atoms in R^e can be combined to form a 5- to 7- membered ring having optionally having from 1-3 heteroatoms selected from N, O or S. The linker X² is C₁₋₈ alkylene, C₁₋₈ heteroalkylene, C₂₋₈ alkenylene, C₂₋₈ alkynylene, arylene or

heteroarylene; and each R^r and R^s is independently selected from hydrogen, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl and heteroaryl. Optionally, R^r and R^s when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members

5 selected from N, O or S. Each R^t substituent is independently selected from the group consisting of C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl and heteroaryl. The symbol V is independently selected from the group consisting of $-R^t$, $-CN$, $-CO_2R^r$ and $-NO_2$, and each of X^2 , R^r , R^s and R^t is optionally further substituted with from one to three members selected from the group consisting of $-OH$, $-OR^u$, $-OC(O)NHR^u$,

10 $-OC(O)N(R^u)_2$, $-SH$, $-SR^u$, $-S(O)R^u$, $-S(O)_2R^u$, $-SO_2NH_2$, $-S(O)_2NHR^u$, $-S(O)_2N(R^u)_2$, $-NHS(O)_2R^u$, $-NR^uS(O)_2R^u$, $-C(O)NH_2$, $-C(O)NHR^u$, $-C(O)N(R^u)_2$, $-C(O)R^u$, $-NHC(O)R^u$, $-NR^uC(O)R^u$, $-NHC(O)NH_2$, $-NR^uC(O)NH_2$, $-NR^uC(O)NHR^u$, $-NHC(O)NHR^u$, $-NR^uC(O)N(R^u)_2$, $-NHC(O)N(R^u)_2$, $-CO_2H$, $-CO_2R^u$, $-NHCO_2R^u$, $-NR^uCO_2R^u$, $-CN$, $-NO_2$, $-NH_2$, $-NHR^u$, $-N(R^u)_2$, $-NR^uS(O)NH_2$ and $-NR^uS(O)_2NHR^u$, wherein each R^u is

15 independently an unsubstituted C_{1-6} alkyl.


[0049] Returning to formula I, each of the ring vertices a, b, c and d is N, N-O, C(H) or $C(R^4)$, wherein the R^4 substituent, at each occurrence, is independently is selected from the group consisting of halogen, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{1-8} alkoxy and C_{1-8} haloalkoxy. Optionally, any two R^4 substituents located on adjacent ring vertices are combined to form a

20 5- to 6-membered ring having from 0- to 2-heteroatoms selected from the group consisting of N, O and S.

[0050] Excluded from the compounds of the present invention are those provided in paragraph [0068].

Preferred embodiments

25 [0051] In certain embodiment of formula I, the compounds of the invention have subformula Ia:




wherein A is N or CH. The substituent R^2 is $-R^e$; the substituent R^3 is selected from $-X^1-R^e$ and $-R^e$, wherein the linker X^1 is C_{1-2} alkylene. The R^e substituent at each occurrence in


formula Ia is each independently a 5- to 6- membered aryl or heteroaryl group that is optionally substituted with 1-5 substituents selected from the group consisting of halogen, -CN, -NO₂, -R^t, -CO₂R^r, -CONR^rR^s, -N₃, -X²NR^rR^s, -X²SR^r, -X²CN, -X²NO₂, -X²CO₂R^r, -X²CONR^rR^s, -X²C(O)R^r, -X²NR^sC(O)R^r, -X²NR^sC(O)₂R^t, -X²N₃, -OR^r, -SR^r, -NR^rR^s, -NR^sC(O)R^r, -NR^sC(O)₂R^t, -X²OR^r and -NR^s-X²CO₂R^r, wherein any two substituents located on adjacent atoms in R^e can be combined to form a 5- to 7- membered ring having optionally having from 1-3 heteroatoms selected from N, O or S. Within this embodiment, the R^e substituent is preferably substituted with from 1 to 2 substituents. The linker X² is C₁₋₄ alkylene or C₁₋₄ heteroalkylene. For brevity, in certain instances, the description of the possible R^e groups for the R² and R³ substituents is recited only once. It should be understood that the R^e group for the R² substituent and for the R³ substituent in formula Ia (and formula I) need not be the same and are to be independently selected from the groups presented. Each R^r and R^s substituent is independently selected from hydrogen, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₃₋₆ cycloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, aryl and heteroaryl, or optionally, R^r and R^s when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O or S. The substituent R^t is independently selected from the group consisting of C₁₋₈ alkyl, C₁₋₈ haloalkyl, aryl and heteroaryl and each of X², R^r, R^s and R^t is optionally further substituted with from one to three members selected from the group consisting of -OH, -OR^u, -OC(O)NHR^u, -OC(O)N(R^u)₂, -SH, -SR^u, -S(O)R^u, -S(O)₂R^u, -SO₂NH₂, -S(O)₂NHR^u, -S(O)₂N(R^u)₂, -NHS(O)₂R^u, -NR^uS(O)₂R^u, -C(O)NH₂, -C(O)NHR^u, -C(O)N(R^u)₂, -C(O)R^u, -NHC(O)R^u, -NR^uC(O)R^u, -NHC(O)NH₂, -NR^uC(O)NH₂, -NR^uC(O)NHR^u, -NHC(O)NHR^u, -NR^uC(O)N(R^u)₂, -NHC(O)N(R^u)₂, -CO₂H, -CO₂R^u, -NHCO₂R^u, -NR^uCO₂R^u, -CN, -NO₂, -NH₂, -NHR^u, -N(R^u)₂, -NR^uS(O)NH₂ and -NR^uS(O)₂NHR^u, wherein each R^u is independently an unsubstituted C₁₋₆ alkyl.

The R² substituent:


[0052] In one embodiment, in compounds having formula I or Ia, the substituent R² which is -R^e is an optionally substituted heteroaryl group. In another embodiment of the invention, R² substituent is an optionally substituted pyridyl group. Within certain embodiments of the invention, the R² that is -R^e is selected from the group consisting of:



[0053] In still other embodiments, the R^2 that is $-R^e$ is selected from the group consisting of:




[0054] In yet another embodiment of the invention, in compounds having formula I or Ia, the R^2 substituent is $-R^e$ that is an optionally substituted phenyl ring. Within certain embodiments of the invention, the R^2 substituent is $-R^e$ that is a phenyl ring having the formula:




wherein R^{2a} , R^{2b} , R^{2c} , R^{2d} and R^{2e} are each independently selected from the group consisting of hydrogen, halogen, $-CN$, $-NO_2$, $-OR^f$, $-SR^f$, $-NR^fR^s$, $-CO_2R^f$, $-C(O)NR^fR^s$, optionally substituted C_{1-8} alkyl, optionally substituted C_{1-8} haloalkyl and optionally substituted C_{3-6} cycloalkyl. In another embodiment, R^{2a} , R^{2d} and R^{2e} are each hydrogen, and R^{2b} and R^{2c} are each independently selected from the group consisting of halogen, $-OR^f$, $-SR^f$, $-NR^fR^s$, optionally substituted C_{1-8} alkyl, optionally substituted C_{1-8} haloalkyl and optionally substituted C_{3-6} cycloalkyl. In yet another embodiment, R^{2a} , R^{2b} , R^{2d} and R^{2e} are each hydrogen, and R^{2c} is selected from the group consisting of halogen, $-OR^f$, $-SR^f$, $-NR^fR^s$, optionally substituted C_{1-8} alkyl, optionally substituted C_{1-8} haloalkyl and optionally substituted C_{3-6} cycloalkyl.

[0055] In yet another embodiment, the R^2 substituent is $-R^e$ that is selected from the group consisting of




[0056] In still another embodiment, the R^2 substituent is $-R^e$ that is selected from the group consisting of:



The R³ substituent:


[0057] As noted above, in compounds having formula I and Ia, the substituent R³ is selected from -X¹-R^e, and -R^e. Within certain embodiments of the invention, the symbol R^e for the R³ substituent in formula I and Ia is an optionally substituted heteroaryl group. In other embodiments, it is an optionally substituted pyridyl group.

[0058] In another embodiment of the invention, in compounds having formula I (or Ia), the symbol R^e for a R³ substituent is a pyridyl group having the formula




wherein R^{3a} is substituent selected from the group consisting of halogen, -CN, -NO₂, -CO₂R^r, -OC(O)R^r, -C(O)NR^rR^s, -C(O)R^r, -S(O)R^t, -S(O)₂R^t, -R^t, -C(NOR^t)R^s, -NR^r-C(O)NR^rR^s, -NH-C(NH₂)=NH, -NR^tC(NH₂)=NH, -NH-C(NH₂)=NR^t, -NH-C(NHR^t)=NH, -NR^rS(O)₂R^t, -NR^rS(O)₂R^t, -NR^rS(O)₂NR^rR^s, -N₃, -C(NR^rV)=NV, -N(V)C(R^r)=NV, -X²C(NOR^t)R^s, -X²C(NR^rV)=NV, -X²N(V)C(R^r)=NV, -X²NR^rR^s, -X²SR^r, -X²CN, -X²NO₂, -X²CO₂R^r, -X²OC(O)R^r, -X²CONR^rR^s, -X²C(O)R^r, -X²OC(O)NR^rR^s, -X²NR^sC(O)R^r, -X²NR^sC(O)₂R^t, -X²NR^rC(O)NR^rR^s, -X²NH-C(NH₂)=NH, -X²NR^tC(NH₂)=NH, -X²NH-C(NH₂)=NR^t, -X²NH-C(NHR^t)=NH, -X²S(O)R^t, -X²S(O)₂R^t, -X²NR^rS(O)₂R^t, -X²S(O)₂NR^rR^s, -X²N₃, -OR^r, -SR^r, -NR^rR^s, -NR^sC(O)R^r, -NR^sC(O)₂R^t, -S(O)₂R^t, -S(O)₂NR^rR^s, -X²OR^r, -O-X²OR^r, -X²NR^rR^s, -O-X²NR^rR^s and -NR^s-X²CO₂R^r. In another embodiment, in compounds of formula I or Ia, the R^{3a} substituent is selected from the group consisting of halogen, -CN, -NO₂, -R^t, -CO₂R^r, -CONR^rR^s, -N₃, -X²NR^rR^s, -X²SR^r, -X²CN, -X²NO₂, -X²CO₂R^r, -X²CONR^rR^s, -X²C(O)R^r, -X²NR^sC(O)R^r, -X²NR^sC(O)₂R^t, -X²N₃, -OR^r, -SR^r, -NR^rR^s, -NR^sC(O)R^r, -NR^sC(O)₂R^t, -X²OR^r and -NR^s-X²CO₂R^r.

[0059] In another embodiment, the symbol R^e for a R^3 substituent is selected from the group consisting of:




[0060] In each of the groups of embodiments above, more preferably R^3 is $-X^1-R^e$ wherein X^1 is CH_2 and R^e is selected from the indicated pyridyl, pyrimidine or pyrazine groups.

[0061] In yet another embodiment of the invention, the symbol R^e for a R^3 substituent is a phenyl ring having the formula



wherein R^{3a} , R^{3b} , R^{3c} , R^{3d} and R^{3e} are each independently selected from the group consisting of hydrogen, halogen, $-CN$, $-NO_2$, OR^f , $-SR^f$, $-NR^fR^s$, $-CO_2R^f$, $-C(O)NR^fR^s$, optionally substituted C_{1-8} alkyl, optionally substituted C_{1-8} haloalkyl and optionally substituted C_{3-6} cycloalkyl.

[0062] Within certain embodiments, the symbol R^e for a R^3 substituent is selected from the group consisting of



[0063] In each of the groups of embodiments above, more preferably R^3 is $-X^1-R^e$ wherein X^1 is CH_2 and R^e is selected from the indicated phenyl groups.

The ring vertices a, b, c and d:

- 5 [0064] In one embodiment of the invention, compounds having formula I or Ia the ring vertices a, b, c and d are each CH. In another embodiment, in compounds having formula I or Ia, the ring vertices a, b, c and d are each independently selected from the group consisting of CH or $C(R^4)$, wherein each R^4 is independently selected from the group consisting of halogen, C_{1-8} alkyl, C_{1-8} haloalkyl and C_{1-8} alkoxy; or alternatively any two R^4 substituents
- 10 located on adjacent ring vertices are combined to form a 5- to 7-membered ring having 1 to 2 heteroatoms selected from the group consisting of N and O. Within this aspect of the invention, in certain embodiments, the ring vertices a, c and d are each CH, and the ring vertex b is CR^4 , wherein the R^4 substituent is a C_{1-4} haloalkyl. In certain other embodiments, the ring vertices a and d are each CH and the ring vertices b and c are each $C(R^4)$ wherein the
- 15 R^4 substituent are combined to form a 5- or 6-membered ring having two oxygen atoms.

[0065] In yet another embodiment of the invention, in compounds having formula I and Ia, at least one ring vertex is N or N-O.

- [0066] In yet another embodiment of the invention, in a compound having formula I or Ia, the ring vertices a, c and d are each C(H) or $C(R^4)$ and the ring vertex b is N or N-O. Within
- 20 certain other embodiments, the ring vertices a, b and d are each C(H) or $C(R^4)$ and the ring vertex c is N or N-O. In yet another embodiment of the invention, the ring vertices a, b and c in compounds having formula I are each C(H) or $C(R^4)$ and the ring vertex d is N or N-O. In yet another embodiment of the invention, in formula I, the ring vertices b, c and d are each

C(H) or C(R⁴) and the ring vertex a is N or N-O. In yet another embodiment, in the compounds of formula I, two ring vertices are N or N-O.

[0067] A family of specific compound of particular interest having formula I or Ia consists of compounds, pharmaceutically acceptable salts, hydrates or N-oxides thereof, as set forth in Table 1.

Table I

1. 1-(3-Methyl-benzyl)-3-(pyridine-4-carbonyl)-1H-quinolin-4-one
2. 3-(Pyridine-4-carbonyl)-1-pyridin-2-ylmethyl-1H-quinolin-4-one
3. 3-(3,4-Dimethyl-benzoyl)-1-(2-fluoro-benzyl)-6-trifluoromethyl-1H-quinolin-4-one
- 10 4. 3-(3,4-Dimethyl-benzoyl)-1-pyridin-2-ylmethyl-6-trifluoromethyl-1H-quinolin-4-one
5. 8-(3,4-Dimethyl-benzoyl)-6-pyridin-4-ylmethyl-2,3-dihydro-6H-[1,4]dioxino[2,3-g]quinolin-9-one
6. 8-(3,4-Dimethyl-benzoyl)-6-pyridin-3-ylmethyl-2,3-dihydro-6H-[1,4]dioxino[2,3-g]quinolin-9-one
- 15 7. 8-(3,4-Dimethyl-benzoyl)-6-pyridin-2-ylmethyl-2,3-dihydro-6H-[1,4]dioxino[2,3-g]quinolin-9-one
8. 3-(3,4-Dimethyl-benzoyl)-1-pyridin-4-ylmethyl-1H-quinolin-4-one
9. 3-(3,4-Dimethyl-benzoyl)-1-pyridin-3-ylmethyl-1H-quinolin-4-one
10. 3-(3,4-Dimethyl-benzoyl)-1-(3-methyl-benzyl)-1H-quinolin-4-one
- 20 11. 6-Cyclopropylmethyl-8-(3,4-dimethyl-benzoyl)-2,3-dihydro-6H-[1,4]dioxino[2,3-g]quinolin-9-one
12. 3-(3,4-Dimethyl-benzoyl)-1-pyridin-2-ylmethyl-1H-quinolin-4-one
13. 8-(3,4-Dimethyl-benzoyl)-6-(2-fluoro-benzyl)-2,3-dihydro-6H-[1,4]dioxino[2,3-g]quinolin-9-one
- 25 14. 8-(3,4-Dimethyl-benzoyl)-6-(2-methyl-benzyl)-2,3-dihydro-6H-[1,4]dioxino[2,3-g]quinolin-9-one

15. 8-(3,4-Dimethyl-benzoyl)-6-(3-methyl-benzyl)-2,3-dihydro-6H-[1,4]dioxino[2,3-g]quinolin-9-one
16. 3-(3,4-Dimethyl-benzoyl)-1-(2-fluoro-benzyl)-1H-quinolin-4-one
17. 7-(3,4-Dimethyl-benzoyl)-5-pyridin-4-ylmethyl-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
18. 7-(3,4-Dimethyl-benzoyl)-5-pyridin-3-ylmethyl-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
19. 7-(3,4-Dimethyl-benzoyl)-5-pyridin-2-ylmethyl-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
20. 3-Benzoyl-1-(3-methyl-benzyl)-1H-quinolin-4-one
21. 7-(3,4-Dimethyl-benzoyl)-2,2-difluoro-5-(2-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
22. 3-(3-Methyl-benzoyl)-1-(3-methyl-benzyl)-1H-quinolin-4-one
23. 1-(2-Fluoro-benzyl)-3-(3-methyl-benzoyl)-1H-quinolin-4-one
24. 3-(3-Methyl-benzoyl)-1-pyridin-2-ylmethyl-1H-quinolin-4-one
25. 3-(3,4-Dimethyl-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one
26. 1-(2-Fluoro-benzyl)-3-(2-methyl-pyridine-4-carbonyl)-1H-quinolin-4-one
27. 3-(2-Methyl-pyridine-4-carbonyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one
28. 1-(3-Methyl-benzyl)-3-(2-methyl-pyridine-4-carbonyl)-1H-quinolin-4-one
29. 3-(3,4-Dimethyl-benzoyl)-1-phenethyl-1H-quinolin-4-one
30. 1-(5-Chloro-[1,2,3]thiadiazol-4-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one
31. 3-(3,4-Dimethyl-benzoyl)-1-(5-methyl-isoxazol-3-ylmethyl)-1H-quinolin-4-one
32. 3-(3,4-Dimethyl-benzoyl)-1-thiazol-4-ylmethyl-1H-quinolin-4-one
33. 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one

34. 1-(2-Fluoro-benzyl)-3-(pyridine-3-carbonyl)-1H-quinolin-4-one
35. 3-(3,4-Dimethyl-benzoyl)-1-[1,2,3,5]oxatriazol-4-ylmethyl-1H-quinolin-4-one
36. 1-(3-Methyl-benzyl)-3-(pyridine-3-carbonyl)-1H-quinolin-4-one
37. 1-(6-Methyl-pyridin-2-ylmethyl)-3-(pyridine-3-carbonyl)-1H-quinolin-4-one
- 5 38. 3-(3,4-Dimethyl-benzoyl)-1-(2-trifluoromethyl-benzyl)-1H-quinolin-4-one
39. 3-(3,4-Dimethyl-benzoyl)-1-(3-fluoro-pyridin-2-ylmethyl)-1H-quinolin-4-one
40. 3-(3,4-Dimethyl-benzoyl)-1-phenyl-1H-quinolin-4-one
41. 1-Cyclohexylmethyl-3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one
- 10 42. 3-(5,6-Dimethyl-pyridine-3-carbonyl)-1-(3-fluoro-pyridin-2-ylmethyl)-1H-quinolin-4-one
43. 3-(5,6-Dimethyl-pyridine-3-carbonyl)-1-(6-oxazol-2-yl-pyridin-2-ylmethyl)-1H-quinolin-4-one
44. 3-(3,4-Dimethyl-benzoyl)-1-(6-phenyl-pyridin-2-ylmethyl)-1H-quinolin-4-one
45. 3-(3,4-Dimethyl-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-cinnolin-4-one
- 15 46. 3-(3,4-Dimethyl-benzoyl)-1-(2-fluoro-3-methyl-benzyl)-1H-quinolin-4-one
47. 3-(3,4-Dimethyl-benzoyl)-1-(2-fluoro-benzyl)-1H-[1,6]naphthyridin-4-one
48. 3-(3,4-Dimethyl-benzoyl)-1-(3-methyl-benzyl)-1H-[1,6]naphthyridin-4-one
49. 3-(3,4-Dimethyl-benzoyl)-1-(3H-[1,2,3]triazol-4-ylmethyl)-1H-quinolin-4-one
50. 3-(5,6-Dimethyl-pyridine-2-carbonyl)-1-(2-fluoro-benzyl)-1H-quinolin-4-one
- 20 51. 3-(5,6-Dimethyl-pyridine-3-carbonyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one
52. 1-(6-Amino-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one
53. N-{6-[3-(3,4-Dimethyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridin-2-yl}-acetamide
- 25 54. 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-6-fluoro-1H-quinolin-4-one

55. 1-(6-Bromo-pyridin-2-ylmethyl)-3-(5,6-dimethyl-pyridine-3-carbonyl)-1H-quinolin-4-one

56. 3-(3,4-Dimethyl-benzoyl)-6-fluoro-1-(3-methyl-benzyl)-1H-quinolin-4-one

57. 3-(3,4-Dimethyl-benzoyl)-1-pyrimidin-2-ylmethyl-1H-quinolin-4-one

5 58. 3-(3,4-Dimethyl-benzoyl)-1-pyrazin-2-ylmethyl-1H-quinolin-4-one

59. 3-(3,4-Dimethyl-benzoyl)-1-(2,6-dimethyl-benzyl)-1H-quinolin-4-one

60. 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one

61. 6-[3-(3,4-Dimethyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridine-2-carbonitrile

[0068] Excluded from the above generic formula are those compounds that are either
 10 commercially available or known in the literature, including: 5-Benzyl-7-(4-methyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-Benzyl-7-(4-ethyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-Benzyl-7-(3,4-dimethyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-Benzyl-7-(4-chloro-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-Benzoyl-5-(4-chloro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(4-Chloro-benzyl)-7-(4-methyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(4-Chloro-benzyl)-7-(4-methoxy-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(4-Chloro-benzyl)-7-(4-ethoxy-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(4-Chloro-benzyl)-7-(4-fluoro-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(2-Fluoro-benzyl)-7-(4-methyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(3,4-Dimethyl-benzoyl)-5-(2-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Ethoxy-benzoyl)-5-(2-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Chloro-benzoyl)-5-(2-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(3-Fluoro-benzyl)-7-(4-methyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(3,4-Dimethyl-benzoyl)-5-(3-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(3-Fluoro-benzyl)-7-(4-methoxy-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-Benzoyl-5-(4-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Methyl-benzoyl)-5-(4-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(3,4-Dimethyl-benzoyl)-5-(4-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Ethoxy-benzoyl)-5-(4-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Fluoro-benzoyl)-5-(4-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Chloro-benzoyl)-5-(4-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(4-Fluoro-benzyl)-7-(4-methyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Ethyl-

benzoyl)-5-(4-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(3,4-Dimethyl-
 benzoyl)-5-(4-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Ethoxy-benzoyl)-5-
 (4-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Chloro-benzoyl)-5-(4-fluoro-
 benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-Benzoyl-5-(3-methyl-benzyl)-5H-
 5 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Methyl-benzoyl)-5-(3-methyl-benzyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(3,4-Dimethyl-benzoyl)-5-(3-methyl-benzyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Methoxy-benzoyl)-5-(3-methyl-benzyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Ethoxy-benzoyl)-5-(3-methyl-benzyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Fluoro-benzoyl)-5-(3-methyl-benzyl)-5H-
 10 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Chloro-benzoyl)-5-(3-methyl-benzyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Ethyl-benzoyl)-5-(2-methoxy-benzyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(3,4-Dimethyl-benzoyl)-5-(2-methoxy-benzyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Ethoxy-benzoyl)-5-(2-methoxy-benzyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; 5-(3-Methoxy-benzyl)-7-(4-methyl-benzoyl)-5H-
 15 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Ethyl-benzoyl)-5-(3-methoxy-benzyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(3,4-Dimethyl-benzoyl)-5-(3-methoxy-benzyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Ethoxy-benzoyl)-5-(3-methoxy-benzyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Chloro-benzoyl)-5-(3-methoxy-benzyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(3,4-Dimethyl-benzoyl)-5-(4-methoxy-benzyl)-5H-
 20 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Chloro-benzoyl)-5-(4-methoxy-benzyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-[7-(4-ethyl-
 benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(2,3-Dihydro-
 benzo[1,4]dioxin-6-yl)-2-[7-(3,4-dimethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-
 yl]-acetamide; N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-[7-(4-methoxy-benzoyl)-8-oxo-8H-
 25 [1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-[7-(4-
 ethoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(2,3-Dihydro-
 benzo[1,4]dioxin-6-yl)-2-[7-(4-fluoro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-
 acetamide; 2-[7-(4-Chloro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(2,3-
 dihydro-benzo[1,4]dioxin-6-yl)-acetamide; N-Benzo[1,3]dioxol-5-yl-2-[7-(4-chloro-
 30 benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-Benzo[1,3]dioxol-5-yl-2-
 [7-(4-methyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-
 Benzo[1,3]dioxol-5-yl-2-[7-(4-ethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-
 acetamide; N-Benzo[1,3]dioxol-5-yl-2-[7-(3,4-dimethyl-benzoyl)-8-oxo-8H-
 [1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-Benzo[1,3]dioxol-5-yl-2-[7-(4-methoxy-

benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-Benzo[1,3]dioxol-5-yl-2-[7-(4-ethoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-Benzo[1,3]dioxol-5-yl-2-[7-(4-fluoro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-Benzo[1,3]dioxol-5-yl-2-[7-(4-chloro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; 2-(7-Benzoyl-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl)-N-(4-methoxy-phenyl)-acetamide; N-(4-Methoxy-phenyl)-2-[7-(4-methyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; 2-[7-(4-Ethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(4-methoxy-phenyl)-acetamide; 2-[7-(3,4-Dimethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(4-methoxy-phenyl)-acetamide; 2-[7-(4-Ethoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(4-methoxy-phenyl)-acetamide; 2-[7-(4-Fluoro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(4-methoxy-phenyl)-acetamide; 2-[7-(4-Chloro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(4-methoxy-phenyl)-acetamide; 2-(7-Benzoyl-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl)-N-(3,4-dimethoxy-phenyl)-acetamide; N-(3,4-Dimethoxy-phenyl)-2-[7-(4-ethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; 2-(7-Benzoyl-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl)-N-(4-ethoxy-phenyl)-acetamide; N-(4-Ethoxy-phenyl)-2-[7-(4-methyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(4-Ethoxy-phenyl)-2-[7-(4-ethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(4-Ethoxy-phenyl)-2-[7-(4-methoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(4-Ethoxy-phenyl)-2-[7-(4-fluoro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; 2-[7-(4-Chloro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(4-ethoxy-phenyl)-acetamide; 2-(7-Benzoyl-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl)-N-(3-methoxy-phenyl)-acetamide; N-(3-Methoxy-phenyl)-2-[7-(4-methyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; 2-[7-(4-Ethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(3-methoxy-phenyl)-acetamide; 2-[7-(3,4-Dimethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(3-methoxy-phenyl)-acetamide; 2-[7-(4-Methoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(3-methoxy-phenyl)-acetamide; 2-[7-(4-Ethoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(3-methoxy-phenyl)-acetamide; 2-[7-(4-Fluoro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(3-methoxy-phenyl)-acetamide; 2-[7-(4-Chloro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(3-methoxy-phenyl)-acetamide; 2-(7-Benzoyl-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl)-N-(3,5-dimethoxy-phenyl)-acetamide; N-(3,5-Dimethoxy-phenyl)-2-[7-(4-methyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(3,5-Dimethoxy-phenyl)-2-[7-(4-ethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-

(3,5-Dimethoxy-phenyl)-2-[7-(3,4-dimethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(3,5-Dimethoxy-phenyl)-2-[7-(4-methoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(3,5-Dimethoxy-phenyl)-2-[7-(4-ethoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(3,5-Dimethoxy-phenyl)-2-[7-(4-fluoro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; 2-[7-(4-Chloro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(3,5-dimethoxy-phenyl)-acetamide; N-(2,5-Dimethoxy-phenyl)-2-[7-(4-ethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; 2-(7-Benzoyl-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl)-N-(2,4-dimethoxy-phenyl)-acetamide; N-(2,4-Dimethoxy-phenyl)-2-[7-(4-methyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(2,4-Dimethoxy-phenyl)-2-[7-(4-ethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(2,4-Dimethoxy-phenyl)-2-[7-(4-methoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(2,4-Dimethoxy-phenyl)-2-[7-(4-ethoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(2,4-Dimethoxy-phenyl)-2-[7-(4-fluoro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; 2-[7-(4-Chloro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(2,4-dimethoxy-phenyl)-acetamide; 2-(7-Benzoyl-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl)-N-(4-fluoro-phenyl)-acetamide; N-(4-Fluoro-phenyl)-2-[7-(4-methyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; 2-[7-(4-Ethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(4-fluoro-phenyl)-acetamide; 2-[7-(3,4-Dimethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(4-fluoro-phenyl)-acetamide; N-(4-Fluoro-phenyl)-2-[7-(4-methoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; 2-[7-(4-Ethoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(4-fluoro-phenyl)-acetamide; 2-[7-(4-Chloro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(4-fluoro-phenyl)-acetamide; N-(3,4-Difluoro-phenyl)-2-[7-(4-methyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(3,4-Difluoro-phenyl)-2-[7-(4-ethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(3,4-Difluoro-phenyl)-2-[7-(4-methoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(3,4-Difluoro-phenyl)-2-[7-(4-ethoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; 2-(7-Benzoyl-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl)-N-(4-chloro-phenyl)-acetamide; N-(4-Chloro-phenyl)-2-[7-(4-methyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(4-Chloro-phenyl)-2-[7-(4-ethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(4-Chloro-phenyl)-2-[7-(3,4-dimethyl-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; N-(4-Chloro-phenyl)-2-[7-(4-ethoxy-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-

acetamide; N-(4-Chloro-phenyl)-2-[7-(4-fluoro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; 2-[7-(4-Chloro-benzoyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(4-chloro-phenyl)-acetamide; 2-[8-Oxo-7-(toluene-4-sulfonyl)-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-phenyl-acetamide; 2-[7-(4-Fluoro-benzenesulfonyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-phenyl-acetamide; 2-[7-(4-Chloro-benzenesulfonyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-phenyl-acetamide; 2-(7-Benzenesulfonyl-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl)-N-(4-chloro-phenyl)-acetamide; 2-(7-Benzenesulfonyl-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl)-N-(4-fluoro-phenyl)-acetamide; N-(4-Fluoro-phenyl)-2-[8-oxo-7-(toluene-4-sulfonyl)-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-acetamide; 2-[7-(4-Fluoro-benzenesulfonyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-(4-fluoro-phenyl)-acetamide; 2-(7-Benzenesulfonyl-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl)-N-p-tolyl-acetamide; 2-[8-Oxo-7-(toluene-4-sulfonyl)-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-p-tolyl-acetamide; 2-[7-(4-Fluoro-benzenesulfonyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-p-tolyl-acetamide; 2-(7-Benzenesulfonyl-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl)-N-(4-methoxy-phenyl)-acetamide; 2-(7-Benzenesulfonyl-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl)-N-(4-ethyl-phenyl)-acetamide; 2-[8-Oxo-7-(toluene-4-sulfonyl)-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-m-tolyl-acetamide; 2-[7-(4-Fluoro-benzenesulfonyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-m-tolyl-acetamide; 2-[8-Oxo-7-(toluene-4-sulfonyl)-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-o-tolyl-acetamide; 2-[7-(4-Fluoro-benzenesulfonyl)-8-oxo-8H-[1,3]dioxolo[4,5-g]quinolin-5-yl]-N-o-tolyl-acetamide; 5-Benzyl-7-(4-fluoro-benzenesulfonyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-Benzyl-7-(4-chloro-benzenesulfonyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Fluoro-benzenesulfonyl)-5-(2-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Isopropyl-benzenesulfonyl)-5-(2-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Chloro-benzenesulfonyl)-5-(2-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(3-Methyl-benzyl)-7-(toluene-4-sulfonyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Chloro-benzenesulfonyl)-5-(3-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Isopropyl-benzenesulfonyl)-5-(4-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Chloro-benzenesulfonyl)-5-(4-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(2-Chloro-benzyl)-7-(toluene-4-sulfonyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(3-Chloro-benzyl)-7-(toluene-4-sulfonyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(4-Chloro-benzyl)-7-(toluene-4-sulfonyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(2-Fluoro-benzyl)-7-(toluene-4-sulfonyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Chloro-benzenesulfonyl)-5-(2-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(3-Fluoro-benzyl)-7-(toluene-4-sulfonyl)-


- 5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(4-Fluoro-benzyl)-7-(4-isopropyl-benzenesulfonyl)-
 5H-[1,3]dioxolo[4,5-g]quinolin-8-one; 5-(3-Methoxy-benzyl)-7-(toluene-4-sulfonyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; 7-(4-Chloro-benzenesulfonyl)-5-(4-methoxy-benzyl)-5H-
 [1,3]dioxolo[4,5-g]quinolin-8-one; 3-Benzoyl-1-benzyl-6-methyl-1H-quinolin-4-one; 3-
 5 Benzoyl-1-benzyl-5,7-dimethoxy-1H-quinolin-4-one; 1-Benzyl-6-methoxy-3-(4-methoxy-
 benzoyl)-1H-quinolin-4-one; ; 1-Benzyl-6-methyl-3-(4-methoxy-benzoyl)-1H-quinolin-4-
 one; 3-(Benzo[1,3]dioxole-5-carbonyl)-1-benzyl-1H-quinolin-4-one; 3-Benzoyl-1-methyl-
 1H-quinolin-4-one; 7-Methyl-3-(4-methylbenzoyl)-1-(3-trifluoromethylbenzyl)-1H-
 [1,8]naphthyridin-4-one; 1-(3-Fluorobenzyl)-7-methyl-3-(4-methylbenzoyl)-1H-
 10 [1,8]naphthyridin-4-one; 7-Methyl-3-(4-methylbenzoyl)-1-(3-methylbenzyl)-1H-
 [1,8]naphthyridin-4-one; 1-(3-Methoxybenzyl)-7-methyl-3-(4-methylbenzoyl)-1H-
 [1,8]naphthyridin-4-one; 7-Methyl-3-(4-methylbenzoyl)-1-(4-methylbenzyl)-1H-
 [1,8]naphthyridin-4-one; 1-(2,5-Dimethylbenzyl)-7-methyl-3-(4-methylbenzoyl)-1H-
 [1,8]naphthyridin-4-one; 1-(3-Chlorobenzyl)-7-methyl-3-(4-methylbenzoyl)-1H-
 15 [1,8]naphthyridin-4-one; 1-(2-Chloro-6-fluorobenzyl)-7-methyl-3-(4-methylbenzoyl)-1H-
 [1,8]naphthyridin-4-one; 1-(4-Fluorobenzyl)-7-methyl-3-(4-methylbenzoyl)-1H-
 [1,8]naphthyridin-4-one; 7-Methyl-3-(4-methylbenzoyl)-1-(2-methylbenzyl)-1H-
 [1,8]naphthyridin-4-one; 1-(4-Chlorobenzyl)-7-methyl-3-(4-methylbenzoyl)-1H-
 [1,8]naphthyridin-4-one; 1-(2-Fluorobenzyl)-7-methyl-3-(4-methylbenzoyl)-1H-
 20 [1,8]naphthyridin-4-one; 1-Benzyl-7-methyl-3-(4-methylbenzoyl)-1H-[1,8]naphthyridin-4-
 one; 7-(3-Aminopyrrolidin-1-yl)-3-benzoyl-1-(2,4-dimethoxybenzyl)-6-fluoro-1H-
 [1,8]naphthyridin-4-one; 3-Benzoyl-7-chloro-1,2-dibenzyl-6-fluoro-1H-[1,8]naphthyridin-4-
 one; 3-Benzoyl-2-benzyl-1-(4-methoxybenzyl)-1H-[1,8]naphthyridin-4-one; 3-Benzoyl-1,2-
 dibenzyl-1H-[1,8]naphthyridin-4-one; 3-Benzoyl-4-hydroxy-1-(4-nitrobenzoyl)-1H-
 25 [1,8]naphthyridin-2-one; 1,3-Dibenzoyl-4-hydroxy-1H-[1,8]naphthyridin-2-one.

Preparation of Compounds

- [0069] Certain compounds of the invention can be prepared following methodology as
 described in Silin, Olexiy V., et al., *Heterocycles* (2004) 63(8): 1883-1890. Compounds can
 also be prepared as shown in the synthetic procedures outlined in the Examples section of this
 30 document. In addition the syntheses of certain intermediate compounds that are useful in the
 preparation of compounds of the invention are described below.

Scheme 1


[0070] Preparation of *tert*-butyl-carbamic acid azidomethyl ester (iii).



- 5 [0071] As shown in Scheme 1, Chloroformate **i** can be combined with *tert*-butyl amine in dichloromethane at lower temperature (e.g., -20 °C to RT) for approximately 1 h to provide carbamate **ii** (see, Step a). Carbamate **ii** when combined with sodium azide in aqueous solution for about 1 day will provide compound **iii** (see, Step b).

Scheme 2

10 [0072] Preparation of 5,6-dimethyl-nicotinoyl chloride hydrochloride (x).



- [0073] As shown in Step a of Scheme 2, 2-butanone **iv** is combined with ethyl formate and sodium methoxide in a mixture of diethyl ether and ethanol at low temperatures (e.g., 10 °C to RT) for 16 h to prepare sodium enolate **v**. Step b shows that pyridinone **vi** can be prepared by combining **v** with cyanoacetamide piperidinium acetate in water and heating the resultant solution at reflux for 4 h. As shown in Step c, pyridinone **vi** can be converted to bromopyridine **vii** upon heating with phosphorus tribromide at 190 °C for 1 h. Dehalogenation of **vii** can be achieved by heating **vii** in a mixture of acetic acid and ethanol in the presence of Zinc metal (e.g., zinc dust) for 1 h to provide the dehalogenated cyano compound **viii**. Hydrolysis of cyanopyridine **viii** can be achieved by heating **viii** in an


aqueous solution of concentrated HCl at reflux for 5 h followed by neutralization of the reaction mixture with a solution of aqueous NaOH to provide carboxylic acid **ix**. The acid **ix** can be further converted to the acid chloride **x** by heating with thionyl chloride in the presence of catalytic amount of DMF at 60 °C for 1 h.

5

Scheme 3

[0074] Preparation of 2-bromomethyl-6-methyl-pyridine (**xii**).

[0075] Bromomethylpyridine **xii** can be prepared following a literature procedure (see, John B. Paine III *J. Het. Chem.* 1987, 351).




10

[0076] As shown in Scheme 3, hydroxymethylpyridine **xi** can be combined with PBr₃ in a dichloromethane solution and stirred at RT for 30 min to provide bromomethylpyridine **xii**.

Scheme 4

[0077] Preparation of 5,6-dimethyl-pyridine-2-carbonyl chloride hydrochloride (**xviii**).




15

[0078] As shown in Step a of Scheme 4, pyridine-N-oxide **xiv** can be prepared by stirring pyridine **xiii** with m-chloroperbenzoic acid in a dichloromethane solution at RT for approximately 10 h. The N-oxide **xiv** oxygen atom can be methylated by using

dimethylsulfate as the alkylating reagent and stirring with **xiv** in a dichloromethane/triethylamine solution for 24 h at RT can provide the methylated compound **xv**. As shown in Step c, the reaction between compound **xv** with KCN in water at elevated temperature (e.g. 60 °C) for 3 hours provided compound cyano product **xvi**. Cyano **xvi** can be hydrolyzed by dissolving the compound in a concentrated HCl solution and heating the resultant solution at reflux for approximately 1 day, and then neutralizing the solution with an aqueous solution of NaOH to provide acid **xvii**. The acid **xvii** can be converted to the acid chloride **xviii** upon heating **xvii** in a solution of thionyl chloride in the presence of a catalytic amount of DMF at 50 °C for 2 hours.

Scheme 5


[0079] Preparation of 2-chloromethyl pyrimidine (**xx**).



[0080] Pyrimidine **xx** can be prepared by stirring hydroxymethyl pyrimidine **xvix** with SOCl₂ at room temperature for 2 h.

Scheme 6


[0081] Preparation of *N*-(6-bromomethyl-pyridin-2-yl)-2,2,2-trifluoro-acetamide (**xxiii**)



[0082] 2,2,2-trifluoro-*N*-(6-methylpyridin-2-yl)-acetamide **xxii** can be prepared from 6-methylpyridin-2-ylamine and trifluoroacetic anhydride in DCM. Radical bromination of **xxii** with *N*-bromosuccinimide and benzoyl peroxide in refluxing carbon tetrachloride affords *N*-(6-bromomethylpyridin-2-yl)-2,2,2-trifluoroacetamide **xxiii**.

Scheme 7


[0083] Preparation of 2-iodo-5,6,7,8-tetrahydro-quinoline (xxvii)



- 5 [0084] 5,6,7,8-tetrahydro-quinolin-2-ol **xxv** can be prepared according to the procedure described by A. I. Meyers and G. Garcia-Munoz in *J. Org. Chem.* **1964** p.1435-38 from 3-(2-oxo-cyclohexyl)-propionitrile **xxiv** and 96% sulfuric acid. Treatment of **xxv** with phosphorus tribromide at 180°C gives 2-bromo-5,6,7,8-tetrahydro-quinoline **xxvi**, which is converted to 2-iodo-5,6,7,8-tetrahydro-quinoline **xxvii** by the action of sodium iodide and trimethylsilyl chloride in acetonitrile in a sealed tube at 130°C.
- 10

Scheme 8


[0085] Preparation of 2-iodo-4,5-dimethyl-pyridine (xxix)



- 15 [0086] 2-iodo-4,5-dimethyl-pyridine **xxix** can be prepared according to the procedure described by T. Kaminski *et al* in *Eur. J. Org. Chem.* **2003** p.3855-60 from 3,4-lutidine **xxviii**, *N,N*-dimethylaminoethanol, *n*-butyllithium in hexanes followed by quenching with iodine in THF.

Scheme 9

20 [0087] Preparation of 2-bromo-6-(1-bromo-ethyl)-pyridine (xxxii)



[0088] 1-(6-Bromo-pyridin-2-yl)-ethanol xxxi can be prepared from 1-(6-bromo-pyridin-2-yl)-ethanone xxx by reduction with sodium borohydride in methanol. The intermediate xxxi is converted to the product xxxii by heating to 80°C in phosphorus tribromide.

B. Compositions

5 [0089] In addition to the compounds provided above, compositions for modulating CCXCKR2 activity in humans and animals will typically contain a pharmaceutical carrier or diluent.

[0090] The term "composition" as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which
10 results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

[0091] The pharmaceutical compositions for the administration of the compounds of this
15 invention may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy and drug delivery. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier
20 or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases.

[0092] The pharmaceutical compositions containing the active ingredient may be in a form
25 suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions and self emulsifications as described in U.S. Patent Application 2002-0012680, hard or soft capsules, syrups, elixirs, solutions, buccal patch, oral gel, chewing gum, chewable tablets, effervescent powder and effervescent tablets. Compositions intended for oral use may be prepared according to any method known to the
30 art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents,

coloring agents, antioxidants and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as cellulose, silicon
5 dioxide, aluminum oxide, calcium carbonate, sodium carbonate, glucose, mannitol, sorbitol, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example PVP, cellulose, PEG, starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated, enterically or otherwise, by
10 known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

15 [0093] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil. Additionally, emulsions can be prepared with a non-water miscible ingredient such as oils
20 and stabilized with surfactants such as mono-diglycerides, PEG esters and the like.

[0094] Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-
propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum
25 acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene
30 sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-

propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

[0095] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil
5 such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

[0096] Dispersible powders and granules suitable for preparation of an aqueous suspension
10 by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

[0097] The pharmaceutical compositions of the invention may also be in the form of oil-in-
15 water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived
20 from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.

[0098] Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a
25 preservative and flavoring and coloring agents. Oral solutions can be prepared in combination with, for example, cyclodextrin, PEG and surfactants.

[0099] The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been
30 mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be

employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

- 5 [0100] The compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.
- 10 Additionally, the compounds can be administered via ocular delivery by means of solutions or ointments. Still further, transdermal delivery of the subject compounds can be accomplished by means of iontophoretic patches and the like. For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention are employed. As used herein, topical application is also meant to include the use
- 15 of mouth washes and gargles.

- [0101] The compounds of this invention may also be coupled a carrier that is a suitable polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore,
- 20 the compounds of the invention may be coupled to a carrier that is a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
- 25 Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stents, tubing, prostheses and the like.

- [0102] In one embodiment, pharmaceutical compositions comprising compounds, pharmaceutically acceptable salts, hydrates or N-oxides thereof having formula I or Ia, as set forth in Table 1 (vide supra) are of particular interest for the present invention. In another
- 30 embodiment, pharmaceutical compositions comprising compounds as set forth in Table 2 (vide infra) are also of particular interest for the present invention.

Table 2

1. 7-(4-Chloro-benzoyl)-5-(3-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
2. 7-(4-Fluoro-benzoyl)-5-(3-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
3. 7-(4-Methyl-benzoyl)-5-(3-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
- 5 4. 5-(3-Fluoro-benzyl)-7-(4-methyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
5. 7-(4-Chloro-benzoyl)-5-(2-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
6. 7-Benzoyl-5-(3-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
7. 7-(3,4-Dimethyl-benzoyl)-5-(3-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
8. 7-(3,4-Dimethyl-benzoyl)-5-(4-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
- 10 9. 7-(3,4-Dimethyl-benzoyl)-5-(4-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
10. 7-(3,4-Dimethyl-benzoyl)-5-(3-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
11. 7-(3,4-Dimethyl-benzoyl)-5-(2-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
12. 5-(4-Methoxy-benzyl)-7-(4-methyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
13. 7-(3,4-Dimethyl-benzoyl)-5-(3-methoxy-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
- 15 one
14. 7-(3,4-Dimethyl-benzoyl)-5-(2-methoxy-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
- one
15. 7-(4-Ethoxy-benzoyl)-5-(3-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
16. 7-(4-Methoxy-benzoyl)-5-(3-methyl-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
- 20 17. 7-(4-Ethoxy-benzoyl)-5-(3-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
18. 5-(4-Chloro-benzyl)-7-(4-ethoxy-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
19. 5-(4-Chloro-benzyl)-7-(4-methoxy-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
20. 5-Benzyl-7-(3,4-dimethyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
21. 5-Benzyl-7-(4-methyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one

C. Methods of Use

[0103] While not wishing to be bound by any particular theory, the compounds and compositions of the present invention are considered to provide a therapeutic effect by inhibiting the binding of SDF-1 and/or I-TAC to the CCXCKR2 receptor. Therefore, the compounds and compositions of the present invention can be used in the treatment or prevention of diseases or disorders in a mammal in which the inhibition of binding of SDF-1 and/or I-TAC to the CCKCR2 receptor would provide a therapeutic effect. Diseases and disorders that can be treated by the compounds or compositions of the present invention include cancer, inflammation, HIV infectivity, progenitor/stem cell disorders, among others. In particular, SDF-1 is known to provide a target for interfering with the development or spread of cancer cells in a mammal, such as a human. Inhibition of the binding of I-TAC to the CCXCKR2 receptor prevents the formation of vascularized tumors. By contacting the compositions described above with a cancer cell that expresses the CCXCKR2 receptor, the response that would otherwise trigger in the cancer cell can be reduced. Accordingly, the present invention is also directed to methods that are useful in the prevention and/or treatment of various disease, including cancer, particularly solid tumor cancers, more particularly breast cancer.

[0104] As determined by radiolabeled SDF-1 binding and I-TAC displacement, CCXCKR2 was preferentially expressed in human transformed cells. Included in Table 3 are those tissue types in which CCXCKR2 was expressed (CCXCKR2⁺) as well as those tissue types in which CCXCKR2 was not expressed (CCXCKR2⁻).

Table 3

CCXCKR2⁺	CCXCKR2⁻
Human Cervical Adenocarcinoma	Normal Mouse Adult Progenitors (c-kit ⁺ & CD34 ⁺ BM derived)
Human Adenocarcinoma, Mammary Gland	Human Acute Lymphoblastic Leukemia, T Cell
Human Burkitt's Lymphoma, B Lymphocyte	Normal Murine Bone Marrow
Human Glioblastoma Multiforme, Brain	Normal Murine Thymus
Human Carcinoma, Prostate	Normal Murine Lung
Murine Lymphoblastic Leukemia, B Lymphocyte	Normal Murine Spleen
Murine Mammary Gland Tumor	Normal Murine Liver
Normal Murine Fetal Liver	Normal Murine PBL
Normal Mouse Brain	Normal Human PBL
Normal Mouse Kidney	Normal Murine Heart
	Normal Murine Pancreas

[0105] In one embodiment, a preferred method of inhibiting the binding of the chemokines SDF-1 and/or I-TAC to a CCXCKR2 receptor includes contacting one or more of the previously mentioned compounds with a cell that expresses the CCXCKR2 receptor for a time sufficient to inhibit the binding of these chemokines to the CCXCKR2 receptor.

Methods of Treating Cancer

[0106] More specifically, the present invention also provides a method of treating cancer. A preferred method of treating cancer, includes administering a therapeutically effective

amount of one or more of the previously mentioned compounds (or salts thereof) to a cancer patient for a time sufficient to treat the cancer.

[0107] For treatment, the compositions of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.

[0108] In addition to primates, such as humans, a variety of other mammals can be treated according to the method of the present invention. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated. However, the method can also be practiced in other species, such as avian species (e.g., chickens).

[0109] Standard *in vivo* assays demonstrating that the compositions of the present invention are useful for treating cancer include those described in Bertolini, F., et al., *Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma*. Blood, No. 1, Vol. 96, pp. 282-87 (1 July 2000); Pengnian, L., *Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2*. Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 8829-34 (July 1998); and Pulaski, B. *Cooperativity of Staphylococcal aureus Enterotoxin B Superantigen, Major Histocompatibility Complex Class II, and CD80 for Immunotherapy of Advanced Spontaneous Metastases in a Clinically Relevant Postoperative Mouse Breast Cancer Model*. Cancer Research, Vol. 60, pp. 2710-15 (May 15, 2000).

[0110] In the treatment or prevention of conditions which require chemokine receptor modulation an appropriate dosage level will generally be about 0.001 to 100 mg per kg patient body weight per day which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.01 to about 25 mg/kg per day; more preferably about 0.05 to about 10 mg/kg per day. A suitable dosage level may be about 0.01 to 25 mg/kg per day, about 0.05 to 10 mg/kg per day, or about 0.1 to 5 mg/kg per day. Within this range the dosage may be 0.005 to 0.05, 0.05 to 0.5 or 0.5 to 5.0 mg/kg per day. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0,

75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

5 [0111] It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, hereditary characteristics, general health, sex and diet of the subject, as well as the mode and time of administration, rate of excretion, drug
10 combination, and the severity of the particular condition for the subject undergoing therapy.

[0112] The compounds and compositions of the present invention can be combined with other compounds and compositions having related utilities to prevent and treat cancer and diseases or conditions associated with CCXCKR2 signaling. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or
15 sequentially with a compound or composition of the present invention. When a compound or composition of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound or composition of the present invention is preferred. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active
20 ingredients or therapeutic agents, in addition to a compound or composition of the present invention. Examples of other therapeutic agents that may be combined with a compound or composition of the present invention, either administered separately or in the same pharmaceutical compositions, include, but are not limited to: cisplatin, paclitaxel, methotrexate, cyclophosphamide, ifosfamide, chlorambucil, carmustine, carboplatin,
25 vincristine, vinblastine, thiotepa, lomustine, semustine, 5-fluorouracil and cytarabine. The weight ratio of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with a second anticancer agent, the weight ratio of the compound of the present
30 invention to the second agent will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.

Methods of Treating Inflammation

[0113] Still further, the compounds and compositions of the present invention are useful for the treatment of inflammation, and can be combined with other compounds and compositions having therapeutic utilities that may require treatment either before, after or simultaneously with the treatment of cancer or inflammation with the present compounds. Accordingly, combination methods and compositions are also a component of the present invention to prevent and treat the condition or disease of interest, such as inflammatory or autoimmune disorders, conditions and diseases, including inflammatory bowel disease, rheumatoid arthritis, osteoarthritis, psoriatic arthritis, polyarticular arthritis, multiple sclerosis, allergic diseases, psoriasis, atopic dermatitis and asthma, and those pathologies noted above.

[0114] For example, in the treatment or prevention of inflammation or autimmunity or for example arthritis associated bone loss, the present compounds and compositions may be used in conjunction with an anti-inflammatory or analgesic agent such as an opiate agonist, a lipoxxygenase inhibitor, such as an inhibitor of 5-lipoxxygenase, a cyclooxygenase inhibitor, such as a cyclooxygenase-2 inhibitor, an interleukin inhibitor, such as an interleukin-1 inhibitor, an NMDA antagonist, an inhibitor of nitric oxide or an inhibitor of the synthesis of nitric oxide, a non steroidal anti-inflammatory agent, or a cytokine-suppressing anti-inflammatory agent, for example with a compound such as acetaminophen, aspirin, codeine, fentanyl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroidal analgesic, sufentanyl, sunlindac, tenidap, and the like. Similarly, the instant compounds and compositions may be administered with an analgesic listed above; a potentiator such as caffeine, an H2 antagonist (*e.g.*, ranitidine), simethicone, aluminum or magnesium hydroxide; a decongestant such as phenylephrine, phenylpropanolamine, pseudoephedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo desoxy ephedrine; an antitussive such as codeine, hydrocodone, caramiphen, carbetapentane, or dextromethorphan; a diuretic; and a sedating or non sedating antihistamine.

[0115] As noted, compounds and compositions of the present invention may be used in combination with other drugs that are used in the treatment, prevention, suppression or amelioration of the diseases or conditions for which compounds and compositions of the present invention are useful. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound or composition of the present invention. When a compound or composition of the present

invention is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound or composition of the present invention is preferred. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients or therapeutic agents, in addition to a compound or composition of the present invention. Examples of other therapeutic agents that may be combined with a compound or composition of the present invention, either administered separately or in the same pharmaceutical compositions, include, but are not limited to: (a) VLA-4 antagonists, (b) corticosteroids, such as beclomethasone, methylprednisolone, betamethasone, prednisone, prednisolone, dexamethasone, fluticasone, hydrocortisone, budesonide, triamcinolone, salmeterol, salmeterol, salbutamol, formeterol; (c) immunosuppressants such as cyclosporine (cyclosporine A, Sandimmune®, Neoral®), tacrolimus (FK-506, Prograf®), rapamycin (sirolimus, Rapamune®) and other FK-506 type immunosuppressants, and mycophenolate, *e.g.*, mycophenolate mofetil (CellCept®); (d) antihistamines (H1-histamine antagonists) such as bromopheniramine, chlorpheniramine, dexchlorpheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, triprolennamine, hydroxyzine, methdilazine, promethazine, trimeprazine, azatadine, cyproheptadine, antazoline, pheniramine, pyrrolamine, astemizole, terfenadine, loratadine, cetirizine, fexofenadine, descarboethoxyloratadine, and the like; (e) non steroidal anti asthmatics (*e.g.*, terbutaline, metaproterenol, fenoterol, isoetharine, albuterol, bitolterol and pirbuterol), theophylline, cromolyn sodium, atropine, ipratropium bromide, leukotriene antagonists (*e.g.*, zafirlukast, montelukast, pranlukast, iralukast, pobilukast and SKB-106,203), leukotriene biosynthesis inhibitors (zileuton, BAY-1005); (f) non steroidal anti-inflammatory agents (NSAIDs) such as propionic acid derivatives (*e.g.*, alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, niroprofen, naproxen, oxaprozin, piroprofen, pranoprofen, suprofen, tiaprofenic acid and tiroxaprofen), acetic acid derivatives (*e.g.*, indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin and zomepirac), fenamic acid derivatives (*e.g.*, flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid), biphenylcarboxylic acid derivatives (*e.g.*, diflunisal and flufenisal), oxicams (*e.g.*, isoxicam, piroxicam, sudoxicam and tenoxicam), salicylates (*e.g.*, acetyl salicylic acid and sulfasalazine) and the pyrazolones (*e.g.*, apazone, bezpiperylon, feprazone, mofebutazone, oxyphenbutazone and phenylbutazone); (g) cyclooxygenase-2 (COX-2) inhibitors such as celecoxib (Celebrex®) and rofecoxib

(Vioxx®); (h) inhibitors of phosphodiesterase type IV (PDE IV); (i) gold compounds such as auranofin and aurothioglucose, (j) etanercept (Enbrel®), (k) antibody therapies such as orthoclone (OKT3), daclizumab (Zenapax®), basiliximab (Simulect®) and infliximab (Remicade®), (l) other antagonists of the chemokine receptors, especially CCR5, CXCR2, CXCR3, CCR2, CCR3, CCR4, CCR7, CX₃CR1 and CXCR6; (m) lubricants or emollients such as petrolatum and lanolin, (n) keratolytic agents (*e.g.*, tazarotene), (o) vitamin D₃ derivatives, *e.g.*, calcipotriene or calcipotriol (Dovonex®), (p) PUVA, (q) anthralin (Drithrocreme®), (r) etretinate (Tegison®) and isotretinoin and (s) multiple sclerosis therapeutic agents such as interferon β -1 β (Betaseron®), interferon (β -1 α) (Avonex®), azathioprine (Imurek®, Imuran®), glatiramer acetate (Capoxone®), a glucocorticoid (*e.g.*, prednisolone) and cyclophosphamide (t) DMARDS such as methotrexate (u) other compounds such as 5-aminosalicylic acid and prodrugs thereof; hydroxychloroquine; D-penicillamine; antimetabolites such as azathioprine, 6-mercaptopurine and methotrexate; DNA synthesis inhibitors such as hydroxyurea and microtubule disrupters such as colchicine.

15 The weight ratio of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with an NSAID the weight ratio of the compound of the present invention to the NSAID will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.

Method of Treating HIV Infectivity

[0116] Still further, the compounds and compositions of the present invention are useful for the (prophylactic, curative or palliative) treatment of HIV infectivity, and can be combined with other compounds and compositions having therapeutic utilities that may require treatment either before, after or simultaneously with the treatment of HIV infectivity with the present compounds.

[0117] In certain aspects, in the treatment of HIV infectivity, an appropriate dosage level will generally be about 0.001 to 100 mg per kg patient body weight per day which can be administered in single or multiple doses. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the

metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

[0118] Included within the scope of the invention are embodiments comprising the co-administration of a compound of the invention with one or more additional therapeutic agents, and compositions containing a compound of the invention along with one or more additional therapeutic agents. Such a combination therapy is especially useful for the prevention and/or treatment of infection by HIV and related retroviruses which may evolve rapidly into strains resistant to any monotherapy. Alternatively, additional therapeutic agents may be desirable to treat diseases and conditions which result from or accompany the disease being treated with the compound of the invention. For example, in the treatment of an HIV or related retroviral infection, it may be desirable to additionally treat opportunistic infections, neoplasms and other conditions which occur as a result of the immuno-compromised state of the patient being treated.

[0119] Preferred combinations of the invention include simultaneous or sequential treatment with a compound of the invention and one or more: (a) reverse transcriptase inhibitors such as abacavir, adefovir, didanosine, lamivudine, stavudine, zalcitabine and zidovudine; (b) non-nucleoside reverse transcriptase inhibitors such as capavirine, delavirdine, efavirenz, and nevirapine; (c) HIV protease inhibitors such as indinavir, nelfinavir, ritonavir, and saquinavir; (d) CCR5 antagonists such as TAK-779 or UK-427,857; (e) CXCR4 antagonists such as AMD-3100; (f) integrase inhibitors, such as L-870,810 or S-1360; (g) inhibitors of viral fusion such as T-20; (h) investigational drugs such as trizivir, KNI-272, amprenavir, GW-33908, FTC, PMPA, MKC-442, MSC-204, MSH-372, DMP450, PNU-140690, ABT-378, KNI-764, DPC-083, TMC-120 or TMC-125; (i) antifungal agents, such as fluconazole, itraconazole or voriconazole; or (j) antibacterial agents, such as azithromycin.

Method of Treating Progenitor/Stem Cell Mobilization Disorders

[0120] Still further, the compounds and compositions of the present invention can be useful for the treatment of progenitor/stem cell differentiation and mobilization disorders using procedures and protocols as described in WO05/000333.

Typical conditions which may be ameliorated or otherwise benefited include hematopoietic disorders, such as aplastic anemia, leukemias, drug-induced

anemias, and hematopoietic deficits from chemotherapy or radiation therapy. Still further, the compounds and compositions of the invention can be used in enhancing the success of transplantation during and following immunosuppressive treatments as well as in effecting more efficient wound healing and treatment of bacterial infections.

5 [0121] In the treatment or prevention of progenitor or stem cell mobilization disorders an appropriate dosage level will generally be about 0.001 to 100 mg per kg patient body weight per day which can be administered in single or multiple doses. The compounds may be administered as a single dose, a dose over time, as in i.v., or transdermal administration, or in multiple doses. The compounds of the invention can also be used in *ex vivo* treatment
10 protocols to prepare cell cultures which are then used to replenish the blood cells of the subject. *Ex vivo* treatment can be conducted on autologous cells harvested from the peripheral blood or bone marrow or from allografts from matched donors.

[0122] The present compounds can be combined with other compounds and compositions having therapeutic utilities that may require treatment either before, after or simultaneously
15 with the treatment of the progenitor/stem cell disorder with the present compounds. Accordingly, combination methods and compositions are also a component of the present invention to prevent and treat the condition or disease of interest.

[0123] In one embodiment, the compounds and pharmaceutical compositions comprising compounds as set forth in Tables 1 and 2 are of particular interest for use in the methods
20 described for the present invention.

IV. Examples

[0124] The following examples are offered to illustrate, but not to limit the claimed invention.

[0125] Reagents and solvents used below can be obtained from commercial sources such as
25 Aldrich Chemical Co. (Milwaukee, Wisconsin, USA). ¹H-NMR spectra were recorded on a Varian Mercury 400 MHz NMR spectrometer. Significant peaks are provided relative to TMS and are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet) and number of protons. Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion (in parenthesis). In the
30 examples, a single m/e value is reported for the M+H (or, as noted, M-H) ion containing the most common atomic isotopes. Isotope patterns correspond to the expected formula in all

cases. Electrospray ionization (ESI) mass spectrometry analysis was conducted on a Hewlett-Packard MSD electrospray mass spectrometer using the HP1100 HPLC for sample delivery. Normally the analyte was dissolved in methanol at 0.1 mg/mL and 1 microlitre was infused with the delivery solvent into the mass spectrometer, which scanned from 100 to 1500 daltons. All compounds could be analyzed in the positive ESI mode, using acetonitrile / water with 1% formic acid as the delivery solvent. The compounds provided below could also be analyzed in the negative ESI mode, using 2 mM NH₄OAc in acetonitrile / water as delivery system.

[0126] The following abbreviations are used in the Examples and throughout the description of the invention: rt, room temperature; HPLC, high pressure liquid chromatography; TFA, trifluoroacetic acid; LC-MSD, liquid chromatograph/mass selective detector; LC-MS, liquid chromatograph/mass spectrometer; Pd₂dba₃, tris(dibenzylideneacetone) dipalladium; THF, tetrahydrofuran; DMF, dimethylformamide or *N,N*-dimethylformamide; DCM, dichloromethane; DMSO, dimethyl sulfoxide; TLC, thin-layer chromatography; KHMDs, potassium hexamethyldisilazane; ES, electrospray; sat., saturated.

[0127] Compounds within the scope of this invention can be synthesized as described below, using a variety of reactions known to the skilled artisan. One skilled in the art will also recognize that alternative methods may be employed to synthesize the target compounds of this invention, and that the approaches described within the body of this document are not exhaustive, but do provide broadly applicable and practical routes to compounds of interest.


[0128] Certain molecules claimed in this patent can exist in different enantiomeric and diastereomeric forms and all such variants of these compounds are claimed.

[0129] The detailed description of the experimental procedures used to synthesize key compounds in this text lead to molecules that are described by the physical data identifying them as well as by the structural depictions associated with them.

[0130] Those skilled in the art will also recognize that during standard work up procedures in organic chemistry, acids and bases are frequently used. Salts of the parent compounds are sometimes produced, if they possess the necessary intrinsic acidity or basicity, during the experimental procedures described within this patent.

Example 1

[0131] Preparation of 1-(6-bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one (4a).



Step 1: Synthesis of 2-(3,4-Dimethyl-benzoyl)-3-phenylamino-acrylic acid methyl ester (2a)

[0132] Crude 2-(3,4-dimethyl-benzoyl)-3-methoxy-acrylic acid methyl ester **1a** (13.7 g, 55.1 mmol) and of aniline (5.12 g, 55.1 mmol) were heated neat at 100 °C for 30 minutes, then cooled down to room temperature and recrystallized from dichloromethane/hexane to yield 7.94 g of 2-(3,4-Dimethyl-benzoyl)-3-phenylamino-acrylic acid methyl ester **2a** as a yellow crystalline solid: LC-MSD, m/z for C₁₉H₁₉NO₃ [M+H]⁺ = 310.4; HPLC retention time: 2.8 min.

Step 2: Synthesis of 3-(3,4-Dimethyl-benzoyl)-1H-quinolin-4-one (3a)

[0133] 2-(3,4-dimethyl-benzoyl)-3-phenylamino-acrylic acid methyl ester **2a** (7.00 g, 22.6 mmol) (prepared as described by Silin, O.V.; et al. Heterocycles, 2004, 63, 1883-90) was heated at 260 °C in 150 mL of diphenyl ether for 6 h, then cooled down and 100 mL of hexane was added to the reaction solution. The mixture was filtered and the solid was washed with hexane to give 5.06 g of 3-(3,4-Dimethyl-benzoyl)-1H-quinolin-4-one **3a** as off-white crystals: LC-MSD, m/z for C₁₈H₁₅NO₂ [M+H]⁺ = 278.4; HPLC retention time: 1.7 min.


Step 3: Synthesis of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one (4a)

[0134] 3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one (1.20 g, 4.32 mmol) **3a** was suspended in 20 mL *N,N*-dimethylformamide followed by the addition of 60% sodium hydride (207 mg, 5.18 mmol). After approximately 5 minutes, 2-bromomethyl-6-methyl-pyridine (1.30 g, 5.18 mmol) was added and the mixture was stirred at rt for 12 hours. Then 100 mL of water was added to the reaction mixture and the precipitate was removed by filtration. Flash

chromatography using 10-80% ethyl acetate in hexane yielded 1.82 g of the product **4a** as white solid: LC-MSD, m/z for $C_{24}H_{19}BrN_2O_2$ $[M+H]^+ = 447.4, 449.4$; HPLC retention time: 2.4 min; 1H NMR (400 MHz, $CDCl_3$): δ 2.3 (s, 3 H), 2.35 (s, 3 H), 5.5 (s, 2H), 6.9-7.0 (m, 1 H), 7.1-7.2 (m, 1 H), 7.3-7.4 (m, 1 H), 7.4-7.55 (m, 3 H), 7.55-7.7 (m, 3 H), 8.3 (s, 1 H), 8.4-8.5 (m, 1 H).

Example 2


[0135] Preparation of 1-cyclohexylmethyl-3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one (**4b**).



[0136] The titled compound was prepared following the procedure described in Step 3 of Example 1. 63 mg (0.23 mmol) of 3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one **3a**, 12 mg (0.30 mmol) of 60 % sodium hydride and 52 mg (0.30 mmol) of cyclohexylmethyl bromide and 0.9 mL *N,N*-dimethylformamide were combined at 90 °C for 5 h. Flash chromatography using 10-75% ethyl acetate in hexane yielded 50 mg of the product **4b** as white solid: LC-MSD, m/z for $C_{25}H_{27}NO_2$ $[M+H]^+ = 374.6$; HPLC retention time: 2.8 min; 1H NMR (400 MHz, $CDCl_3$): δ 1.0-1.3 (m, 6 H), 1.7-1.85 (m, 4 H), 1.9-2.0 (m, 1 H), 2.3 (s, 3 H), 2.35 (s, 3 H), 4.0-4.05 (m, 2H), 7.15-7.2 (m, 1 H), 7.4-7.5 (m, 2 H), 7.5-7.6 (m, 1 H), 7.6 (s, 1 H), 7.65-7.75 (m, 1 H), 8.05 (s, 1 H), 8.45-8.5 (m, 1 H).

Example 3

[0137] Preparation of 3-(3,4-dimethyl-benzoyl)-1-(1H-[1,2,3]triazol-4-ylmethyl)-1H-quinolin-4-one (4d).



Step 1: Synthesis of 3-(3,4-Dimethyl-benzoyl)-1-prop-2-ynyl-1H-quinolin-4-one (4c)


[0138] Compound 4c was prepared following the procedure described in Step 3 of Example 1. briefly described here, 60 mg (0.22 mmol) of 3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one 3a, 10 mg (0.26 mmol) of 60% sodium hydride and 39 mg (0.26 mmol) of 80% propargyl bromide in toluene were combined in 0.5 mL *N,N*-dimethylformamide at and stirred at rt for 2 h. Flash chromatography using 30-100% ethyl acetate in hexane yielded 62 mg of the product 4d as white solid: LC-MSD, *m/z* for C₂₁H₁₇NO₂ [M+H]⁺ = 316.5; HPLC retention time: 2.1 min.

Step 2: Synthesis of 3-(3,4-Dimethyl-benzoyl)-1-(1H-[1,2,3]triazol-4-ylmethyl)-1H-quinolin-4-one (4d)

[0139] 29 mg (0.092 mmol) of 3-(3,4-dimethyl-benzoyl)-1-prop-2-ynyl-1H-quinolin-4-one 4c (prepared as described by Paine, J.B.; *J. Het. Chem.* **1987**, 351), 19 mg (0.11 mmol) of *tert*-butyl-carbamic acid azidomethyl ester, 5.0 mg (0.078 mmol) of copper powder, and 2.0 mg (0.008 mmol) of copper(II) sulfate pentahydrate were combined in a mixture of 0.5 mL *tert*-butanol and 0.2 mL water and stirred at 80 °C for 4 h. Then 70 mg (1.75 mmol) of sodium hydroxide in 1 mL water was added to that mixture and the resultant mixture was stirred at 80 °C for another hour. The mixture was filtered and purified using reverse phase HPLC (mobile phase with a gradient 15-80 % acetonitrile in 50 min). Lyophilization of the HPLC fractions containing purified 4d provided 18 mg of a pale yellow product as the trifluoroacetate salt: LC-MSD, *m/z* for C₂₁H₁₈N₄O₂, [M+H]⁺ = 359.5, HPLC retention time: 1.5 min; ¹H NMR (400 MHz, CDCl₃): δ 2.25 (s, 3 H), 2.3 (s, 3 H), 6.7 (s, 2H), 7.1-7.2 (m, 1 H), 7.4-7.45 (m, 1 H), 7.45-7.5 (m, 2 H), 7.75-7.85 (m, 3 H), 8.4-8.5 (m, 1 H), 8.65 (s, 1 H).

Example 4

[0140] Preparation of 3-(3,4-dimethyl-benzoyl)-1-phenyl-1H-quinolin-4-one (4e).



5 Step 1: Synthesis of 2-(3,4-Dimethyl-benzoyl)-3-diphenylamino-acrylic acid methyl ester (**2b**)


[0141] Compound **2b** was prepared following the procedure described in Step 2 of Example 1 using 1.08 g (4.36 mmol) of the crude 2-(3,4-dimethyl-benzoyl)-3-methoxyacrylic acid a methyl ester and 738 mg (4.36 mmol) of diphenylamine. The crude product
 10 was purified using flash chromatography (0-40% ethyl acetate in hexane) to yield 955 mg of 2-(3,4-dimethyl-benzoyl)-3-diphenylamino-acrylic acid methyl ester **2b** as a yellow crystalline solid: LC-MSD, m/z for C₂₅H₂₄NO₃, [M+H]⁺ = 386.5, retention time: 2.9 min.

Step 2: 3-(3,4-Dimethyl-benzoyl)-1-phenyl-1H-quinolin-4-one (**4e**)

[0142] 2-(3,4-dimethyl-benzoyl)-3-diphenylamino-acrylic acid methyl ester **2b** (450 mg, 1.27 mmol) was heated in 2 mL of polyphosphoric acid at 90 °C for 1 h, then quenched using water/dichloromethane. The organic layer was dried and concentrated to provide the crude product which was purified using flash chromatography (30-100% ethyl acetate in hexane) to
 15 yield 26 mg of 3-(3,4-dimethyl-benzoyl)-1-phenyl-1H-quinolin-4-one **4e** as a dark yellow crystalline solid: LC-MSD, m/z for C₂₄H₁₉NO₂, [M+H]⁺ = 354.1; HPLC retention time: 2.6 min; ¹H NMR (400 MHz, CDCl₃): δ 2.3 (s, 3 H), 2.35 (s, 3 H), 7.0-7.1 (m, 1 H), 7.1-7.2 (m, 1 H), 7.4-7.5 (m, 3 H), 7.5-7.7 (m, 4 H), 7.7 (s, 1 H), 8.2 (s, 1 H), 8.4-8.5 (m, 1 H).
 20

Example 5

[0143] Preparation of 3-(3,4-dimethyl-benzoyl)-1-(2-fluoro-benzyl)-6-trifluoromethyl-1H-quinolin-4-one (4f).



Step 1: Synthesis of 2-(3,4-Dimethyl-benzoyl)-3-(4-trifluoromethyl-phenylamino)-acrylic acid methyl ester (**2c**)

[0144] Compound **2c** was prepared following the procedure described in Step 2 of Example 1 using 598 mg (2.41 mmol) of the crude 2-(3,4-dimethyl-benzoyl)-3-methoxy-acrylic acid methyl ester **1a** and 427 mg (2.65 mmol) of 4-trifluoromethyl-phenylamine. The product **2c** was purified by flash chromatography (0-40% ethyl acetate in hexane) to yield 151 mg of 2-(3,4-dimethyl-benzoyl)-3-(4-trifluoromethyl-phenylamino)-acrylic acid methyl ester as a yellow crystalline solid: LC-MSD, m/z for $C_{20}H_{18}F_3NO_3$ $[M+H]^+ = 378.5$; HPLC retention time: 3.0 min.

Step 2: Synthesis of 3-(3,4-Dimethyl-benzoyl)-6-trifluoromethyl-1H-quinolin-4-one (**3b**)

[0145] 2-(3,4-dimethyl-benzoyl)-3-(4-trifluoromethyl-phenylamino)-acrylic acid methyl ester **2c** (151 mg, 0.40 mmol) was refluxed in 5 mL of nitrobenzene for 3 h, then cooled down and to it was added 10 mL of hexane. The crude product precipitated out of solution and was isolated by filtration. The crude product was washed with hexane to give 115 mg of 3-(3,4-dimethyl-benzoyl)-6-trifluoromethyl-1H-quinolin-4-one as off-white crystals **3b**: LC-MSD, m/z for $C_{19}H_{14}F_3NO_2$, $[M+H]^+ = 346.4$; HPLC retention time: 2.3 min.


Step 3: Synthesis of 3-(3,4-Dimethyl-benzoyl)-1-(2-fluoro-benzyl)-6-trifluoromethyl-1H-quinolin-4-one (**4f**)

[0146] Compound **4f** was prepared following the procedure described in Step 3 of Example 1. Briefly described here, 55 mg (0.16 mmol) of 3-(3,4-dimethyl-benzoyl)-6-trifluoromethyl-1H-quinolin-4-one **3b**, 8 mg (0.21 mmol) of 60% sodium hydride and 40 mg (0.21 mmol) of 2-fluorobenzyl bromide were combined in 0.5 mL *N,N*-dimethylformamide at rt for 16 h.

Flash chromatography of the crude product using 10-80% ethyl acetate in hexane yielded 58 mg of the product **4f** as white solid: LC-MSD, m/z for $C_{26}H_{19}F_4NO_2$ $[M+H]^+ = 454.5$, HPLC retention time: 2.9 min: 1H NMR (400 MHz, $CDCl_3$): δ 2.3 (s, 3 H), 2.35 (s, 3 H), 5.5 (s, 2H), 7.05-7.2 (m, 4 H), 7.3-7.4 (m, 1 H), 7.5-7.6 (m, 2 H), 7.65 (s, 1 H), 7.8-7.85 (m, 1 H), 8.3 (s, 1 H), 8.75-8.8 (m, 1 H).

Example 6

[0147] Preparation of 3-(5,6-dimethyl-pyridine-3-carbonyl)-1-(2-fluoro-benzyl)-1H-quinolin-4-one (4g).



Step 1: Synthesis of 2-(5,6-Dimethyl-pyridine-3-carbonyl)-3-phenylamino-acrylic acid ethyl ester (**2d**)

[0148] 3.31 g (16.0 mmol) of 5,6-dimethyl-nicotinoyl chloride hydrochloride **6a** (prepared as described by Paine, J.B.; *J. Het. Chem.* **1987**, 351) was dissolved in 35 mL of dry tetrahydrofuran and cooled down to -10 °C under nitrogen atmosphere. To the resultant solution was added 1.60 g (40.0 mmol) of 60% sodium hydride and the mixture was stirred for 15 minutes, followed by the addition of 3.06 g (16.0 mmol) of 3-phenylamino-acrylic acid ethyl ester **5a**. The mixture was stirred at -10 °C for 2 hours, followed by the addition of 100 mL of water to the reaction mixture. The product was extracted twice with 100 mL dichloromethane. The combined organic extracts were dried with $MgSO_4$ and concentrated in vacuo. Purification of the crude product using flash chromatography (10-75% ethyl acetate in hexane) yielded 400 mg of 2-(5,6-dimethyl-pyridine-3-carbonyl)-3-phenylamino-acrylic acid ethyl ester **2d** as a yellow solid.

Step 2: Synthesis of 3-(5,6-Dimethyl-pyridine-3-carbonyl)-1H-quinolin-4-one (**3c**)

[0149] Compound **3c** was prepared following the procedure described in Step 2 of Example 1 using 400 mg (1.23 mmol) of 2-(5,6-dimethyl-pyridine-3-carbonyl)-3-phenylamino-acrylic acid ethyl ester **2d**, and 50 mL of diphenyl ether. The reaction time was 1h. Purification of


the crude product by flash chromatography using 60-100% ethyl acetate in hexane followed by 0-25% methanol in ethyl acetate yielded 201 mg of the product **3c** as off-white solid: LC-MSD, m/z for $C_{17}H_{14}N_2O_2$ $[M+H]^+ = 279.4$, HPLC retention time: 0.25 min.

Step 3: Synthesis of 3-(5,6-Dimethyl-pyridine-3-carbonyl)-1-(2-fluoro-benzyl)-1H-quinolin-4-one (**4g**)

[0150] Compound **4g** was prepared following the procedure described in Step 3 of Example 1. 63 mg (0.23 mmol) of 3-(5,6-dimethyl-pyridine-3-carbonyl)-1H-quinolin-4-one **3c**, 11 mg (0.27 mmol) of 60% sodium hydride and 51 mg (0.27 mmol) of 2-fluorobenzyl bromide were combined in 1 mL *N,N*-dimethylformamide at rt for 1 h. The product was purified using reverse phase HPLC, mobile phase with a gradient 10-70% acetonitrile in 50 min. The HPLC fractions containing pure product were combined and the combined solutions was lyophilized with 1 mL of 1 M HCl to give 82 mg of a pale yellow solid **4g** as its HCl salt: LC-MSD, m/z for $C_{24}H_{19}FN_2O_2$ $[M+H]^+ = 387.5$, HPLC retention time: 1.2 min; 1H NMR (400 MHz, $CDCl_3$): δ 2.55 (s, 3 H), 2.9 (s, 3 H), 5.55 (s, 2 H), 7.05-7.2 (m, 3 H), 7.3-7.4 (m, 1 H), 7.45-7.55 (m, 2 H), 7.65-7.75 (m, 1 H), 8.35-8.45 (m, 2 H), 8.6 (s, 1 H), 8.85 (s, 1H).

Example 7

[0151] Preparation of 3-(5,6-dimethyl-pyridine-3-carbonyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one (**4h**).


**3c****4h**

[0152] Compound **4h** was prepared following the procedure described in Step 3 of Example 1. Briefly described here, 65 mg (0.23 mmol) of 3-(5,6-dimethyl-pyridine-3-carbonyl)-1H-quinolin-4-one **3c**, 11 mg (0.28 mmol) of 60% sodium hydride and 52 mg (0.28 mmol) of 2-bromomethyl-6-methyl-pyridine (prepared as described by Paine, J.B.; *J. Het. Chem.* **1987**, 351) in 0.7 mL *N,N*-dimethylformamide were stirred at rt for 2 h. The product was purified using reverse phase HPLC, mobile phase with a gradient 10-70% acetonitrile in

50 min. HPLC fractions containing pure product **4h** were lyophilized to give 41 mg of a white solid as trifluoroacetate salt: LC-MSD, m/z for $C_{24}H_{21}N_3O_2$ $[M+H]^+ = 384.5$, HPLC retention time: 0.4 min; 1H NMR (400 MHz, $CDCl_3$): δ 2.5 (s, 3 H), 2.8 (s, 3 H), 2.85 (s, 3 H), 6.05 (s, 2 H), 7.2-7.3 (m, 1 H), 7.4-7.5 (m, 2 H), 7.5-7.6 (m, 1 H), 7.6-7.7 (m, 1 H), 8.0-8.1 (m, 1 H), 8.3-8.4 (m, 1 H), 8.4 (s, 1 H), 8.7 (s, 1H), 8.9 (s, 1 H).

Example 8

[0153] Preparation of 3-(5,6-dimethyl-pyridine-2-carbonyl)-1-(2-fluoro-benzyl)-1H-quinolin-4-one (4i).



Step 1: 2-(5,6-Dimethyl-pyridine-2-carbonyl)-3-phenylamino-acrylic acid ethyl ester (**2e**)

[0154] Compound **2e** was prepared following the procedure outlined in Step 1 of Example 6 using 2.28 g (11.0 mmol) of 5,6-dimethyl-pyridine-2-carbonyl chloride hydrochloride (prepared as described by Paine, J.B.; *J. Het. Chem.* **1987**, 351), 1.91 g (10.0 mmol) of 3-phenylamino-acrylic acid ethyl ester, 1.08 g (27.0 mmol) of 60% sodium hydride and 25 mL tetrahydrofuran. Flash chromatography using 10-80% ethyl acetate in hexane yielded 575 mg of the product as yellow solid. LC-MSD, m/z for $C_{19}H_{20}N_2O_3$ $[M+H]^+ = 325.5$, HPLC retention time: 1.9 min.

Step 2: 3-(5,6-Dimethyl-pyridine-2-carbonyl)-1H-quinolin-4-one (**3d**)


[0155] Compound **3d** was prepared following the procedure outlined in Step 2 of Example 1 using 575 mg (1.77 mmol) of 2-(5,6-dimethyl-pyridine-3-carbonyl)-3-phenylamino-acrylic acid ethyl ester **2e**, 30 mL of diphenyl ether. The reaction time was 2 h. Flash chromatography using 50-100% ethyl acetate in hexane followed by 0-30% methanol in ethyl acetate yielded 100 mg of the product **3d** as off-white solid: LC-MSD, m/z for $C_{17}H_{14}N_2O_2$ $[M+H]^+ = 279.4$, HPLC retention time: 0.4 min.

Step 3: 3-(5,6-Dimethyl-pyridine-2-carbonyl)-1-(2-fluoro-benzyl)-1H-quinolin-4-one (**4i**)

[0156] Compound **4i** was prepared following the procedure outlined in Step 3 of Example 1. Briefly described here, 32 mg (0.12 mmol) of 3-(5,6-dimethyl-pyridine-2-carbonyl)-1H-quinolin-4-one **3d**, 6 mg (0.14 mmol) of 60% sodium hydride and 26 mg (0.14 mmol) of 2-fluorobenzyl bromide were combined in 0.5 mL *N,N*-dimethylformamide and stirred at rt for 2 h. The product was purified using reverse phase HPLC, mobile phase with a gradient 10-70% acetonitrile in 50 min. The HPLC fractions containing pure product were lyophilized to give 43 mg of a pale yellow solid **4i** as trifluoroacetate salt: LC-MSD, *m/z* for $C_{24}H_{19}FN_2O_2$ $[M+H]^+ = 387.5$, HPLC retention time: 1.8 min; 1H NMR (400 MHz, $CDCl_3$): δ 2.5 (s, 3 H), 2.8 (s, 3 H), 5.7 (s, 2 H), 7.1-7.2 (m, 3 H), 7.3-7.4 (m, 1 H), 7.5-7.6 (m, 1 H), 7.6-7.7 (m, 1 H), 7.7-7.8 (m, 1 H), 8.1-8.2 (m, 1 H), 8.5-8.6 (m, 1 H), 9.05 (s, 1H).

Example 9

[0157] Preparation of 3-(3,4-dimethyl-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-cinnolin-4-one (**9a**).



15

7a**8a****9a**

Step 1: 3-(3,4-Dimethyl-benzoyl)-1H-cinnolin-4-one (**8a**)


[0158] 1.49 g (6.61 mmol) of 3-bromo-1H-cinnolin-4-one **7a** (Prepared as described in U S Patent 4,379,929), 2.48 g (16.5 mmol) of 3,4-dimethylphenylboronic acid, 4.57 g (33.1 mmol) of potassium carbonate and 464 mg (0.661 mmol) of bis(triphenylphosphine)palladium(II) dichloride were stirred in 50 mL of anisole at 150 °C under the atmosphere of carbon monoxide for 3 h. The mixture was cooled down, filtered and concentrated in vacuo. Flash chromatography of the crude product **8a** using 10-80% ethyl acetate in hexane to give 78 mg of the product as off-white solid: LC-MSD, *m/z* for $C_{17}H_{14}N_2O_2$ $[M+H]^+ = 279.1$, HPLC retention time: 1.9 min.

Step 2: 3-(3,4-Dimethyl-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-cinnolin-4-one (**9a**)

[0159] Compound **9a** was prepared following the procedure outlined in Step 3 of Example 1. Briefly described here, 36 mg (0.13 mmol) of 3-(3,4-dimethyl-benzoyl)-1H-cinnolin-4-one **8a**, 7 mg (0.17 mmol) of 60% sodium hydride and 33 mg (0.17 mmol) of 2-bromomethyl-6-methyl-pyridine in 0.7 mL *N,N*-dimethylformamide at rt for 3 h. The product was purified using reverse phase HPLC, mobile phase with a gradient 10-70% acetonitrile in 50 min. The HPLC fractions containing pure product were combined and lyophilized to give 34 mg of a pale yellow solid **9a** as the trifluoroacetate salt: LC-MSD, *m/z* for $C_{24}H_{21}N_3O_2$ $[M+H]^+ = 384.5$, HPLC retention time: 2.3 min; 1H NMR (400 MHz, $CDCl_3$): δ 2.3 (s, 3 H), 2.35 (s, 3 H), 2.85 (s, 3 H), 6.1 (s, 2H), 7.15-7.2 (m, 1 H), 7.25-7.3 (m, 1 H), 7.45-7.55 (m, 2 H), 7.6-7.7 (m, 3 H), 7.7-7.8 (m, 1 H), 8.0-8.1 (m, 1 H), 8.3-8.4 (m, 1 H).

Example 10


[0160] Preparation of 3-(3,4-dimethyl-benzoyl)-1-thiazol-4-ylmethyl-1H-quinolin-4-one (**4j**).



[0161] Compound **4j** was prepared following the procedure outlined in Step 3 of Example 1. Briefly described here, 50 mg (0.18 mmol) of 3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one **3a**, 19 mg (0.47 mmol) of 60% sodium hydride and 40 mg (0.25 mmol) of 4-chloromethyl thiazole hydrochloride were combined in 1 mL *N,N*-dimethylformamide and stirred at 70°C for 2 h. The crude product was purified by flash chromatography using 20-100% ethyl acetate in hexane yielded 54 mg of the product as white solid: LC-MSD, *m/z* for $C_{22}H_{18}N_2O_2S$ $[M+H]^+ = 375.5$; HPLC retention time: 2.1 min; 1H NMR (400 MHz, $CDCl_3$): δ 2.3 (s, 3 H), 2.35 (s, 3 H), 5.6 (s, 2H), 7.1-7.2 (m, 2 H), 7.4-7.5 (m, 1 H), 7.5-7.6 (m, 2 H), 7.6-7.7 (m, 2 H), 8.3 (s, 1 H), 8.45-8.5 (m, 1 H), 8.8-8.85 (m, 1 H).

Example 11


[0162] Preparation of 3-(3,4-dimethyl-benzoyl)-1-pyrimidin-2-ylmethyl-1H-quinolin-4-one (4k).



[0163] Compound 4k was prepared following the procedure outlined in Step 3 of Example 1. Briefly described here, 97 mg (0.35 mmol) of 3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one, 18 mg (0.45 mmol) of 60% sodium hydride and 66 mg (0.51 mmol) of 2-chloromethyl pyrimidine (prepared as described by Paine, J.B.; *J. Het. Chem.* **1987**, 351) were combined in 1 mL *N,N*-dimethylformamide and heated at 80 °C for 2 h. The product was purified using reverse phase HPLC (mobile phase with a gradient 10-50% acetonitrile in 50 min), to give 57 mg of a pale yellow solid 4k as trifluoroacetate salt: LC-MSD, m/z for C₂₃H₁₉N₃O₂ [M+H]⁺ = 370.5, HPLC retention time: 2.4 min; ¹H NMR (400 MHz, CDCl₃): δ 2.3 (s, 3 H), 2.35 (s, 3 H), 5.6 (s, 2 H), 7.15-7.2 (m, 1 H), 7.25-7.3 (m, 1 H), 7.4-7.5 (m, 1 H), 7.5-7.55 (m, 1 H), 7.6-7.7 (m, 3 H), 8.4-8.5 (m, 2 H), 8.7-8.75 (m, 2 H).

Example 12

[0164] Preparation of 3-(3,4-dimethyl-benzoyl)-1-(2-fluoro-benzyl)-2,3-dihydro-1H-quinolin-4-one (4l).




[0165] In 3 mL of anhydrous dimethylformamide was suspended 16 mg (0.4 mmol) of sodium hydride (60%), 86 mg (0.31 mmol) of 3-(3,4-dimethyl-benzoyl)-2,3-dihydro-1H-quinolin-4-one 3a was added and the mixture was stirred at rt. After 30 minutes, 75.6 mg

(0.40 mmol) of 2-fluorobenzylbromide was added and the reaction was stirred at room temperature for 1 hour. The reaction mixture was quenched by the addition of 10 mL of water. The crude product precipitated out were isolated by filtration and purified by flash chromatography to yield 25 mg of colorless solid **4l**: LC-MSD, m/z for C₂₅H₂₀FNO₂

5 [M+H]⁺ = 386.4, [M+2H]⁺ = 387.4; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.526 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.2-2.3 (d, 6 H), 5.7 (s, 2 H), 7.1-7.3 (m, 4 H), 7.3-7.4 (m, 1 H), 7.4-7.5 (m, 2 H), 7.54 (s, 1 H), 7.6-7.66 (d, 1 H), 7.67-7.74 (t, 1 H), 8.2 (d, 1 H), 8.58 (s, 1H).

Example 13


10 [0166] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(3-methyl-benzyl)-2,3-dihydro-1H-quinolin-4-one (**4m**).



[0167] Compound **4m** was prepared following the procedure outlined in Step 3 of Example 1 using 16 mg (0.4 mmol) of sodium hydride (60%), 86 mg (0.31 mmol) of 3-(3, 4-dimethylbenzoyl)-2, 3-dihydro-1H-quinolin-4-one **3a**, 3 mL of anhydrous dimethylformamide, and 74.0 mg (0.40 mmol) of 3-methylbenzylbromide. The crude product **4m** was purified by flash chromatograph to yield 55 mg of colorless solid: LC-MSD, m/z for C₂₆H₂₃NO₂, [M+H]⁺: 382.5, [M+H]⁺: 383.5; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.628 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.3-2.4 (t, 9 H), 5.4 (s, 2 H), 7.0 (d, 2 H), 7.12 (d, 1 H), 7.18 (d, 1 H), 7.25 (d, 1 H), 7.4 (t, 2 H), 7.58 (m, 2 H), 7.65 (s, 1 H), 8.26 (s, 1 H), 7.48 (s, 1 H).

Example 14

[0168] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-pyridin-2-ylmethyl-2,3-dihydro-1*H*-quinolin-4-one (4n).



5

3a

4n


[0169] Compound 4n was prepared following the procedure outlined in Step 3 of Example 1 using 32 mg (0.8 mmol) of sodium hydride (60%), 86 mg (0.31 mmol) of 3-(3,4-dimethylbenzoyl)-2,3-dihydro-1*H*-quinolin-4-one 3 mL of anhydrous dimethylformamide, and 101.2 mg (0.40 mmol) of 2-bromomethylpyridine hydrobromide. The crude product 4n was

10 purified by flash chromatography to yield 32 mg pale yellow solid (29%): LC-MSD, *m/z* for $C_{24}H_{20}N_2O_2$, $[M+H]^+ = 369.4$, $[M+2H]^+ = 370.4$; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.084 min; 1H NMR (400 MHz, $CDCl_3/HCl$): δ 2.32 (d, 6 H), 5.50 (s, 2 H), 7.1 (d, 1 H), 7.2 (d, 1 H), 7.25-7.3 (m, 1 H), 7.3-7.5 (m, 2 H), 7.54-7.62 (m, 2 H), 7.62-7.7 (m, 2 H), 8.34 (s, 1 H), 8.4-8.5 (m, 1 H), 8.62 (d, 1H).

15

Example 15

[0170] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-pyridin-3-ylmethyl-2,3-dihydro-1*H*-quinolin-4-one (4o).



3a


4o

20 [0171] Compound 4o was prepared following the procedure outlined in Step 3 of Example 1 using 32 mg (0.8 mmol) of sodium hydride (60%), 86 mg (0.31 mmol) of 3-(3,4-dimethylbenzoyl)-2,3-dihydro-1*H*-quinolin-4-one 3a, 3 mL of anhydrous dimethylformamide, and 101.2 mg (0.40 mmol) of 3-bromomethylpyridine hydrobromide. The crude product was

purified by flash chromatography to yield 29 mg of pale yellow solid **4o**: LC-MSD, m/z for $C_{24}H_{20}N_2O_2$, $[M+H]^+ = 369.4$, $[M+2H]^+ = 370.4$; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 1.436 min; 1H NMR (400 MHz, $CDCl_3/HCl$): δ 2.30 (d, 6 H), 5.4 (s, 2 H), 7.17 (d, 1 H), 7.26-7.32 (m, 2 H), 7.40 (t, 1 H), 7.52-7.64 (m, 3 H),
 5 8.27 (s, 1 H), 8.46 (d, 1 H), 8.58-8.64 (m, 2 H).

Example 16

[0172] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-pyridin-3-ylmethyl-2,3-dihydro-1*H*-quinolin-4-one (**4p**).




10

[0173] Compound **4p** was prepared following the procedure outlined in Step 3 of Example 1 using 32 mg (0.8 mmol) of sodium hydride (60%), 86 mg (0.31 mmol) of 3-(3,4-dimethylbenzoyl)-2,3-dihydro-1*H*-quinolin-4-one **3a**, 3 mL of anhydrous dimethylformamide, and 101.2 mg (0.40 mmol) of 4-bromomethylpyridine hydrobromide. The crude product was
 15 purified by flash chromatography to yield 27 mg of yellowish solid **4p**: LC-MSD, m/z for $C_{24}H_{20}N_2O_2$, $[M+H]^+ = 369.4$, $[M+2H]^+ = 370.4$; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 1.334 min; 1H NMR (400 MHz, $CDCl_3/HCl$): δ 2.30 (d, 6 H), 5.4 (s, 2 H), 7.10 (d, 1 H), 7.16-7.22 (m, 2 H), 7.42 (t, 1 H), 7.52-7.66 (m, 3 H), 8.26 (d, 1 H), 8.48 (m, 1 H), 8.58-8.64 (m, 2 H).

Example 17


[0174] Preparation of 1-(2-Fluoro-benzyl)-3-(pyridine-4-carbonyl)-1*H*-quinolin-4-one (4q).



[0175] Compound **4q** was prepared following the procedure outlined in Step 3 of Example 1 using 15.6 mg (0.39 mmol) of sodium hydride (60%), 75 mg (0.30 mmol) of 3-(pyridine-4-carbonyl)-1*H*-quinolin-4-one **3d**, 3 mL of anhydrous dimethylformamide, and 73.7 mg (0.39 mmol) of 2-fluorobenzylbromide. The crude product was purified by flash chromatograph to yield 27 mg of pale yellow solid **4q**: LC-MSD, *m/z* for C₂₂H₁₅FN₂O₂ [M+H]⁺ = 359.4, [M+2H]⁺ = 360.4; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 1.444 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 5.50 (s, 2 H), 7.06 (t, 1 H), 7.12 (t, 1 H), 7.17 (t, 1 H), 7.35 (m, 1 H), 7.4-7.5 (m, 2 H), 7.54-7.68 (m, 2 H), 7.62-7.68 (m, 1 H), 8.40-8.46 (m, 1 H), 8.48 (s, 1 H), 8.70-8.78 (m, 2 H).

Example 18

[0176] Preparation of 3-(Pyridine-4-carbonyl)-1-pyridin-2-ylmethyl-1*H*-quinolin-4-one (4r).




[0177] Compound **4r** was prepared following the procedure outlined in Step 3 of Example 1 using 21 mg (0.52 mmol) of sodium hydride (60%), 100 mg (0.40 mmol) of 3-(pyridine-4-carbonyl)-1*H*-quinolin-4-one **3d**, 3 mL of anhydrous dimethylformamide, and 131 mg (0.52 mmol) of 2-bromomethylpyridine hydrobromide. The crude product was purified by preparative HPLC to yield 27 mg of pale yellow solid **4r**: LC-MSD, *m/z* for C₂₁H₁₅N₃O₂,

[M+H]⁺ = 342.5, [M+2H]⁺ = 343.5; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 0.321 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 5.55 (s, 2 H), 7.16 (d, 1 H), 7.26-7.3 (m, 1 H), 7.40-7.48 (m, 2 H), 7.57-7.62 (m, 3 H), 7.68 (t, 1 H), 8.42 (d, 1 H), 8.54 (s, 1 H), 8.61 (d, 2 H), 8.72-8.76 (m, 2 H).

5

Example 19

[0178] Preparation of 1-(3-Methyl-benzyl)-3-(pyridine-4-carbonyl)-1*H*-quinolin-4-one (4s).




10

15

[0179] Compound 4s was prepared following the procedure outlined in Step 3 of Example 1 using 21 mg (0.52 mmol) of sodium hydride (60%), 100 mg (0.40 mmol) of 3-(pyridine-4-carbonyl)-1*H*-quinolin-4-one **3d**, 3 mL of anhydrous dimethylformamide, and 74.3 mg (0.52 mmol) of 3-methylbenzylbromide. The crude product was purified by flash chromatograph to yield 55 mg of pale yellow solid: LC-MSD, m/z for C₂₃H₁₈N₂O₂, [M+H]⁺ = 355.4, [M+2H]⁺ = 356.4; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 1.770 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.35 (s, 3 H), 5.42 (s, 2 H), 7.01 (d, 2 H), 7.16 (d, 1 H), 7.24-7.3 (m, 1 H), 7.41-7.47 (t, 2 H), 7.56-7.66 (m, 3 H), 8.43-8.48 (m, 2 H), 8.73-8.77 (m, 2 H).

Example 20


[0180] Preparation of 3-Benzoyl-1-(3-methyl-benzyl)-1*H*-quinolin-4-one (4t).



- 5 [0181] Compound 4t was prepared following the procedure outlined in Step 3 of Example 1 using 16 mg (0.4 mmol) of sodium hydride (60%), 75 mg (0.31 mmol) of 3-benzoyl-2,3-dihydro-1*H*-quinolin-4-one 3e, 3 mL of anhydrous dimethylformamide, 75.6 mg (0.40 mmol) of 3-methylbenzylbromide. The crude product 4t was purified by flash chromatography to yield 45 mg of colorless solid: LC-MSD, *m/z* for C₂₄H₁₉NO₂, [M+H]⁺ = 354.4, [M+2H]⁺ = 355.4; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.146 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.35 (s, 3 H), 5.38 (s, 2 H), 7.00 (d, 2 H), 7.33 (d, 1 H), 7.22-7.26 (m, 1 H), 7.36-7.45 (m, 4 H), 7.50-7.60 (m, 2 H), 7.82-7.86 (m, 2 H), 8.31 (s, 1 H), 8.44-8.48 (m, 1 H).

Example 21

15 [0182] Preparation of 3-Benzoyl-1-(2-fluoro-benzyl)-1*H*-quinolin-4-one (4u).




- 20 [0183] Compound 4u was prepared following the procedure outlined in Step 3 of Example 1 using 16 mg (0.4 mmol) of sodium hydride (60%), 75 mg (0.31 mmol) of 3-benzoyl-2,3-dihydro-1*H*-quinolin-4-one, 3 mL of anhydrous dimethylformamide, and 74 mg (0.40 mmol) of 2-fluorobenzylbromide. The crude product was purified by flash chromatography to yield 42 mg of a colorless solid 4u: LC-MSD, *m/z* for C₂₃H₁₆FNO₂, [M+H]⁺ = 358.4, [M+2H]⁺ =

359.4; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.291 min; ^1H NMR (400 MHz, CDCl_3/HCl): δ 5.42 (s, 2 H), 7.00-7.20 (m, 3 H), 7.28-7.46 (m, 5 H), 7.51 (t, 1 H), 7.61 (t, 1 H), 7.78-7.86 (m, 2 H), 8.32 (d, 1 H), 8.46 (m, 1 H).

Example 22


- 5 [0184] Preparation of 7-(3,4-Dimethyl-benzoyl)-2,2-difluoro-5-(2-fluoro-benzyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one (4v).



- 10 [0185] Compound 4v was prepared following the procedure outlined in Step 3 of Example 1 using 10.4 mg (0.26 mmol) of sodium hydride (60%), 71 mg (0.20 mmol) of 7-(3,4-dimethyl-benzoyl)-2,2-difluoro-5H-[1,3]dioxolo[4,5-g]quinolin-8-one, 3 mL of anhydrous dimethylformamide, and 49.1 mg (0.26 mmol) of 2-fluorobenzylbromide. The crude product was purified by flash chromatography to yield 29 mg of 4v as a colorless solid: Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.922 min;
- 15 LC-MSD, m/z for $\text{C}_{24}\text{H}_{18}\text{F}_3\text{NO}_4$, $[\text{M}+\text{H}]^+ = 466.4$, $[\text{M}+2\text{H}]^+ = 467.4$; ^1H NMR (400 MHz, CDCl_3/HCl): δ 2.2-2.4 (d, 6 H), 5.40 (s, 2 H), 7.02-7.10 (m, 2 H), 7.12-7.22 (m, 3H), 7.34-7.42 (m, 1 H), 7.52-7.57 (d, 1 H), 7.62 (s, 1 H), 8.10 (s, 1 H), 8.24 (s, 1 H).

Example 23


[0186] Preparation of 3-(3-Methyl-benzoyl)-1-pyridin-2-ylmethyl-1*H*-quinolin-4-one (4w).



[0187] Compound **4w** was prepared following the procedure outlined in Step 3 of Example 1 using 52 mg (1.3 mmol) of sodium hydride (60%), 132 mg (0.5 mmol) of 3-(3-methylbenzoyl)-2,3-dihydro-1*H*-quinolin-4-one **3g**, 3 mL of anhydrous dimethylformamide, and 164 mg (0.65 mmol) of 2-bromomethylpyridine hydrobromide. The crude product was purified by flash chromatography to yield 55 mg of a pale yellow solid **4w**: Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 1.913 min; LC-MSD, *m/z* for C₂₃H₁₈N₂O₂, [M+H]⁺ = 355.4, [M+2H]⁺ = 356.4; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.40 (s, 3 H), 5.50 (s, 2 H), 7.12 (d, 1 H), 7.22-7.35 (m, 3 H), 7.38-7.46 (m, 2 H), 7.56-7.68 (m, 4 H), 8.56 (s, 1 H), 8.46 (d, 1 H), 8.62 (d, 1 H).

Example 24

[0188] Preparation of 1-(2-Fluoro-benzyl)-3-(3-methyl-benzoyl)-1*H*-quinolin-4-one (4x).




[0189] Compound **4x** was prepared following the procedure outlined in Step 3 of Example 1 using 26 mg (0.65 mmol) of sodium hydride (60%), 132 mg (0.50 mmol) of 3-(3-methylbenzoyl)-2,3-dihydro-1*H*-quinolin-4-one, 3 mL of anhydrous dimethylformamide, and 123 mg (0.65 mmol) of 2-fluorobenzylbromide. The crude product was purified by flash chromatography to yield 85 mg of a colorless solid **4x**: LC-MSD, *m/z* for C₂₄H₁₈FNO₂,

[M+H]⁺ = 372.4, [M+2H]⁺ = 373.4; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.687 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.40 (s, 3 H), 5.42 (s, 2 H), 7.02-7.18 (m, 3 H), 7.28-7.36 (m, 3 H), 7.36-7.42 (m, 2 H), 7.58-7.66 (m, 3 H), 8.31 (s, 1 H), 8.43-8.47 (m, 1 H).

5

Example 25


[0190] **Preparation of 3-(3-Methyl-benzoyl)-1-(3-methyl-benzyl)-1*H*-quinolin-4-one (4y).**



- 10 [0191] Compound 4y was prepared following the procedure outlined in Step 3 of Example 1 using 26 mg (0.65 mmol) of sodium hydride (60%), 132 mg (0.50 mmol) of 3-(3-methylbenzoyl)-2,3-dihydro-1*H*-quinolin-4-one, 3 mL of anhydrous dimethylformamide, and 120 mg (0.65 mmol) of 3-methylbenzylbromide. The crude product was purified by flash chromatography to yield 92 mg of a colorless solid 4y: LC-MSD, m/z for C₂₅H₂₁NO₂,
- 15 [M+H]⁺ = 368.5, [M+2H]⁺ = 369.5; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.586 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.37 (s, 3 H), 2.42 (s, 3 H), 5.39 (s, 2 H), 7.01 (d, 2 H), 7.15 (d, 1 H), 7.22-7.44 (m, 5 H), 7.55-7.58 (m, 3 H), 8.29 (s, 1 H), 8.47 (d, 1 H).

Example 26


[0192] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1*H*-quinolin-4-one (4z).



[0193] Compound **4z** was prepared following the procedure outlined in Step 3 of Example 1 using 15.6 mg (0.39 mmol) of sodium hydride (60%), 83.2 mg (0.30 mmol) of 3-(3,4-dimethylbenzoyl)-2,3-dihydro-1*H*-quinolin-4-one, 3 mL of anhydrous dimethylformamide, and 73.0 mg (0.39 mmol) of 3-methylbenzylbromide. The crude product was purified by flash chromatography to yield 61 mg of a colorless solid **4z**: LC-MSD, *m/z* for C₂₅H₂₂N₂O₂, [M+H]⁺ = 383.4, [M+2H]⁺ = 384.4; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.484 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.32 (d, 6 H), 2.58 (s, 3 H), 5.42 (s, 2 H), 6.83 (d, 1 H), 7.08 (d, 1 H), 7.16 (d, 1 H), 7.36-7.43 (m, 2 H), 7.48-7.60 (m, 3 H), 7.64 (s, 1 H), 8.31 (s, 1 H), 8.46 (d, 1 H).

Example 27

[0194] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-phenethyl-1*H*-quinolin-4-one (4aa).




[0195] Compound **4aa** was prepared following the procedure outlined in Step 3 of Example 1 using 26 mg (0.65 mmol) of sodium hydride (60%), 138.6 mg (0.50 mmol) of 3-(3,4-dimethylbenzoyl)-2,3-dihydro-1*H*-quinolin-4-one **3a**, 3 mL of anhydrous dimethylformamide, and 120.3 mg (0.65 mmol) of phenethylbromide. The crude product was purified by flash chromatograph to yield 44 mg of a colorless solid **4aa**: LC-MSD, *m/z*

for $C_{26}H_{23}NO_2$, $[M+H]^+ = 382.5$, $[M+2H]^+ = 383.5$; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.551 min; 1H NMR (400 MHz, $CDCl_3/HCl$): δ 2.30 (d, 6 H), 3.20 (t, 2 H), 4.40 (t, 3 H), 7.08 (d, 2 H), 7.13 (d, 1 H), 7.20-7.32 (m, 3 H), 7.38-7.47 (m, 2 H), 7.53-7.58 (d, 2 H), 7.73 (t, 1 H), 7.80 (s, 1 H), 8.48 (d, 1 H).

Example 28


[0196] Preparation of 1-(5-Chloro-[1,2,3]thiadiazol-4-ylmethyl)-3-(3,4-dimethylbenzoyl)-1H-quinolin-4-one (4bb).



[0197] In 3 mL of anhydrous dimethylformamide was suspended 26 mg (0.65 mmol) of sodium hydride (60%), and to it was added 138.7 mg (0.50 mmol) of 3-(3,4-dimethylbenzoyl)-2,3-dihydro-1H-quinolin-4-one **3a**. The mixture was stirred at rt for 30 min. 110 mg (0.65 mmol) of 5-chloro-4-chloromethyl-1,2,3-thodiazole was added to the reaction mixture and the reaction solution was stirred at 80 °C for 3 hour. The reaction solution was quenched by the addition of 10 mL of water. The crude product **4bb** precipitated out of solution and was isolated by filtration. Purification of the crude product by flash chromatograph provided 25 mg of the product **4bb** as a colorless solid: LC-MSD, m/z for $C_{21}H_{16}ClN_3O_2S$, $[M+H]^+ = 410.4$, $[M+2H]^+ = 411.4$; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.308 min; 1H NMR (400 MHz, $CDCl_3/HCl$): δ 2.32 (d, 6 H), 5.72 (s, 2 H), 7.17 (d, 1 H), 7.42 (t, 1 H), 7.55 (d, 1 H), 7.62 (d, 1 H), 7.67 (t, 1 H), 7.77 (d, 1 H), 8.42-8.48 (m, 2 H).

Example 29

[0198] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(5-methyl-isoxazol-3-ylmethyl)-1H-quinolin-4-one (4cc).




5
10
15
20

[0199] 26 mg (0.65 mmol) of sodium hydride (60%) was suspended in 3 mL of anhydrous dimethylformamide and to it was added 138.7 mg (0.50 mmol) of 3-(3,4-dimethyl-benzoyl)-2,3-dihydro-1H-quinolin-4-one **3a** and the resultant mixture was stirred at rt for 30 min. Then 77.4 mg (0.65 mmol) of 3-chloromethyl-1,2,4-oxadiazole was added to the reaction solution and the mixture was stirred at 80 °C for 1 h. The reaction solution was quenched by the addition of 10 mL of water. The crude product precipitated out of solution and was isolated by filtration. Purification of the crude product by flash chromatography provided 55 mg of **4cc** as a colorless solid: LC-MSD, m/z for C₂₃H₂₀N₂O₃, [M+H]⁺ = 373.4, [M+2H]⁺ = 374.4; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.639 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.30 (d, 6 H), 2.36 (s, 3 H), 5.38 (s, 2 H), 5.90 (s, 1 H), 7.15 (d, 1 H), 7.42 (t, 1 H), 7.50-7.68 (m, 4 H), 8.27 (s, 1 H), 8.44 (d, 1 H).

Example 30

[0200] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(5-methyl-isoxazol-3-ylmethyl)-1H-quinolin-4-one (4dd).




[0201] 26 mg (0.65 mmol) of sodium hydride (60%) was suspended in 3 mL of anhydrous dimethylformamide and to it was added 138.7 mg (0.50 mmol) of 3-(3,4-dimethyl-benzoyl)-2,3-dihydro-1H-quinolin-4-one **3a** and the mixture was stirred at rt for 30 min. Then 86 mg

(0.65 mmol) of 3-chloromethyl-5-methylisoxazole was added and the reaction mixture was stirred at 80 °C for 3 hour. The reaction solution was quenched by the addition of 10 mL of water. The crude product precipitated out of solution and was isolated by filtration.

Purification of the crude product by flash chromatography provided 52 mg of a colorless solid **4dd**: LC-MSD, m/z for C₂₁H₁₇N₃O₃, [M+H]⁺ = 359.4, [M+2H]⁺ = 360.4; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.002 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.28 (d, 6 H), 5.52 (s, 2 H), 7.17 (d, 1 H), 7.42 (t, 1 H), 7.55-7.70 (m, 4 H), 8.34 (s, 1 H), 8.42 (d, 1 H), 8.72 (s, 1 H).

Example 31


[0202] Preparation of 1-(2-Fluoro-benzyl)-3-(2-methyl-pyridine-4-carbonyl)-1H-quinolin-4-one (4ee).



[0203] Compound **4ee** was prepared following the procedure outlined in Step 3 of Example 1 using 10.4 mg (0.26 mmol) of sodium hydride (60%), 53 mg (0.20 mmol) of 3-(2-methylpyridine-4-carbonyl)-1H-quinolin-4-one **3h**, 3 mL of anhydrous dimethylformamide, and 49 mg (0.26 mmol) of 2-fluorobenzylbromide. The crude product **4ee** was purified by flash chromatography to yield 21 mg of a colorless solid **4ee**: LC-MSD, m/z for C₂₃H₁₇FN₂O₂, [M+H]⁺ = 373.5, [M+2H]⁺ = 374.5; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 1.296 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.60 (s, 3 H), 5.43 (s, 2 H), 7.02-7.20 (m, 3 H), 7.32-7.40 (m, 2 H), 7.40-7.47 (m, 3 H), 7.64 (t, 1 H), 8.44 (m, 2 H), 8.60 (d, 1 H).

Example 32


[0204] Preparation of 3-(2-Methyl-pyridine-4-carbonyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one (4ff).



[0205] Compound 4ff was prepared following the procedure outlined in Step 3 of Example 1 using 10.4 mg (0.26 mmol) of sodium hydride (60%), 53 mg (0.20 mmol) of 3-(2-methyl-pyridine-4-carbonyl)-1H-quinolin-4-one 3h, 3 mL of anhydrous dimethylformamide, and 48.7 mg (0.26 mmol) of 2-bromomethyl-6-methyl-pyridine. The crude product was purified by preparative HPLC to yield 15 mg of colorless solid 4ff: LC-MSD, m/z for C₂₃H₁₉N₃O₂, [M+H]⁺ = 370.5, [M+2H]⁺ = 371.5; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 1.976 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.57 (s, 3 H), 2.61 (s, 3 H), 5.43 (s, 2 H), 6.87 (d, 1 H), 7.10 (d, 1 H), 7.32-7.48 (m, 4 H), 7.53 (t, 1 H), 7.59 (t, 1 H), 8.41 (d, 1 H), 8.49 (d, 1 H), 8.59 (d, 1 H).

Example 33

[0206] Preparation of 1-(3-Methyl-benzyl)-3-(2-methyl-pyridine-4-carbonyl)-1H-quinolin-4-one (4gg).




[0207] Compound 4gg was prepared following the procedure outlined in Step 3 of Example 1 using 10.4 mg (0.26 mmol) of sodium hydride (60%), 53 mg (0.20 mmol) of 3-(2-methyl-

pyridine-4-carbonyl)-1*H*-quinolin-4-one **3h**, 3 mL of anhydrous dimethylformamide, and 48 mg (0.26 mmol) of 3-methylbenzylbromide. The crude product was purified by preparative HPLC to yield 27 mg of a colorless solid **4gg**: LC-MSD, *m/z* for C₂₄H₂₀N₂O₂, [M+H]⁺ = 369.5, [M+2H]⁺ = 370.5; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 1.605 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.35 (s, 3 H), 2.61 (s, 3 H), 5.40 (s, 2 H), 7.00 (d, 2 H), 7.15 (d, 1 H), 7.25 (t, 1 H), 7.35 (d, 1 H), 7.39-7.46 (m, 3 H), 7.60 (t, 1 H), 8.40-8.46 (m, 2 H), 8.60 (d, 1 H).

Example 34


[0208] Preparation of 1-(3-Methyl-benzyl)-3-(pyridine-3-carbonyl)-1*H*-quinolin-4-one (**4hh**).



[0209] Compound **4hh** was prepared following the procedure outlined in Step 3 of Example 1 using 16 mg (0.40 mmol) of sodium hydride (60%), 75 mg (0.30 mmol) of 3-(pyridine-3-carbonyl)-1*H*-quinolin-4-one, 3 mL of anhydrous dimethylformamide, and 74.0 mg (0.4 mmol) of 3-methylbenzylbromide. The crude product was purified by flash chromatography to yield 35 mg of **4hh** as a colorless solid: LC-MSD, *m/z* for C₂₃H₁₈N₂O₂, [M+H]⁺ = 355.4, [M+2H]⁺ = 356.4; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 1.710 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.36 (s, 3 H), 5.41 (s, 2 H), 7.00 (d, 2 H), 7.12-7.28 (m, 2 H), 7.34-7.45 (m, 3 H), 7.60 (m, 1 H), 8.09 (m, 1 H), 8.42-8.46 (m, 2 H), 8.71 (m, 2 H), 8.99 (s, 1 H).

Example 35


[0210] Preparation of 1-(2-Fluoro-benzyl)-3-(pyridine-3-carbonyl)-1H-quinolin-4-one (4ii).



[0211] Compound **4ii** was prepared following the procedure outlined in Step 3 of Example 1 using 16 mg (0.40 mmol) of sodium hydride (60%), 75 mg (0.30 mmol) of 3-(pyridine-3-carbonyl)-1H-quinolin-4-one, 3 mL of anhydrous dimethylformamide, and 75.6 mg (0.4 mmol) of 2-fluorobenzylbromide. The crude product was purified by flash chromatography to yield 35 mg of a colorless solid **4ii**: LC-MSD, m/z for C₂₂H₁₅FN₂O₂, [M+H]⁺ = 359.4, [M+2H]⁺ = 360.4; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 1.432 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 5.46 (s, 2 H), 7.02-7.20 (m, 3 H), 7.32-7.38 (m, 2 H), 7.40-7.46 (m, 2 H), 7.64 (t, 1 H), 8.08 (d, 1 H), 8.45 (d, 2 H), 8.71 (d, 1 H), 8.98 (s, 1 H).

Example 36

[0212] Preparation of 1-(6-Methyl-pyridin-2-ylmethyl)-3-(pyridine-3-carbonyl)-1H-quinolin-4-one (4jj).



[0213] Compound **4p** was prepared following the procedure outlined in Step 3 of Example 1 using 16 mg (0.40 mmol) of sodium hydride (60%), 75 mg (0.30 mmol) of 3-(pyridine-3-carbonyl)-1H-quinolin-4-one, 3 mL of anhydrous dimethylformamide, and 74.9 mg (0.4

mmol) of 2-bromomethyl-6-methyl-pyridine. The crude product was purified by flash chromatography to yield 55 mg of **4jj** as a colorless solid: LC-MSD, m/z for $C_{23}H_{17}N_3O_2$, $[M+H]^+ = 356.4$, $[M+2H]^+ = 357.4$; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 0.355 min; 1H NMR (400 MHz, $CDCl_3/HCl$): δ 2.56 (s, 3 H), 5.44 (s, 2 H), 6.87 (d, 1 H), 7.10 (d, 1 H), 7.34-7.46 (m, 3 H), 7.52 (t, 1 H), 7.58 (t, 1 H), 8.08 (m, 1 H), 8.43 (d, 1 H), 8.49 (s, 1 H), 8.71 (d, 1 H), 8.99 (s, 1 H).

Example 37


[0214] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(2-trifluoromethyl-benzyl)-1H-quinolin-4-one (**4kk**).

**3a****4kk**

[0215] Compound **4kk** was prepared following the procedure outlined in Step 3 of Example 1 using 26 mg (0.65 mmol) of sodium hydride (60%), 138.6 mg (0.50 mmol) of 3-(3,4-Dimethyl-benzoyl)-2,3-dihydro-1H-quinolin-4-one **3a**, 3 mL of anhydrous dimethylformamide, and 155.4 mg (0.65 mmol) of 2-trifluoromethylbenzylbromide. The crude product was purified by flash chromatography to yield 96 mg of **4kk** as a colorless solid: LC-MSD, m/z for $C_{26}H_{20}F_3NO_2$, $[M+H]^+ = 436.5$, $[M+2H]^+ = 437.5$; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.709 min; 1H NMR (400 MHz, $CDCl_3/HCl$): δ 2.32 (d, 6 H), 5.60 (s, 2 H), 6.92 (m, 1 H), 7.17 (t, 2 H), 7.39-7.47 (m, 3 H), 7.54-7.60 (m, 2 H), 7.65 (s, 1 H), 7.79 (m, 1 H), 8.22 (s, 1 H), 8.50 (m, 1 H).

Example 38


[0216] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(3-fluoro-pyridin-2-ylmethyl)-1H-quinolin-4-one (4II).



[0217] Compound 4II was prepared following the procedure outlined in Step 3 of Example 1 using 26 mg (0.65 mmol) of sodium hydride (60%), 138.6 mg (0.50 mmol) of 3-(3,4-Dimethyl-benzoyl)-2,3-dihydro-1H-quinolin-4-one 3a, 3 mL of anhydrous dimethylformamide, and 123.5 mg (0.65 mmol) of 2-bromomethyl-3-fluoro-pyridine. The crude product was purified by flash chromatography to yield 96 mg of 4II as a colorless solid: LC-MSD, m/z for C₂₄H₁₉FN₂O₂, [M+H]⁺ = 387.5, [M+2H]⁺ = 388.5; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.192 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.30 (d, 6 H), 5.56 (s, 2 H), 7.17 (d, 1 H), 7.31 (m, 1 H), 7.38 (t, 1 H), 7.46 (t, 1 H), 7.56-7.70 (m, 4 H), 8.35-8.42 (m, 2 H), 8.42-8.47 (m, 1 H).

Example 39

[0218] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(6-oxazol-2-yl-pyridin-2-ylmethyl)-1H-quinolin-4-one (4mm).




[0219] 90 mg (0.2 mmol) of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one, 143 mg (0.40 mmol) of 2-tri-*t*-butylstannyloxazole, 23 mg (0.02 mmol) of tetrakis(triphenylphosphine)palladium were dissolved in 2 mL of anhydrous tetrahydrofuran. The resultant mixture was stirred at 75 °C for 18 h. The reaction solution

was quenched by pouring into a container having 20 mL of water. The crude product precipitated out of solution and was isolated by filtration. The crude product was purified by flash chromatography to yield 16 mg of **4nn** as a colorless solid: LC-MSD, m/z for $C_{27}H_{21}N_3O_3$, $[M+H]^+ = 436.5$, $[M+2H]^+ = 437.5$; Reverse phase HPLC(gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.136 min; 1H NMR (400 MHz, $CDCl_3/HCl$): δ 2.35 (d, 6 H), 5.62 (s, 2 H), 7.06 (d, 1 H), 7.19 (d, 1 H), 7.35-7.44 (m, 3 H), 7.54-7.62 (m, 2 H), 7.66 (s, 1 H), 7.78 (t, 1 H), 7.84 (d, 1 H), 8.08 (d, 1 H), 8.34 (s, 1 H), 8.48 (d, 1 H).

Example 40


[0220] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(6-pyrimidin-5-yl-pyridin-2-ylmethyl)-1H-quinolin-4-one (**4oo**).



[0221] 90 mg (0.2 mmol) of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one **4mm**, 50 mg (0.40 mmol) of pyrimidin-5-boronic acid, 18.3 mg (0.02 mmol) of $Pd_2(dba)_3$, 21 mg (0.08 mmol) of triphenylphosphine were dissolved in 2 mL of tetrahydrofuran. To the resultant solution was added 0.5 mL (1.0 mmol) of 2N Na_2CO_3 aqueous solution and the mixture was stirred at 75 °C for 18 h. The reaction mixture was quenched by pouring into a container having 20 mL of water. The crude product precipitated out of solution and was isolated by filtration. The crude product **4oo** was purified by flash chromatography to yield 14 mg of colorless a solid: LC-MSD, m/z for $C_{28}H_{22}N_4O_2$, $[M+H]^+ = 447.5$, $[M+2H]^+ = 448.5$; Reverse phase HPLC (gradient acetonitrile 0.1% TFA 20-95% in 4 min) retention time = 2.055 min; 1H NMR (400 MHz, $CDCl_3/HCl$): δ 2.35 (d, 6 H), 5.56 (s, 2 H), 7.17 (d, 1 H), 7.36-7.48 (m, 2 H), 7.52-7.66 (m, 3 H), 7.72 (d, 1 H), 7.81 (t, 1 H), 8.37 (s, 1 H), 8.42-8.50 (m, 1 H), 9.22-9.32 (m, 3 H).

Example 41


[0222] Preparation of 1-(6-Amino-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-isoquinolin-4-one (4pp).



[0223] 16 mg (0.4 mmol) of sodium hydride (60%) was suspended in 3 mL of anhydrous dimethylformamide. 86 mg (0.31 mmol) of 3-(3,4-dimethyl-benzoyl)-2,3-dihydro-1H-quinolin-4-one 3a was added and the mixture was stirred at rt for 30 min. To the resultant mixture was added 34 mg (0.12 mmol) of (6-bromomethyl-pyridin-2-yl)-carbamic acid tert-butyl ester and the reaction solution was stirred at room temperature for 1 hour. The reaction solution was quenched upon the addition of 100 mL of water. The mixture was extracted with 100 mL of chloroform (2x) and the combined organic layer was dried over anhydrous MgSO₄ and evaporated in vacuo. The crude product was dissolved in 2 mL of dichloromethane and 0.3 mL of trifluoroacetic acid was added. The mixture was stirred at room temperature for 1 hour followed by the addition of 10 mL of saturated NaHCO₃ aqueous solution. The mixture was extracted with 50 mL of chloroform (2x). The combined organic layer was dried over anhydrous MgSO₄ and evaporated in vacuo. The crude product 4pp was purified by preparative HPLC to yield 4 mg of a colorless solid: LC-MSD, m/z for C₂₄H₂₁N₃O₂, [M+H]⁺ = 374.5, [M+2H]⁺ = 385.5; Reverse phase HPLC (gradient acetonitrile with 0.1% TFA 20-95% in 4 min) retention time = 1.902 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.32 (d, 6 H), 4.50 (s, 2 H), 5.26 (s, 2 H), 6.42 (d, 2 H), 7.18 (d, 1 H), 7.30-7.50 (m, 3 H), 7.58 (t, 2 H), 7.62 (s, 1 H), 8.24 (d, 1 H), 8.46 (d, 1 H).

Example 42

[0224] Preparation of N-{6-[3-(3,4-Dimethyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridin-2-yl}-acetamide (**4qq**).



5

[0225] 8 mg (0.021 mmol) of 1-(6-amino-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-isoquinolin-4-one **4pp** was dissolved in 2 mL of dichloromethane. To the resultant solution was added 10 mg (0.13 mmol) of acetyl chloride and 15 mg (0.15 mmol) of triethylamine and the reaction mixture was stirred for 1 h followed by the addition of 30 mL of water to quench the reaction. The reaction solution was extracted with 30 mL of chloroform (2x) and the combined organic layer was dried over anhydrous MgSO₄ and evaporated in vacuo. The crude product **4qq** was purified by preparative HPLC to yield 4 mg of **4qq** as a colorless solid: LC-MSD, m/z for C₂₆H₂₃N₃O₃ [M+H]⁺ = 426.5, [M+2H]⁺ = 427.5; Reverse phase HPLC (gradient acetonitrile with 0.1% TFA 20-95% in 4 min) retention time = 2.038 min; ¹H NMR (400 MHz, CDCl₃/HCl): δ 2.20 (s, 3 H), 2.34 (d, 6 H), 5.32 (s, 2 H), 6.94 (d, 1 H), 7.18 (d, 1 H), 7.32-7.43 (m, 2 H), 7.54-7.60 (m, 2 H), 7.62-7.72 (m, 2 H), 8.20 (s, 1 H), 8.14 (d, 1 H), 8.30 (s, 1 H), 8.47 (d, 1 H).


10

15

Example 43

[0226] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(2-fluoro-benzyl)-1H-1[1,6]naphthyridin-4-one (**11a**).

20



Step 1: 3-(3,4-Dimethyl-benzoyl)-1H-[1,6]naphthyridin-4-one (**10a**)


[0227] 273 g (0.88 mmol) of 2-(3,4-Dimethyl-benzoyl)-3-(pyridine-4-ylamino)-acrylic acid methyl ester **2f** was dissolved in 30 mL of diphenyl ether and the resultant solution was heated at 250 °C. After 2.5 h, the reaction solution was cooled to room temperature and diluted with 50 mL of hexane. The crude product precipitated out of solution and was isolated by filtration. The crude product was purified by washing with hexane to yield 119 mg of 3-(3,4-Dimethyl-benzoyl)-1H-[1,6]naphthyridin-4-one **10a** as white crystals.

Step 2: 3-(3,4-Dimethyl-benzoyl)-1-(2-fluoro-benzyl)-1H-1[1,6]naphthyridin-4-one (**11a**)

[0228] 8.0 mg (.32 mmol) of 60 % sodium hydride was added to a mixture of 0.045 g (.162 mmol) of 3-(3,4-Dimethyl-benzoyl)-1H-[1,6]naphthyridin-4-one **10a** in 0.5 mL of *N,N*-dimethylformamide and the resultant solution was stirred at rt for 5 min. Then 23.4 µL (.194 mmol) of 2-fluorobenzyl bromide was added to the solution and the reaction mixture was stirred for 2.5 h at room temperature. The reaction solution was quenched upon the addition of water. The crude product **11a** was purified on the reverse phase HPLC (with a C18 column, gradient of 20-70% acetonitrile with 0.1% TFA) to yield 40.8 mg of 3-(3,4-Dimethyl-benzoyl)-1-(2-fluoro-benzyl)-1H-1[1,6]naphthyridin-4-one **11a** as a white crystalline solid: LC-MSD, *m/z* for: C₂₄H₁₉FN₂O₂, [M+H] = 387.5; Reverse phase HPLC gradient, 20-95% acetonitrile with 0.1% TFA in 4 minutes, retention time = 2.1 min; ¹H NMR (400 MHz, CDCl₃): δ 9.40 (1H, s), 8.80 (1H, m), 8.56 (1H, m), 7.93 (1H, m), 7.64 (1H, m), 7.59 (1H, m), 7.41 (2H, m), 7.23 (3H, m) 5.59 (2H, s), 2.36 (3H, s), 2.32 (3H, s).

Example 44

[0229] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(3-methyl-benzyl)-1H-1[1,6]naphthyridin-4-one (**11b**).




[0230] Compound **11a** was prepared following the procedure outlined in Step 3 of Example 1 using 0.045 g (0.162 mmol) of 3-(3,4-Dimethyl-benzoyl)-1H-[1,6]naphthyridin-4-one **10a**, 8.0 mg (0.32 mmol) of 60% sodium hydride, 26.2 µL (0.30 mmol) of 3-methylbenzyl

bromide, and 0.5 mL *N,N*-dimethylformamide. The reaction time was 3 h. Purification of the crude product by reverse phase HPLC using 20-70% acetonitrile yielded 13 mg of 3-(3,4-Dimethyl-benzoyl)-1-(3-methyl-benzyl)-1H-1[1,6]naphthyridin-4-one **11b** as white solid: LC-MSD, *m/z* for $C_{25}H_{22}N_2O_2$, $[M+H] = 383.5$; Reverse phase HPLC gradient, 20-95% acetonitrile with 0.1% TFA in 4 minutes, retention time = 2.3 min; 1H NMR (400 MHz, $CDCl_3$): δ 9.43 (1H, s), 8.67 (1H, m), 8.56 (1H, m), 7.81 (1H, m), 7.64 (1H, m), 7.60 (1H, m), 7.26 (2H, m), 7.17 (2H, m), 7.31 (1H, m), 5.57 (2H, s), 2.34 (9H, m).

Example 45


[0231] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(2-fluoro-3-methyl-benzyl)-1H-1-quinolin-4-one (**4rr**).



[0232] Compound **4rr** was prepared following the procedure outlined in Step 3 of Example 1 using 0.100 g (0.361 mmol) of 3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one **3a**, 17.3 mg (0.721 mmol) of 60% sodium hydride and 87.9 mg (0.433 mmol) of 2-fluoro-3-methylbenzyl bromide, and 0.7 mL *N,N*-dimethylformamide. The reaction mixture was stirred for 3 h. The crude product was washed with dichloromethane to yield 56.4 mg of 3-(3,4-Dimethyl-benzoyl)-1-(2-fluoro-3-methyl-benzyl)-1H-1-quinolin-4-one **4rr** as a yellow solid: LC-MSD, *m/z* for $C_{26}H_{22}FNO_2$, $[M+H] = 400.5$; Reverse phase HPLC gradient, 20-95% acetonitrile with 0.1% TFA in 4 minutes, retention time = 2.6 min; 1H NMR (400 MHz, $CDCl_3$): δ 8.57 (1H, s), 8.19 (1H, m), 7.71 (1H, m), 7.63 (1H, m), 7.54 (1H, s), 7.47 (1H, m), 7.42 (1H, m), 7.22 (2H, m), 7.02 (1H, m), 6.98 (1H, m), 5.68 (2H, s), 2.29 (3H, s), 2.49 (6H, m).

Example 46

[0233] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(2,6-dimethyl-benzyl)-1H-1-quinolin-4-one (4ss).




5

[0234] Compound 4ss was prepared following the procedure outlined in Step 3 of Example 1 using 0.100 g (0.361 mmol) of 3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one 3a, 17.3 mg (0.721 mmol) of 60% sodium hydride and 86.2 mg (0.433 mmol) of 2-Bromomethyl-1,3-dimethyl-benzene (prepared according to literature procedures: Soloshonok, V. A. *et al.*, *Tetrahedron* **2001**, 57, 6375-6382.), and 0.7 mL *N,N*-dimethylformamide. The reaction solution was stirred at room temperature for 2 h. Purification of the crude product by reverse phase HPLC using 20-70% acetonitrile followed by neutralization with aqueous saturated sodium bicarbonate provided 98 mg of 3-(3,4-Dimethyl-benzoyl)-1-(2,6-dimethyl-benzyl)-1H-1-quinolin-4-one 4ss as a white solid: LC-MSD, *m/z* for C₂₇H₂₅NO₂, [M+H] = 396.5; Reverse phase HPLC gradient, 20-95% acetonitrile with 0.1% TFA in 4 minutes, retention time = 2.9 min; ¹H NMR (400 MHz, CDCl₃): δ 8.54 (1H, m), 7.79 (2H, m), 7.57 (1H, s), 7.50 (2H, m), 7.43 (1H, m), 7.22 (1H, m), 7.13 (2H, m), 7.09 (1H, m), 5.27 (2H, s), 2.28-2.24 (12H, m).

10

15

[0235] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-6-fluoro-1H-quinolin-4-one (4tt).




[0238] To a solution of 0.050 g (0.169 mmol) of 3-(3,4-dimethyl-benzoyl)-6-fluoro-1H-quinolin-4-one **4tt** in 1.0 mL of tetrahydrofuran was added 0.4 mL (0.5 M in toluene, .203 mmol) of potassium hexamethyldisilazide and the reaction solution was stirred for 5 min, followed by the addition of 50.9 mg (0.203 mmol) of 2-bromo-6-bromomethyl-pyridine in 0.5 ml of tetrahydrofuran. The resultant solution was stirred at 60 °C for 3 h. The reaction solution was quenched by the addition of water and the aqueous phase was extracted with 3 x

5 mL of ether. The combined organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo to yield 58 mg of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-6-fluoro-1H-quinolin-4-one **4tt** as a yellow solid: LC-MSD, m/z for $C_{24}H_{18}BrFN_2O_2$, $[M+H] = 465.4, 466.5, 467.4, 468.4$; Reverse phase HPLC gradient, 20-95% acetonitrile with 0.1% TFA in 4 minutes, retention time = 2.8 min; 1H NMR (400 MHz, $CDCl_3$): δ 8.27 (1H, s), 8.12 (1H, m), 7.64 (1H, s), 7.56 (1H, m), 7.51 (1H, m), 7.47 (1H, m), 7.40-7.34 (2H, m), 7.19 (1H, m), 7.00 (1H, m), 5.46 (2H, s), 2.32 (3H, s), 2.31 (3H, s).

Example 48


[0239] Preparation of 3-(3,4-Dimethyl-benzoyl)-6-fluoro-1-(3-methyl-benzyl)-1H-quinolin-4-one (**4uu**).

**3j****4uu**

[0240] Compound **4uu** was prepared following the procedure outlined in Step 3 of Example 1. Briefly described here, 0.050 g (0.169 mmol) of 3-(3,4-dimethyl-benzoyl)-6-fluoro-1H-quinolin-4-one **3j**, 0.4 mL of potassium hexamethyldisilazide (0.5 M in toluene, 0.203 mmol) and 37.6 mg (0.203 mmol) of 3-methylbenzyl bromide were combined in 1.5 mL of tetrahydrofuran and heated at 60 °C for 3 h. Purification of the crude product using flash chromatography (30-50% ethyl acetate in hexane) yielded 52.2 mg of 3-(3,4-dimethyl-benzoyl)-6-fluoro-1-(3-methyl-benzyl)-1H-quinolin-4-one as a white solid **4uu**: LC-MSD, m/z for $C_{26}H_{22}FNO_2$, $[M+H] = 400.5$; Reverse phase HPLC gradient, 20-95% acetonitrile with 0.1% TFA in 4 minutes, retention time = 2.9 min; 1H NMR (400 MHz, $CDCl_3$): δ 8.26 (1H, s), 8.11 (1H, m), 7.64 (1H, s), 7.56 (1H, m), 7.38 (1H, m), 7.32-7.23 (2H, m), 7.18 (1H, m), 7.15 (1H, m), 6.97 (2H, m), 5.37 (2H, s), 2.33 (3H, s), 2.32 (3H, s), 2.31 (3H, s).

Example 49

[0241] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-7-fluoro-1H-quinolin-4-one (4vv).



Step 1: 2-(3,4-Dimethyl-benzoyl)-3-(3-fluoro-phenylamino)-acrylic acid methyl ester (**2h**)

[0242] Compound **2h** was prepared following the procedure described in Step 1 of Example 1 using from 2 g (8.06 mmol) of crude 2-(3,4-Dimethyl-benzoyl)-3-methoxyacrylic acid methyl ester **1a** and 0.806 g (7.26 mmol) 3-fluoroaniline. The crude product **2h** was purified by recrystallization with dichloromethane/hexane to yield 1.19 g of 2-(3,4-Dimethyl-benzoyl)-3-(3-fluoro-phenylamino)-acrylic acid methyl ester as a brown solid.

Step 2: 3-(3,4-dimethyl-benzoyl)-7-fluoro-1H-quinolin-4-one (**3k**)

[0243] Compound **3k** was prepared following the procedure described in Step 2 of Example 5 using 1.19 g (3.64 mmol) of 2-(3,4-Dimethyl-benzoyl)-3-(3-fluoro-phenylamino)-acrylic acid methyl ester **2h** and 30 mL of diphenyl ether to yield 0.858 g of 3-(3,4-dimethyl-benzoyl)-7-fluoro-1H-quinolin-4-one **3k** as a brown solid.


Step 3: 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-7-fluoro-1H-quinolin-4-one (**4vv**)

[0244] Compound **4vv** was prepared following the procedure described in Step 3 of Example 1 using 0.050 g (0.169 mmol) of 3-(3,4-dimethyl-benzoyl)-7-fluoro-1H-quinolin-4-one **3k**, 0.4 mL of potassium hexamethyldisilazide (0.5 M in toluene, .203 mmol) and 50.9 mg (0.203 mmol) of 2-bromo-6-bromomethyl-pyridine in 1.5 mL of tetrahydrofuran and heating the reaction solution at 60 °C for 24 h. The crude product was purified by flash chromatography using 10-80 % ethyl acetate in hexane to yield 37.8 mg of 3-(3,4-Dimethyl-benzoyl)-7-fluoro-1-(3-methyl-benzyl)-1H-quinolin-4-one **4vv** as a white solid: LC-MSD, m/z for C₂₄H₁₈BrFN₂O₂ [M+H]: 465.4, 466.5, 467.4, 468.4; Reverse phase HPLC gradient, 20-95 % acetonitrile with 0.1% TFA in 4 minutes, retention time = 2.8 min; ¹H NMR (400

MHz, CDCl₃): δ 8.47 (1H, m), 8.23 (1H, s), 7.64 (1H, s), 7.56 (1H, m), 7.53 (1H, m), 7.47 (1H, m), 7.18 (1H, m), 7.12 (1H, m), 7.05-7.02 (2H, m), 5.39 (2H, s), 2.32 (3H, s), 2.31 (3H, s).

Example 50


5 [0245] Preparation of 1-(6-bromo-pyridin-2-ylmethyl)-3-(5,6-dimethyl-pyridine-2-carbonyl)-1H-quinolin-4-one (4ww).



[0246] Compound 4ww was prepared following the procedure described in Step 3 of Example using 45 mg (0.16 mmol) of 3-(5,6-dimethyl-pyridine-2-carbonyl)-1H-quinolin-4-one 3d, 8 mg (0.21 mmol) of 60 % sodium hydride and 53 mg (0.21 mmol) of 2-bromo-6-bromomethyl-pyridine in 0.7 mL *N,N*-dimethylformamide and stirring the reaction mixture at rt for 2 h. The product was purified using reverse phase HPLC (mobile phase with a gradient 10-50% acetonitrile in 50 min). The HPLC fractions containing pure product were combined, evaporated under vacuum and neutralized using methanolic ammonia and purified by flash chromatography (using 30-100% ethyl acetate in hexane) to give 18 mg of a pale yellow solid: LC-MSD, *m/z* for C₂₃H₁₈BrN₃O₂ [M+H]⁺: 448.4, 450.4; Reverse phase HPLC gradient, 20-95% acetonitrile with 0.1% TFA in 4 minutes, retention time = 2.1 min; ¹H NMR (400 MHz, CDCl₃): δ 2.35 (s, 3 H), 2.5 (s, 3 H), 5.5 (s, 2 H), 7.0-7.1 (m, 1 H), 7.3-7.35 (m, 1 H), 7.35-7.4 (m, 1 H), 7.4-7.6 (m, 4 H), 7.6-7.7 (m, 1 H), 8.4-8.45 (m, 1 H), 8.5 (s, 1 H).

Example 51

[0247] Preparation of 3-(3,4-dimethyl-benzoyl)-1-(6-trifluoromethyl-pyridin-2-ylmethyl)-1H-quinolin-4-one (4xx).



5

3a**4xx**


[0248] Compound **4xx** was prepared following the procedure described in Step 3 of Example 1 using 55 mg (0.20 mmol) of 3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one, 10 mg (0.26 mmol) of 60% sodium hydride and 62 mg (0.26 mmol) of 2-bromomethyl-6-trifluoromethyl-pyridine, and 1.7 mL *N,N*-dimethylformamide and stirring the reaction mixture for 6 h at rt. The crude product was purified by flash chromatography using 20-75% ethyl acetate in hexane yielded to provide 45 mg of the product as white solid: LC-MSD, *m/z* for $C_{25}H_{19}F_3N_2O_2$ $[M+H]^+$: 437.3; Reverse phase HPLC gradient, 20-95% acetonitrile with 0.1% TFA in 4 minutes, retention time = 2.8 min; 1H NMR (400 MHz, $CDCl_3$): δ 2.25 (s, 3 H), 2.3 (s, 3 H), 5.6 (s, 2H), 7.1-7.2 (m, 1 H), 7.2-7.3 (m, 1 H), 7.3-7.4 (m, 2 H), 7.5-7.65 (m, 4 H), 7.8-7.9 (m, 1 H), 8.35 (s, 1 H), 8.4-8.5 (m, 1 H).

10

15

Example 52

[0249] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-[1,5]naphthyridin-4-one



Step 1: 2-(3,4-Dimethyl-benzoyl)-3-(pyridin-3-ylamino)-acrylic acid methyl ester

[0250] 1 g (4.02 mmol) of the crude 2-(3,4-Dimethyl-benzoyl)-3-methoxy-acrylic acid methyl ester and 0.38 g (4.02 mmol) of 3-aminopyridine were heated neat at 100 °C for 2 h. The product crystallized upon cooling the reaction to rt to yield 1.12 g of 2-(3,4-Dimethyl-benzoyl)-3-(pyridin-3-ylamino)-acrylic acid methyl ester as brown crystalline solid.

Step 2: 3-(3,4-Dimethyl-benzoyl)-1H-[1,5]naphthyridin-4-one

[0251] 1.12 g (3.61 mmol) of 2-(3,4-Dimethyl-benzoyl)-3-(pyridin-3-ylamino)-acrylic acid methyl ester was dissolved in 30 mL of diphenyl ether and the solution was heated at 250 °C. After 2.5 h the solution was cooled to rt and 50 mL of hexane was added. The mixture was filtered and the solid washed with hexane to yield 0.67 g of 3-(3,4-Dimethyl-benzoyl)-1H-[1,5]naphthyridin-4-one as a brown solid.


Step 3: 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-[1,5]naphthyridin-4-one

[0252] To a solution of 0.060 g (0.216 mmol) of 3-(3,4-Dimethyl-benzoyl)-1H-[1,5]naphthyridin-4-one in 2.0 mL of N,N-dimethylformamide was added 10.4 mg (0.259 mmol, 60% dispersion in oil) of sodium hydride and the reaction was stirred for 5 min. 65 mg (0.259 mmol) of 2-bromo-6-bromomethyl-pyridine was added and the reaction was stirred at room temperature for 3 h. Water was added and the solid collected by filtration. The crude brown solid was purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to yield 11.8 mg of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-[1,5]naphthyridin-4-one as an off white solid.

LC-MSD, m/z for C₂₃H₁₈BrN₃O₂ [M+H]: 448.06 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.2 min

Example 53

[0253] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,5]naphthyridin-4-one




[0254] Experimental conditions analogous to those described for Step 3 of Example 1 were used with 0.100 g (0.359 mmol) of 3-(3,4-Dimethyl-benzoyl)-1H-[1,5]naphthyridin-4-one, 17.2 mg (0.431 mmol, 60% dispersion in oil) of sodium hydride, 80.2 mg (0.431 mmol) of 2-methyl-6-bromomethyl-pyridine and 3.5 mL of N,N dimethylformamide. The crude brown solid was purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to yield 61.7 mg of 3-(3,4-Dimethyl-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,5]naphthyridin-4-one as an off white solid. LC-MSD, m/z for C₂₄H₂₁N₃O₂ [M+H]: 384.2 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 1.8 min

10

Example 54

[0255] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-7-methyl-1H-[1,8]naphthyridin-4-one



Step 1: 2-(3,4-Dimethyl-benzoyl)-3-(6-methyl-pyridin-2-ylamino)-acrylic acid methyl ester

[0256] Experimental conditions analogous to those described for Step 1 of Example 1 were used with 0.50 g (2.01 mmol) of the crude 2-(3,4-Dimethyl-benzoyl)-3-methoxy-acrylic acid methyl ester and 0.22 g (2.01 mmol) of 2-amino-6-picoline to yield 1.12 g of 2-(3,4-Dimethyl-benzoyl)-3-(6-methyl-pyridin-2-ylamino)-acrylic acid methyl ester as brown crystalline solid.

Step 2: 3-(3,4-Dimethyl-benzoyl)-7-methyl-1H-[1,8]naphthyridin-4-one

[0257] Experimental conditions analogous to those described for Step 2 of Example 1 were used with 0.59 g (1.82 mmol) of 2-(3,4-Dimethyl-benzoyl)-3-(6-methyl-pyridin-2-ylamino)-acrylic acid methyl ester in 30 mL of diphenyl ether to yield 0.33 g of 3-(3,4-Dimethyl-benzoyl)-7-methyl-1H-[1,8]naphthyridin-4-one as a brown solid.


Step 3: 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-7-methyl-1H-[1,8]naphthyridin-4-one

[0258] Experimental conditions analogous to those described for Step 3 of Example 1 were used with 0.100 g (0.342 mmol) of 3-(3,4-Dimethyl-benzoyl)-7-methyl-1H-

5 [1,8]naphthyridin-4-one, 16.4 mg (0.410 mmol, 60% dispersion in oil) of sodium hydride, 0.103 g (0.410 mmol) of 2-bromo-6-bromomethyl-pyridine and 3.5 mL of N,N-dimethylformamide. The crude brown solid was purified on the reverse phase HPLC with a C18 column, gradient of 20-70% acetonitrile -0.1% TFA to yield 29.5 mg of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-7-methyl-1H-[1,8]naphthyridin-4-one as an off
10 white solid. LC-MSD, m/z for $C_{24}H_{20}BrN_3O_2$ [M+H]: 463.07 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.7 min

Example 55

[0259] Preparation of 3-(3,4-Dimethyl-benzoyl)-7-methyl-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,8]naphthyridin-4-one




15

[0260] Experimental conditions analogous to those described for Step 3 of Example 1 were used with 0.100 g (0.342 mmol) of 3-(3,4-Dimethyl-benzoyl)-7-methyl-1H-

[1,8]naphthyridin-4-one, 16.4 mg (0.410 mmol, 60% dispersion in oil) of sodium hydride, 76.3 mg (0.410 mmol) of 2-methyl-6-bromomethyl-pyridine and 3.5 mL of
20 N,N-dimethylformamide. The crude brown solid was purified by flash column chromatography using 30-100% ethyl acetate in hexane to yield 38 mg of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-7-methyl-1H-[1,8]naphthyridin-4-one as an off white solid. LC-MSD, m/z for $C_{25}H_{23}N_3O_2$ [M+H]: 398.2 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.3 min

Example 56

[0261] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-6,8-dimethyl-1H-[1,7]naphthyridin-4-one



5 Step 1: 3-(3,4-Dimethyl-benzoyl)-6,8-dimethyl-1H-[1,7]naphthyridin-4-one


[0262] 0.50 g (2.01 mmol) of 2-(3,4-Dimethyl-benzoyl)-3-methoxy-acrylic acid methyl ester and 0.25 g (2.01 mmol) of 2,6-Dimethyl-pyridin-3-ylamine were heated at 100 °C for two hours. After cooling to room temperature 30 mL of diphenyl ether was added and heated at 250 °C for two hours. The reaction was allowed to cool to room temperature and hexane
10 was added. The brown precipitate was collected by filtration to yield 45 mg of 3-(3,4-Dimethyl-benzoyl)-6,8-dimethyl-1H-[1,7]naphthyridin-4-one.

Step 2: 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-6,8-dimethyl-1H-[1,7]naphthyridin-4-one

[0263] Experimental conditions analogous to described for Step 3 of Example 1 were used
15 with 42 mg (0.137 mmol) of 3-(3,4-Dimethyl-benzoyl)-6,8-dimethyl-1H-[1,7]naphthyridin-4-one, 6 mg (0.165 mmol, 60% dispersion in oil) of sodium hydride, 41.3 mg (0.165 mmol) of 2-bromo-6-bromomethyl-pyridine and 1.5 mL of N,N-dimethylformamide. The crude brown solid was purified by flash column chromatography using 30-100% ethyl acetate in hexane to yield 7.9 mg of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-6,8-dimethyl-1H-
20 [1,7]naphthyridin-4-one as an off white solid. LC-MSD, m/z for C₂₅H₂₂BrN₃O₂ [M+H]: 477.37 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.9 min

Example 57

[0264] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-8-methyl-1H-[1,5]naphthyridin-4-one
25




Step 1: 3-(3,4-Dimethyl-benzoyl)-8-methyl-1H-[1,5]naphthyridin-4-one

[0265] Experimental conditions analogous to those described for Step 1 of Example 1 were used with 0.50 g (2.01 mmol) 2-(3,4-Dimethyl-benzoyl)-3-methoxy-acrylic acid methyl ester, 0.22 g (2.01 mmol) of 4-Methyl-pyridin-3-ylamine, and 30 mL of diphenyl ether to yield 94.4 mg of 3-(3,4-Dimethyl-benzoyl)-8-methyl-1H-[1,5]naphthyridin-4-one as a brown solid.

Step 2: 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-8-methyl-1H-[1,5]naphthyridin-4-one

[0266] Experimental conditions analogous to described for Step 3 of Example 1 were used with 93 mg (0.318 mmol) of 3-(3,4-Dimethyl-benzoyl)-8-methyl-1H-[1,5]naphthyridin-4-one, 15 mg (0.382 mmol, 60% dispersion in oil) of sodium hydride, 95.8 mg (0.382 mmol) of 2-bromo-6-bromomethyl-pyridine and 3.0 mL of N,N-dimethylformamide. The crude brown solid was purified by flash column chromatography using 30-100% ethyl acetate in hexane to yield 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-8-methyl-1H-[1,5]naphthyridin-4-one as an off white solid. LC-MSD, m/z for C₂₄H₂₀BrN₃O₂ [M+H]: 462.07 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 3.0 min.

Example 58**[0267] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one****Step 1: 3-(3,4-Dimethyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one**

[0268] Experimental conditions analogous to those described for step 1 of Example 1 were used with 0.50 g (2.01 mmol) 2-(3,4-Dimethyl-benzoyl)-3-methoxy-acrylic acid methyl ester, 0.22 g (2.01 mmol) of 6-Methyl-pyridin-3-ylamine, and 15 mL of diphenyl ether to yield 129 mg of 3-(3,4-Dimethyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one as a brown solid.


Step 2: 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one

[0269] Potassium hexamethyldisilazane (0.49 mL, 0.246 mmol, 0.5 M in THF) was added to a solution of 3-(3,4-Dimethyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one (60 mg,

0.205) in 2 mL of tetrahydrofuran. After the reaction was stirred at room temperature for 20 minutes 2-bromo-6-bromomethyl-pyridine (61.8 mg, 0.246 mmol) was added and stirred overnight at room temperature. Water and ethyl acetate were added and the two phases were separated. The aqueous phase was extracted with ethyl acetate (3 x 20 mL). The combined
 5 organic layers were dried with magnesium sulfate, filtered and concentrated in vacuo. The crude brown solid was purified by reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to yield 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one as an off white solid. LC-MSD, m/z for $C_{24}H_{20}BrN_3O_2$ [M+H]: 462.07 LC retention time on HPLC, C18 column gradient 20-95%
 10 acetonitrile with 0.1% TFA in 4 minutes: 2.3 min.

Example 59


[0270] Preparation of 3-(3,4-Dimethyl-benzoyl)-6-methyl-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,5]naphthyridin-4-one



15 **[0271]** Experimental conditions analogous to those described for Step 3 of Example 1 were used with 65 mg (0.222 mmol) of 3-(3,4-Dimethyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one, 11 mg (0.267 mmol, 60% dispersion in oil) of sodium hydride, 49.6 mg (0.267 mmol) of 2-methyl-6-bromomethyl-pyridine and 2.0 mL of N,N-dimethylformamide. The crude brown solid was purified by reverse phase HPLC with a
 20 C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to yield 3-(3,4-Dimethyl-benzoyl)-6-methyl-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,5]naphthyridin-4-one as an off white solid. LC-MSD, m/z for $C_{25}H_{23}N_3O_2$ [M+H]: 398.18 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.0 min.

Example 60

[0272] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-7-methyl-1H-[1,8]naphthyridin-4-one



5 Step 1: 2-[(6-Methyl-pyridin-2-ylamino)-methylene]-malonic acid diethyl ester

[0273] 20 g (92.5 mmol) of 2-ethoxymethylene-malonic acid diethyl ester and 10 g (92.5 mmol) of 2-amino-6-methylpyridine were heated neat at 110 °C for 2 h. The reaction was allowed to cool to room temperature and the product was recrystallized from dichloromethane and hexane to afford 21.8 g of 2-[(6-Methyl-pyridin-2-ylamino)-methylene]-malonic acid diethyl ester as a white solid.

Step 2: 7-Methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester

[0274] 21.8 g (3.61 mmol) of 2-[(6-Methyl-pyridin-2-ylamino)-methylene]-malonic acid diethyl ester was dissolved in 300 mL of diphenyl ether and the solution was heated at 250 °C. After 2.5 h the solution was cooled to rt and 50 mL of hexane was added. The mixture was filtered and the solid washed with hexane to yield 18.5 g of 7-Methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester as a brown solid.

Step 3: 1-(6-Bromo-pyridin-2-ylmethyl)-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester

[0275] 25.6 mL of potassium hexamethyldisilazane (12.91 mmol, 0.5 M in toluene) was added to 2.5 g (10.76 mmol) of 7-Methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester dissolved in 22 mL of tetrahydrofuran and was stirred at room temperature for 15 minutes. 3.24 g (12.91 mmol) of 2-Bromo-6-bromomethyl-pyridine was added and stirred at room temperature for 2.5 h. Water and ethyl acetate were added and the layers separated. The aqueous layer was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over magnesium sulfate, filtered and dried in vacuo. The crude

product was purified on silica gel eluting with 50/50 ethyl acetate/hexane to yield 0.620 g of 1-(6-Bromo-pyridin-2-ylmethyl)-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester as a brown solid.

Step 4: 1-(6-Bromo-pyridin-2-ylmethyl)-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid

[0276] 0.110 g (4.62 mmol) of lithium hydroxide was added to 0.620 g of 1-(6-Bromo-pyridin-2-ylmethyl)-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester dissolved in 50 mL methanol and 100 mL of water and was heated at 60 °C for 3 hours. After the reaction was cooled to room temperature 1M HCl was added until the product precipitated from solution. The white solid was collected by vacuum filtration to yield 0.400 g of 1-(6-Bromo-pyridin-2-ylmethyl)-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid as a white solid.

Step 5: 1-(6-Bromo-pyridin-2-ylmethyl)-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid methoxy-methyl-amide

[0277] 0.667 mL (3.75 mmol, 50% solution in ethyl acetate) of 1-propanephosphonic anhydride solution was added to 0.400 g (1.07 mmol) of 1-(6-Bromo-pyridin-2-ylmethyl)-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, 0.208 g (2.13 mmol) of *N,O*-dimethylhydroxyl amine, and 0.653 mL (3.75 mmol) of diisopropylethylamine dissolved in 1 mL of dichloromethane. After the reaction was stirred at room temperature for 1 hour water was added and was extracted with dichloromethane (3 x 25 mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated in vacuo. The crude product was purified on silica gel eluting with 100% ethyl acetate to yield 0.355 g of 1-(6-Bromo-pyridin-2-ylmethyl)-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid methoxy-methyl-amide as a white solid.


Step 6: 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-7-methyl-1H-[1,8]naphthyridin-4-one

[0278] 0.896 mL of 3,4-(ethylenedioxy)phenylmagnesium bromide (.448 mmol, 0.5M in THF) was added to 85 mg (0.204 mmol) of 1-(6-Bromo-pyridin-2-ylmethyl)-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid methoxy-methyl-amide dissolved in 1 mL of THF and the reaction was stirred at room temperature for 1 hour. Saturated ammonium chloride was added and the aqueous layer was extracted with dichloromethane (3 x 10 mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated in

vacuo. The crude product was purified by flash column chromatography using 20-100% ethyl acetate in hexane and further purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to yield 38.2 mg of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-7-methyl-1H-[1,8]naphthyridin-4-one as a white solid. LC-MSD, m/z for C₂₄H₁₈BrN₃O₄ [M+H]: 492.05 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.4 min

Example 62


[0279] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methoxy-3-methyl-benzoyl)-7-methyl-1H-[1,8]naphthyridin-4-one



[0280] Experimental conditions analogous to those described for Step 6 of Example 60 were used with 85 mg (0.204 mmol) of 1-(6-Bromo-pyridin-2-ylmethyl)-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid methoxy-methyl-amide and 0.896 mL 0.448 mL, 0.5 M in THF) of 4-methoxy-3-methylphenylmagnesium bromide in 1 mL of THF. The crude product was purified by flash column chromatography using 20-100% ethyl acetate in hexane and further purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to afford 27.9 mg of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methoxy-3-methyl-benzoyl)-7-methyl-1H-[1,8]naphthyridin-4-one as a white solid. LC-MSD, m/z for C₂₄H₂₀BrN₃O₃ [M+H]: 478.07 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.6 min.

Example 63


[0281] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(5,6-dimethyl-pyridine-3-carbonyl)-7-methyl-1H-[1,8]naphthyridin-4-one



- 5 **[0282]** 0.23 mL (0.469 mmol, 2M in THF) isopropylmagnesium chloride was added to a solution of 104.4 mg (0.448 mmol) of 5-iodo-2,3-dimethyl-pyridine in 1 mL of tetrahydrofuran. After the reaction was stirred for 40 min at room temperature 85 mg (0.204 mmol) of 1-(6-Bromo-pyridin-2-ylmethyl)-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid methoxy-methyl-amide in 0.6 mL of tetrahydrofuran was added and the
- 10 reaction stirred for 1 h. Water was added and was extracted with dichloromethane (3 x 10 mL). The combined organic layers were dried over magnesium sulfate, filtered and dried in vacuo. The crude product was purified by flash column chromatography using 20-100% ethyl acetate in hexane to yield 37.4 mg of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(5,6-dimethyl-pyridine-3-carbonyl)-7-methyl-1H-[1,8]naphthyridin-4-one. LC-MSD, m/z for
- 15 $C_{23}H_{19}BrN_4O_2$ [M+H]: 463.07 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 1.7 min

Example 64

[0283] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-6,7-dimethyl-1H-[1,8]naphthyridin-4-one



Step 1 : 3-(3,4-Dimethyl-benzoyl)-6,7-dimethyl-1H-[1,8]naphthyridin-4-one

[0284] Experimental conditions analogous to those described for Step 1 of Example 1 were used with 0.50 g (2.01 mmol) 2-(3,4-Dimethyl-benzoyl)-3-methoxy-acrylic acid methyl ester, 0.25 g (2.01 mmol) of 5,6-Dimethyl-pyridin-2-ylamine, and 15 mL of diphenyl ether to


yield 68.7 mg of 3-(3,4-Dimethyl-benzoyl)-6,7-dimethyl-1H-[1,8]naphthyridin-4-one as a brown solid.

Step 2: 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-6,7-dimethyl-1H-[1,8]naphthyridin-4-one

- 5 **[0285]** Experimental conditions analogous to those described for Step 2 of Example 1 were used with 69 mg (0.224 mmol) of 3-(3,4-Dimethyl-benzoyl)-6,7-dimethyl-1H-[1,8]naphthyridin-4-one, 11 mg (0.269 mmol, 60% dispersion in oil) of sodium hydride, 67.5 mg (0.269 mmol) of 2-bromo-6-bromomethyl-pyridine and 2.0 mL of N,N dimethylformamide. The crude brown solid was purified by flash column chromatography using 30-100% ethyl acetate in hexane to yield 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-6,7-dimethyl-1H-[1,8]naphthyridin-4-one as an off white solid. LC-MSD, m/z for C₂₅H₂₂BrN₃O₂ [M+H]: 476.09 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.8 min

Example 65

- 15 **[0286]** Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-6,7-dimethyl-1H-[1,8]naphthyridin-4-one



Step 1: 2-[(5,6-Dimethyl-pyridin-2-ylamino)-methylene]-malonic acid diethyl ester

- 20 **[0287]** Experimental conditions analogous to those described for Step 1 of Example 60 were used with 5g (40.93 mmol) of 5,6-Dimethyl-pyridin-2-ylamine and 8.2 mL (40.93 mmol) of 2-ethoxymethylene malonic acid diethyl ester to afford 10.61 g of 2-[(5,6-Dimethyl-pyridin-2-ylamino)-methylene]-malonic acid diethyl ester.

Step 2: 6,7-Dimethyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester

- 25 **[0288]** Experimental conditions analogous to those described for Step 2 of Example 60 were used with 10.61 g (36.29 mmol) of 2-[(5,6-Dimethyl-pyridin-2-ylamino)-methylene]-

malonic acid diethyl ester and 150 mL of diphenyl ether to yield 7.21 g of 6,7-Dimethyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester.

Step 3: 6,7-Dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester

- 5 [0289] Experimental conditions analogous to those described for Step 3 of Example 60 were used with 3 g (12.17 mmol) of 6,7-Dimethyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester, 2.49g (13.39 mmol) of 2-Bromomethyl-6-methyl-pyridine, 0.54 g (13.39 mmol, 60% dispersion in oil), and 60 mL of *N,N*-dimethylformamide to give 1.61 g of 6,7-Dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-[1,8] naphthyridine-3-carboxylic acid ethyl ester.
- 10

Step 4: 6,7-Dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid

- [0290] Experimental conditions analogous to those described for Step 4 of Example 60 were used with 1.60 g (4.55 mmol) of 6,7-Dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-[1,8] naphthyridine-3-carboxylic acid ethyl ester, 0.33 g (13.66 mmol) of lithium hydroxide, 100 mL of water and 50 mL of methanol to afford 1.26 g of 6,7-Dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-[1,8] naphthyridine-3-carboxylic acid.
- 15

Step 5: 6,7-Dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid methoxy-methyl amide

- 20 [0291] Experimental conditions analogous to those described for Step 5 of Example 60 were used with 1.26 g (3.89 mmol), 0.76 g (7.79 mmol) of *N,O* dimethylhydroxylamine, 2.43 mL (4.08 mmol, 50% solution in ethyl acetate), 4.10 mL (23.34 mmol) of diisopropylethylamine and 4 mL of dichloromethane to give 1.32 g of 6,7-Dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-[1,8] naphthyridine-3-carboxylic acid methoxy-methyl amide.
- 25


Step 6: 3-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-6,7-dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,8]naphthyridin-4-one

- [0292] Experimental conditions analogous to those described for Step 6 of Example 60 were used with 100 mg (0.273 mmol) of 6,7-Dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-[1,8] naphthyridine-3-carboxylic acid methoxy-methyl amide, 1.2 mL (0.60 mmol, 0.5M solution in tetrahydrofuran) of 3,4-(ethylenedioxy)phenylmagnesium bromide, and 1 mL of THF. The crude product was purified by flash column chromatography using
- 30

20-100% ethyl acetate in hexane and further purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to afford 42.7 mg of 3-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-6,7-dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,8]naphthyridin-4-one. LC-MSD, m/z for C₂₆H₂₃N₃O₄ [M+H]: 442.17 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 1.9 min.

Example 66

[0293] Preparation of 3-(4-Methoxy-3-methyl-benzoyl)-6,7-dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,8]naphthyridin-4-one




10 [0294] Experimental conditions analogous to those described for Step 6 of Example 60 were used with 100mg (0.273 mmol) of 6,7-Dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-[1,8] naphthyridine-3-carboxylic acid methoxy-methyl amide, 1.2 mL (0.60 mmol, 0.5 M in tetrahydrofuran) of 4-methoxy-3-methylphenylmagnesium bromide and 1.2 mL of THF. The crude product was purified by flash column chromatography using 20-
15 100% ethyl acetate in hexane and further purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to give 40.1 mg of 3-(4-Methoxy-3-methyl-benzoyl)-6,7-dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,8]naphthyridin-4-one. LC-MSD, m/z for C₂₆H₂₅N₃O₃ [M+H]: 428.19 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.2 min.

20

Example 67


[0295] Preparation of 3-(3-Fluoro-4-methoxy-benzoyl)-6,7-dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,8]naphthyridin-4-one



[0296] Experimental conditions analogous to those described for Step 6 of Example 60 were used with 100mg (0.273 mmol) of 6,7-Dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-[1,8] naphthyridine-3-carboxylic acid methoxy-methyl amide, 1.2 mL (0.60 mmol, 0.5 M in tetrahydrofuran) of 3-fluoro-4-methoxyphenylmagnesium bromide and 1.2 mL of THF. The crude product was purified by flash column chromatography using a gradient of 20-100% ethyl acetate in hexane and further purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to yield 58.7 mg 3-(3-Fluoro-4-methoxy-benzoyl)-6,7-dimethyl-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,8]naphthyridin-4-one. LC-MSD, m/z for C₂₅H₂₂FN₃O₃ [M+H]: 432.16 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.1 min

Example 68

[0297] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methoxy-3-methyl-benzoyl)-1H-[1,5]naphthyridin-4-one



15 Step 1: 3-(4-Methoxy-3-methyl-benzoyl)-1H-[1,5]naphthyridin-4-one

[0298] Experimental conditions analogous to those described for Step 1 of Example 1 were used with 0.60 g (2.27 mmol) of 3-ethoxy-2-(4-methoxy-3-methyl-benzoyl)-acrylic acid methyl ester, 0.214 g (2.27 mmol) of 3-aminopyridine, and 15 mL of diphenyl ether to yield 0.435g of 3-(4-Methoxy-3-methyl-benzoyl)-1H-[1,5]naphthyridin-4-one.


20 Step 2: 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methoxy-3-methyl-benzoyl)-1H-[1,5]naphthyridin-4-one

[0299] Experimental conditions analogous to those described for Step 1 of Example 2 using 75 mg (0.255 mmol) of 3-(4-Methoxy-3-methyl-benzoyl)-1H-[1,5]naphthyridin-4-one, 76.8 mg (0.306 mmol) of 2-bromo-6-bromomethyl-pyridine, 0.61 mL (0.306 mmol, 0.5 M in toluene) of potassium hexamethyldisilazane, and 2.5 mL of THF. The crude product was purified by flash column chromatography using a gradient of 20-100% ethyl acetate in hexane and further purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to yield 20 mg of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methoxy-3-methyl-benzoyl)-1H-[1,5] naphthyridin-4-one. LC-MSD, m/z for C₂₃H₁₈BrN₃O₃

[M+H]: 464.05 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.0 min.

Example 69


[0300] Preparation of 3-(4-Methoxy-3-methyl-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,5]naphthyridin-4-one



[0301] Experimental conditions analogous to those described for Step 3 of Example 1 using 75 mg (0.255 mmol) of 3-(4-Methoxy-3-methyl-benzoyl)-1H-[1,5]naphthyridin-4-one, 56.9 mg (0.306 mmol) of 2-bromomethyl-6-methyl-pyridine, 0.61 mL (0.306 mmol, 0.5 M in toluene) of potassium hexamethyldisilazane, and 2.5 mL of THF. The crude product was purified by flash column chromatography using a gradient of 20-100% ethyl acetate in hexane and further purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to yield 38.6 mg of 3-(4-Methoxy-3-methyl-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,5]naphthyridin-4-one. LC-MSD, m/z for C₂₄H₂₁N₃O₃ [M+H]: 400.16 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 1.8 min.

Example 70

[0302] Preparation of 6-[3-(4-Methoxy-3-methyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridine-2-carbonitrile



Step 1: 3-(4-Methoxy-3-methyl-benzoyl)-1H-quinolin-4-one

[0303] Experimental conditions analogous to those described for Step 1 of Example 1 were used with 1 g (3.78 mmol) of 3-ethoxy-2-(4-methoxy-3-methyl-benzoyl)-acrylic acid methyl


ester, 0.214 g (3.78 mmol) of aniline, and 20 mL of diphenyl ether to yield 1.12 g of 3-(4-Methoxy-3-methyl-benzoyl)-1H-quinolin-4-one.

Step 2: 6-[3-(4-Methoxy-3-methyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridine-2-carbonitrile

- 5 **[0304]** Experimental conditions analogous to those described for Step 3 of Example 1 were used with 100 mg (0.341 mmol) of 3-(4-Methoxy-3-methyl-benzoyl)-1H-quinolin-4-one, 80.6 mg (0.409 mmol) of 6-bromomethyl-pyridine-2-carbonitrile, 16.4 mg (0.409 mmol, 60% dispersion in oil), and 3.5 mL of *N,N*-dimethylformamide. The crude product was purified by flash column chromatography using a gradient of 20-100% ethyl acetate in hexane to yield 58
10 mg of 6-[3-(4-Methoxy-3-methyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridine-2-carbonitrile. LC-MSD, *m/z* for $C_{25}H_{19}N_3O_3$ [*M*+*H*]: 410.14 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.3 min.

Example 71


- 15 **[0305]** Preparation of 3-(4-Methoxy-3-methyl-benzoyl)-1-(6-trifluoromethyl-pyridin-2-ylmethyl)-1H-quinolin-4-one



- 20 **[0306]** Experimental conditions analogous to those described for Step 3 of Example 1 were used with 100 mg (0.341 mmol) of 3-(4-Methoxy-3-methyl-benzoyl)-1H-quinolin-4-one, 98.2 mg (0.409 mmol) of 2-bromomethyl-6-trifluoromethyl-pyridine, 16.4 mg (0.409 mmol, 60% dispersion in oil), and 3.5 mL of *N,N*-dimethylformamide. The crude product was purified by flash column chromatography using a gradient of 20-100% ethyl acetate in hexane to yield 39 mg of 3-(4-Methoxy-3-methyl-benzoyl)-1-(6-trifluoromethyl-pyridin-2-ylmethyl)-1H-quinolin-4-one. LC-MSD, *m/z* for $C_{25}H_{19}F_3N_2O_3$ [*M*+*H*]: 453.13 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.5
25 min.

Example 72

[0307] Preparation of 1-(6-Amino-pyridin-2-ylmethyl)-3-(4-methoxy-3-methyl-benzoyl)-1H-quinolin-4-one




5 **Step 1:** 2,2,2-Trifluoro-N-{6-[3-(4-methoxy-3-methyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridin-2-yl}-acetamide

10 **[0308]** Potassium hexamethyldisilazane (2.44 mL, 1.22 mmol, 0.5 M in THF) was added to a solution of 3-(4-Methoxy-3-methyl-benzoyl)-1H-quinolin-4-one (0.30 g, 1.02) in 10 mL of tetrahydrofuran. After the reaction was stirred at rt for 20 minutes, N-(6-Bromomethyl-pyridin-2-yl)-2,2,2-trifluoro-acetamide (0.35 g, 0.246 mmol) was added and stirred overnight at room temperature. Water and ethyl acetate were added and the two phases were separated. The aqueous phase was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried with magnesium sulfate, filtered and concentrated in vacuo. The crude brown solid was purified by reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to yield 212 mg of 2,2,2-Trifluoro-N-{6-[3-(4-methoxy-3-methyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridin-2-yl}-acetamide

Step 2: 1-(6-Amino-pyridin-2-ylmethyl)-3-(4-methoxy-3-methyl-benzoyl)-1H-quinolin-4-one.

20 **[0309]** A solution of 212 mg (0.43 mmol) 2,2,2-Trifluoro-N-{6-[3-(4-methoxy-3-methyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridin-2-yl}-acetamide, excess diethylamine and 5 mL of methanol were heated at 45 °C overnight. The solid was collected by filtration and purified by reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to yield 32.4 mg of 1-(6-Amino-pyridin-2-ylmethyl)-3-(4-methoxy-3-methyl-benzoyl)-1H-quinolin-4-one. LC-MSD, m/z for C₂₄H₂₁N₃O₃ [M+H]: 400.16 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 1.5 min.


Example 73

[0310] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methoxy-3-methyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one**5 Step 1: 3-(4-Methoxy-3-methyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one**

[0311] Experimental conditions analogous to those described for Step 1 of Example 1 were used with 0.50 g (1.88 mmol) of 3-ethoxy-2-(4-methoxy-3-methyl-benzoyl)-acrylic acid methyl ester, 0.20 g (1.88 mmol) of 6-Methyl-pyridin-3-ylamine, and 10 mL of diphenyl ether to yield 0.33 g of 3-(4-Methoxy-3-methyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one.


Step 2: 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methoxy-3-methyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one

[0312] Experimental conditions analogous to those described for Step 3 of Example 1 were used with 100 mg (0.324 mmol) of 3-(4-Methoxy-3-methyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one, 97.7 mg (0.389 mmol) of 2-bromo-6-bromomethyl-pyridine, 15.6 mg (0.389 mmol, 60% dispersion in oil), and 1 mL of *N,N*-dimethylformamide. The crude product was purified by flash column chromatography using a gradient of 20-100% ethyl acetate in hexane and further purified on the reverse phase HPLC with a C18 column, gradient of 20-70% acetonitrile -0.1% TFA to yield 52.6 mg of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methoxy-3-methyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one. LC-MSD, *m/z* for C₂₄H₂₀BrN₃O₃ [M+H]: 478.07 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.1 min

Example 74**[0313] Preparation of 3-(4-Methoxy-3-methyl-benzoyl)-6-methyl-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,5]naphthyridin-4-one**

5 [0314] Experimental conditions analogous to those described for Step 3 of Example 1 were used with 100 mg (0.324 mmol) of 3-(4-Methoxy-3-methyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one, 72.4 mg (0.389 mmol) of 2-Bromomethyl-6-methyl-pyridine, 15.6 mg (0.389 mmol, 60% dispersion in oil), and 1 mL of *N,N*-dimethylformamide. The crude product was purified by flash column chromatography using a gradient of 20-100% ethyl
 10 acetate in hexane and further purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile -0.1% TFA to yield 34.8 mg of 3-(4-Methoxy-3-methyl-benzoyl)-6-methyl-1-(6-methyl-pyridin-2-ylmethyl)-1H-[1,5]naphthyridin-4-one. LC-MSD, *m/z* for $C_{25}H_{23}N_3O_3$ [*M*+*H*]: 414.17 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 1.8 min.

15


Example 75**[0315] Preparation of 1-(3-Bromo-benzyl)-3-(4-methoxy-3-methyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one**

20 [0316] Experimental conditions analogous to those described for Step 3 of Example 1 were used with 120 mg (0.390 mmol) of 3-(4-Methoxy-3-methyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one, 116.8 mg (0.467 mmol) of 1-bromo-3-bromomethyl-benzene, 19 mg (0.467 mmol, 60% dispersion in oil), and 1 mL of *N,N* dimethylformamide. The crude product was purified by flash column chromatography using a gradient of 20-100% ethyl

acetate in hexane and further purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to yield 36.6 mg of 1-(3-Bromo-benzyl)-3-(4-methoxy-3-methyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one. LC-MSD, m/z for $C_{25}H_{21}BrN_2O_3$ [M+H]: 477.07 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.4 min.

Example 76


[0317] Preparation of 1-(3-Chloro-benzyl)-3-(4-methoxy-3-methyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one.



[0318] Experimental conditions analogous to those described for Step 3 of Example 1 were used with 120mg (0.390 mmol) of 3-(4-Methoxy-3-methyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one, 75.2 mg (0.467 mmol) of 3-chlorobenzyl chloride, 19 mg (0.467 mmol, 60% dispersion in oil), and 1 mL of *N,N* dimethylformamide. The solid was collected by filtration and was purified by flash column chromatography using a gradient of 20-100% ethyl acetate in hexane to yield 65.7 mg of 1-(3-Chloro-benzyl)-3-(4-methoxy-3-methyl-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one. LC-MSD, m/z for $C_{25}H_{21}ClN_2O_3$ [M+H]: 433.12 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.5 min.

Example 77


[0319] Preparation of 3-(3-Fluoro-4-methoxy-benzoyl)-1-(6-trifluoromethyl-pyridin-2-ylmethyl)-1H-quinolin-4-one



[0320] Experimental conditions analogous to those described for Step 3 of Example 1 were used with 150mg (0.505 mmol) of 3-(3-Fluoro-4-methoxy-benzoyl)-1H-quinolin-4-one, 145.3 mg (0.605 mmol) of 2-bromomethyl-6-trifluoromethyl-pyridine, 24.2 mg (0.605 mmol, 60% dispersion in oil), and 1 mL of *N,N* dimethylformamide. Water was added and the solid was collected by filtration. The crude product was purified by flash column chromatography using a gradient of 20-100% ethyl acetate in hexane to yield 195.9 mg of 3-(3-Fluoro-4-methoxy-benzoyl)-1-(6-trifluoromethyl-pyridin-2-ylmethyl)-1H-quinolin-4-one. LC-MSD, m/z for $C_{24}H_{16}F_4N_2O_3$ $[M+H]^+$: 457.11 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.5 min.

Example 78

[0321] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-fluoro-4-methoxy-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one



Step 1: 3-(3-Fluoro-4-methoxy-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one

[0322] Experimental conditions analogous to those described for Step 1 of Example 1 were used with 0.50 g (1.86mmol) of 3-Ethoxy-2-(3-fluoro-4-methoxy-benzoyl) acrylic acid methyl ester, 0.20 g (1.86 mmol) of 6-Methyl-pyridin-3-ylamine, and 15 mL of diphenyl ether to yield 0.233 g of 3-(3-Fluoro-4-methoxy-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one.


Step 2: 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-fluoro-4-methoxy-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one

[0323] Experimental conditions analogous to those described for Step 3 of Example 1 were used with 110 mg (0.352 mmol) of 3-(3-Fluoro-4-methoxy-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one, 106.1 mg (0.423 mmol) of 2-bromo-6-bromomethyl-pyridine, 16.9 mg (0.423 mmol, 60% dispersion in oil), and 2 mL of *N,N* dimethylformamide. The crude product was purified by flash column chromatography using a gradient of 20-100% ethyl acetate in hexane and further purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile -0.1% TFA to yield 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-fluoro-4-methoxy-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one. LC-MSD, m/z for

$C_{23}H_{17}BrFN_3O_3$ [M+H]: 482.04 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.6 min.

Example 79


[0324] Preparation of 1-(3-Bromo-benzyl)-3-(3-fluoro-4-methoxy-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one



[0325] Experimental conditions analogous to those described for Step 3 of Example 1 were used with 112mg (0.358 mmol) of 3-(3-Fluoro-4-methoxy-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one, 107.5 mg (0.430 mmol) of 3-bromobenzyl bromide, 17.2 mg (0.430 mmol, 60% dispersion in oil), and 2 mL of *N,N*-dimethylformamide. The crude product was purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile – 0.1% TFA to yield 67mg of 1-(3-Bromo-benzyl)-3-(3-fluoro-4-methoxy-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one. LC-MSD, *m/z* for $C_{24}H_{18}BrFN_2O_3$ [M+H]: 481.05. LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.7 min

Example 80

[0326] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-fluoro-4-methoxy-benzoyl)-1H-[1,5]naphthyridin-4-one



20 Step 1: 3-(3-Fluoro-4-methoxy-benzoyl)-1H-[1,5]naphthyridin-4-one


[0327] Experimental conditions analogous to those described for Step 1 of Example 1 were used with 0.70 g (2.61 mmol) of 3-Ethoxy-2-(3-fluoro-4-methoxy-benzoyl) acrylic acid methyl ester, 0.25 g (2.61 mmol) of 3-aminopyridine, and 15 mL of diphenyl ether to yield 3-(3-Fluoro-4-methoxy-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one.

Step 2: 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-fluoro-4-methoxy-benzoyl)-1H-[1,5]naphthyridin-4-one

[0328] Experimental conditions analogous to those described for Step 3 of Example 1 were used with 120mg (0.402 mmol) of 3-(3-Fluoro-4-methoxy-benzoyl)-1H-[1,5]naphthyridin-4-one, 121.1 mg (0.483 mmol) of 2-bromo-6-bromomethyl-pyridine, 19.3 mg (0.483 mmol, 60% dispersion in oil), and 2 mL of *N,N* dimethylformamide. The crude product was purified by flash column chromatography using a gradient of 20-100% ethyl acetate in hexane and further purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile -0.1% TFA to yield 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-fluoro-4-methoxy-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one. LC-MSD, m/z for C₂₂H₁₅BrFN₃O₃ [M+H]: 468.03.

Example 81

[0329] Preparation of 1-(3-Bromo-benzyl)-3-(3-fluoro-4-methoxy-benzoyl)-1H-[1,5]naphthyridin-4-one




15

[0330] Experimental conditions analogous to those described for Step 3 of Example 1 were used with 120 mg (0.402 mmol) of 3-(3-Fluoro-4-methoxy-benzoyl)-1H-[1,5]naphthyridin-4-one, 120.7 mg (0.483 mmol) of 3-bromobenzyl bromide, 19.3 mg (0.483 mmol, 60% dispersion in oil), and 2 mL of *N,N* dimethylformamide. The crude product was purified by flash column chromatography using a gradient of 20-100% ethyl acetate in hexane and further purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile -0.1% TFA to yield 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-fluoro-4-methoxy-benzoyl)-6-methyl-1H-[1,5]naphthyridin-4-one. LC-MSD, m/z for C₂₃H₁₆BrFN₂O₃ [M+H]: 467.03.

20

Example 82

[0331] Preparation of 1-(3-Bromo-benzyl)-3-(5-methyl-pyridine-2-carbonyl)-1H-quinolin-4-one



5 Step 1: 1-(4-Methoxy-benzyl)-3-(5-methyl-pyridine-2-carbonyl)-1H-quinolin-4-one


[0332] Experimental conditions analogous to those described for Step 6 of Example 60 with 0.82 mg (2.33 mmol), 20.5 mL (5.12 mmol, 0.25 M in tetrahydrofuran) of 2-methyl-2-pyridylmagnesium bromide, and 10 mL of tetrahydrofuran. The crude product was purified by flash column chromatography using a gradient of 70:30 ethyl acetate/methanol to obtain
10 0.381 g of 1-(4-Methoxy-benzyl)-3-(5-methyl-pyridine-2-carbonyl)-1H-quinolin-4-one.

Step 2: 3-(5-Methyl-pyridine-2-carbonyl)-1H-quinolin-4-one


[0333] A 4M solution of hydrochloric acid in dioxane (4mL) was added to 381 mg (0.991 mmol) of 1-(4-Methoxy-benzyl)-3-(5-methyl-pyridine-2-carbonyl)-1H-quinolin-4-one and was heated in a pressure tube at 120 °C for 18 h. The reaction was concentrated and saturated
15 sodium bicarbonate was added and the aqueous phase was extracted with dichloromethane (3 x 20 mL). The crude product was purified by flash column chromatography using a gradient of 70:30 ethyl acetate/methanol to afford 68.4 mg of 3-(5-Methyl-pyridine-2-carbonyl)-1H-quinolin-4-one.

Step 3: 1-(3-Bromo-benzyl)-3-(5-methyl-pyridine-2-carbonyl)-1H-quinolin-4-one

20 [0334] Experimental conditions analogous to those described for Example 1 step 3 were used with 68 mg (0.257 mmol) of 3-(5-Methyl-pyridine-2-carbonyl)-1H-quinolin-4-one, 77.2 mg (0.309 mmol) of 3-bromobenzyl bromide, 12.4 mg (0.309 mmol, 60% dispersion in oil), and 1 mL of DMF. The crude product was purified by reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to yield 39.1 mg of 1-(3-Bromo-benzyl)-
25 3-(5-methyl-pyridine-2-carbonyl)-1H-quinolin-4-one as a white solid. LC-MSD, m/z for C₂₃H₁₇BrN₂O₂ [M+H]: 433.05 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 2.5 min.

Example 83**[0335] Preparation of 3-(5-Methyl-pyridine-2-carbonyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one**

- 5 **[0336]** Experimental conditions analogous to those described for Step 6 of Example 60 with 200 mg (0.593 mmol) of 1-(6-Methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl amide, 5.2 mL (1.30 mmol, 0.25 M in tetrahydrofuran) of 5-methyl-2-pyridylmagnesium bromide, and 2.6 mL of tetrahydrofuran. The crude product was purified by flash column chromatography using a gradient of 20-100% ethyl acetate in
- 10 hexane and further purified on the reverse phase HPLC with a C 18 column, gradient of 20-70% acetonitrile –0.1% TFA to yield 77.6 mg of 3-(5-Methyl-pyridine-2-carbonyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one. LC-MSD, m/z for $C_{23}H_{19}N_3O_2$ [M+H]: 370.15 LC retention time on HPLC, C18 column gradient 20-95% acetonitrile with 0.1% TFA in 4 minutes: 0.91 min.

Example 84**[0337] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(5,6-dimethyl-pyridine-3-carbonyl)-1H-quinolin-4-one**

Step 1: 4-Oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester

- 20 **[0338]** 31.7 g (147 mmol) of 2-Ethoxymethylene-malonic acid diethyl ester and 13.7 g (147 mmol) of aniline were stirred neat at 110°C for 1h, then 300 mL of diphenyl ether was

added and the temperature of the oil bath was raised to 260 °C for 2 h. The solution was then cooled down to rt, diluted with 600 mL of hexanes and filtered. The solids were washed with 200 mL of hexanes and dried to yield 23.7 g of the product as a light brown powder. LC-MSD, m/z for C₁₂H₁₁NO₃ [M+H]⁺ = 218.2, HPLC retention time: 2.5 min.

5 Step2: 1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester.

[0339] 8.75 g (40.3 mmol) of 4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester was dissolved/suspended in 100 mL DMF followed by the addition of 1.93 g (48.3 mmol) of 60% sodium hydride. After the bubbling has ceased 12.1 g (48.3 mmol) of 2-bromo-6-bromomethyl-pyridine was added and the solution was stirred at r.t. overnight. The reaction was quenched using 900 mL of water, filtered and washed with 200 mL of water. The solid was further washed with 100 mL DCM. The DCM washes were evaporated and chromatographed on silica using 0-30% methanol in DCM. The purified compound was combined with the washed solid to give 14.9 g of the product as an off-white solid.

15 Step 3: 1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid.

[0340] 14.9 g (38.5 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester was dissolved/suspended in 300 mL of a 1:1 methanol-water mixture. 1.11 g (46.2 mmol) of lithium hydroxide was added and the mixture was heated up to 65 °C and stirred overnight. The mixture was cooled down to r.t., 300 mL of methanol and 4 mL of concentrated aqueous HCl were added and the solids were filtered off. The solids were then dissolved/suspended in 300 mL ethanol, brought to reflux, cooled down to rt, filtered, washed with 50 mL diethyl ether and dried to yield 9.5 g of the product as a white solid.

25 Step 4: 1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide.

[0341] 9.45 g (26.3 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid, 2.82 g (28.9 mmol) of *N,O*-dimethylhydroxylamine hydrochloride, 22 mL (16 g, 158 mmol) of triethylamine and 18.8 mL (20.1 g, 31.6 mmol) of 50% 1-propanephosphonic acid cyclic anhydride were sequentially added to 250 mL acetonitrile at rt. After 1 h 400 mL of water were added and the mixture was extracted two times with 300 mL DCM. Combined organic layers were evaporated and the residue purified

on silica flash column using 0-15% methanol in EtOAc to give 9.62 g of the product as an off-white solid.


Step 5: 1-(6-Bromo-pyridin-2-ylmethyl)-3-(5,6-dimethyl-pyridine-3-carbonyl)-1H-quinolin-4-one

- 5 [0342] Prepared from 402 mg (1.0 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 3 mL THF and 513 mg (2.2 mmol) of 5-iodo-2,3-dimethyl-pyridine in 5 mL THF with 1.15 mL 2M isopropylmagnesium chloride. Yield: 296 mg of a white powder. LC-MSD, m/z for $C_{23}H_{18}BrN_3O_2$ $[M+H]^+ = 448.0, 450.0$; HPLC retention time: 1.9 min.

10

Example 85

[0343] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(5,6,7,8-tetrahydro-quinoline-2-carbonyl)-1H-quinolin-4-one




- 15 [0344] Experimental conditions analogous to those described for Step 6 of Example 60 from 327 mg (0.81 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 4 mL THF and 527 mg (2.03 mmol) of 2-iodo-5,6,7,8-tetrahydro-quinoline in 2 mL THF with 1.01 mL 2M isopropylmagnesium chloride. Yield: 28 mg of a white powder. LC-MSD, m/z for $C_{25}H_{20}BrN_3O_2$ $[M+H]^+ = 474.0, 476.0$; HPLC retention time: 2.5 min.

20

Example 86

[0345] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4,5-dimethyl-pyridine-2-carbonyl)-1H-quinolin-4-one




- 25 [0346] Experimental conditions analogous to those described for Step 6 of Example 60 from 86 mg (0.21 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 125 mg (0.54 mmol) of 2-iodo-4,5-

dimethyl-pyridine in 1 mL THF with 0.28 mL 2M isopropylmagnesium chloride using. Yield: 21 mg of a white powder. LC-MSD, m/z for $C_{23}H_{18}BrN_3O_2$ $[M+H]^+ = 448.0, 450.0$; HPLC retention time: 2.2 min.

Example 87


5. [0347] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-dimethylamino-benzoyl)-1H-quinolin-4-one



- 10 [0348] Experimental conditions analogous to those described for Step 6 of Example 60 from 120 mg (0.30 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 1.3 mL 0.5M 3-*N,N*-dimethylanilinemagnesium bromide. Yield: 97 mg of a yellow solid. LC-MSD, m/z for $C_{24}H_{20}BrN_3O_2$ $[M+H]^+ = 462.0, 464.0$; HPLC retention time: 2.2 min.

Example 88


- 15 [0349] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methoxy-3-methylbenzoyl)-1H-quinolin-4-one



- 20 [0350] Experimental conditions analogous to those described for Step 6 of Example 60 from 120 mg (0.30 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 1.3 mL 0.5M 4-methoxy-3-methylphenylmagnesium bromide. Yield: 102 mg of a white solid. LC-MSD, m/z for $C_{24}H_{19}BrN_2O_3$ $[M+H]^+ = 463.0, 465.0$; HPLC retention time: 2.5 min.

Example 89


[0351] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dichloro-benzoyl)-1H-quinolin-4-one



[0352] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.98 mL 0.5M 3,4-dichlorophenylmagnesium bromide. Yield: 64 mg of a white solid. LC-MSD, m/z for $C_{22}H_{13}BrCl_2N_2O_2$ $[M+H]^+ = 487.0, 489.0, 491.0$; HPLC retention time: 2.9 min.

Example 90


[0353] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2,4-dimethyl-benzoyl)-1H-quinolin-4-one



[0354] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.98 mL 0.5M 2,4-dimethylphenylmagnesium bromide. Yield: 57 mg of a white solid. LC-MSD, m/z for $C_{24}H_{19}BrN_2O_2$ $[M+H]^+ = 447.0, 449.0$; HPLC retention time: 2.7 min.

Example 91


[0355] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2,5-dimethyl-benzoyl)-1H-quinolin-4-one



- [0356] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.98 mL 0.5M 2,5-dimethylphenylmagnesium bromide. Yield: 57 mg of a white solid. LC-MSD, m/z for $C_{24}H_{19}BrN_2O_2$ $[M+H]^+ = 447.0, 449.0$; HPLC retention time: 2.7 min.

Example 92


[0357] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2,3-dimethyl-benzoyl)-1H-quinolin-4-one



- [0358] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.98 mL 0.5M 2,3-dimethylphenylmagnesium bromide. Yield: 54 mg of a white solid. LC-MSD, m/z for $C_{24}H_{19}BrN_2O_2$ $[M+H]^+ = 447.0, 449.0$; HPLC retention time: 2.6 min.

Example 93


[0359] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,5-dimethyl-benzoyl)-1H-quinolin-4-one



- [0360] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.98 mL 0.5M 3,5-dimethylphenylmagnesium bromide. Yield: 66 mg of a white solid. LC-MSD, m/z for $C_{24}H_{19}BrN_2O_2$ $[M+H]^+ = 447.0, 449.0$; HPLC retention time: 2.7 min.

Example 94


[0361] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-1H-quinolin-4-one



[0362] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.98 mL 0.5M 3,4-(ethylenedioxy)phenylmagnesium bromide. Yield: 77 mg of a white solid. LC-MSD, m/z for $C_{24}H_{17}BrN_2O_4$ $[M+H]^+ = 477.0, 479.0$; HPLC retention time: 2.4 min.

Example 95


[0363] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-tert-butyl-benzoyl)-1H-quinolin-4-one



[0364] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.25 mL 2M 4-tert-butylphenylmagnesium bromide. Yield: 80 mg of a white solid. LC-MSD, m/z for $C_{26}H_{23}BrN_2O_2$ $[M+H]^+ = 475.0, 477.0$; HPLC retention time: 2.9 min.

Example 96


[0365] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-ethyl-benzoyl)-1H-quinolin-4-one



- [0366] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.98 mL 0.5M 4-ethylphenylmagnesium bromide. Yield: 80 mg of a white solid. LC-MSD, m/z for $C_{24}H_{19}BrN_2O_2$ $[M+H]^+ = 447.0, 449.0$; HPLC retention time: 2.7 min.

Example 97


[0367] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-dimethylamino-benzoyl)-1H-quinolin-4-one



- [0368] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.98 mL 0.5M 4-*N,N*-dimethylanilinemagnesium bromide. Yield: 52 mg of a yellow solid. LC-MSD, m/z for $C_{24}H_{20}BrN_3O_2$ $[M+H]^+ = 462.0, 464.0$; HPLC retention time: 2.6 min.

Example 98


[0369] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2-methyl-benzoyl)-1H-quinolin-4-one



- [0370] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.49 mL 1M 4-ethylphenylmagnesium bromide. Yield: 55 mg of a white solid. LC-MSD, m/z for $C_{23}H_{17}BrN_2O_2$ $[M+H]^+ = 433.0, 435.0$; HPLC retention time: 2.5 min.

Example 99


[0371] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-ethoxy-3-methyl-benzoyl)-1H-quinolin-4-one



- 5 **[0372]** Experimental conditions analogous to those described for Step 6 of Example 60 from 120 mg (0.30 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 172 mg (0.66 mmol) of 1-ethoxy-4-iodo-2-methyl-benzene in 1 mL THF with 0.34 mL 2M isopropylmagnesium chloride. Yield: 53 mg of a white powder. LC-MSD, m/z for $C_{25}H_{21}BrN_2O_3$ $[M+H]^+ = 477.0, 479.0$;
- 10 HPLC retention time: 2.6 min.

Example 100


[0373] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-[4-(2-methoxy-ethoxy)-3-methyl-benzoyl]-1H-quinolin-4-one



- 15 **[0374]** Experimental conditions analogous to those described for Step 6 of Example 60 from 120 mg (0.30 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 2 mL THF and 192 mg (0.66 mmol) of 4-iodo-1-(2-methoxy-ethoxy)-2-methyl-benzene in 2 mL THF with 0.34 mL 2M isopropylmagnesium chloride. Yield: 39 mg of a white powder. LC-MSD, m/z for $C_{26}H_{23}BrN_2O_4$ $[M+H]^+ =$
- 20 507.0, 509.0; HPLC retention time: 2.5 min.

Example 101


[0375] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(5-bromo-pyrimidine-2-carbonyl)-1H-quinolin-4-one



- 5 **[0376]** Experimental conditions analogous to those described for Step 6 of Example 60 from 120 mg (0.30 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 187 mg (0.66 mmol) of 5-bromo-2-iodo-pyrimidine in 2 mL THF with 0.34 mL 2M isopropylmagnesium chloride. Yield: 31 mg of a white powder. LC-MSD, m/z for $C_{20}H_{12}Br_2N_4O_2$ $[M+H]^+ = 498.9, 500.9, 502.9$;
- 10 HPLC retention time: 2.2 min.

Example 102


[0377] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(6-trifluoromethyl-pyridine-3-carbonyl)-1H-quinolin-4-one



- 15 **[0378]** Experimental conditions analogous to those described for Step 6 of Example 60 from 120 mg (0.30 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 179 mg (0.66 mmol) of 5-iodo-2-trifluoromethyl-pyridine in 1 mL THF with 0.34 mL 2M isopropylmagnesium chloride. Yield: 76 mg of a white powder. LC-MSD, m/z for $C_{22}H_{13}BrF_3N_3O_2$ $[M+H]^+ = 488.0, 490.0$;
- 20 HPLC retention time: 2.5 min.

Example 103


[0379] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(6-trifluoromethyl-pyridine-2-carbonyl)-1H-quinolin-4-one



- 5 **[0380]** Experimental conditions analogous to those described for Step 6 of Example 60 from 120 mg (0.30 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 239 mg (0.66 mmol) of 75% 5-iodo-2-trifluoromethyl-pyridine in 1 mL THF with 0.37 mL 2M isopropylmagnesium chloride. Yield: 78 mg of a white powder. LC-MSD, m/z for $C_{22}H_{13}BrF_3N_3O_2$ $[M+H]^+ =$
- 10 488.0, 490.0; HPLC retention time: 2.4 min.

Example 104


[0381] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethoxy-benzoyl)-1H-quinolin-4-one



- 15 **[0382]** Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.98 mL 0.5M 3,4-dimethoxyphenylmagnesium bromide. Yield: 55 mg of a white solid. LC-MSD, m/z for $C_{24}H_{19}BrN_2O_4$ $[M+H]^+ =$ 479.0, 481.0; HPLC retention time: 2.1 min.

Example 105


[0383] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-methoxy-benzoyl)-1H-quinolin-4-one



[0384] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1.5 mL THF and 0.49 mL 1M 3-methoxyphenylmagnesium bromide. Yield: 53 mg of a white solid. LC-MSD, m/z for $C_{23}H_{17}BrN_2O_3$ $[M+H]^+ = 449.0, 451.0$; HPLC retention time: 2.3 min.

Example 106


[0385] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4,5-dimethyl-thiazole-2-carbonyl)-1H-quinolin-4-one




[0386] 585 mg (5.17 mmol) of 4,5-dimethylthiazole was dissolved in 10 mL of anhydrous THF and cooled down to -78°C . 2.07 mL of 2.5 M BuLi in hexanes was added dropwise, followed after 15 minutes by 1.0 g of anhydrous magnesium bromide. The solution was warmed up to rt. The final compound was prepared from 120 mg (0.30 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 2 mL THF and 1.64 mL of the thiazole salt solution. Yield: 13 mg of a white solid. LC-MSD, m/z for $C_{21}H_{16}BrN_3O_2S$ $[M+H]^+ = 454.0, 456.0$; HPLC retention time: 2.2 min.

Example 107


[0387] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methoxy-benzoyl)-1H-quinolin-4-one



[0388] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.98 mL 0.5M 4-methoxyphenylmagnesium bromide. Yield: 51 mg of a white solid. LC-MSD, m/z for $C_{23}H_{17}BrN_2O_3$ $[M+H]^+ = 449.0, 451.0$; HPLC retention time: 2.3 min.

Example 108**[0389] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-fluoro-4-methoxy-benzoyl)-1H-quinolin-4-one**


5 [0390] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.98 mL 0.5M 3-fluoro-4-methoxyphenylmagnesium bromide. Yield: 57 mg of a white solid. ¹H NMR (400 MHz, CDCl₃): δ 4.0 (s, 3 H), 5.5 (s, 2H), 6.9-7.0 (m, 2 H), 7.3-7.4 (m, 1 H), 7.4-7.6 (m, 3 H), 7.6-7.7 (m, 3 H), 8.3 (s, 1 H), 8.4-8.5 (m, 1 H). LC-MSD, m/z for C₂₃H₁₆BrFN₂O₃ [M+H]⁺ = 467.0, 469.0; HPLC retention time: 2.3 min.

Example 109**[0391] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-isopropyl-benzoyl)-1H-quinolin-4-one**

15 [0392] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.98 mL 0.5M 4-*iso*-propylphenylmagnesium bromide. Yield: 52 mg of a white solid. LC-MSD, m/z for C₂₅H₂₁N₂O₂ [M+H]⁺ = 461.0, 463.0; HPLC retention time: 2.7 min.

Example 110

[0393] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-methyl-pyridine-2-carbonyl)-1H-quinolin-4-one




5 **[0394]** Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 1.96 mL 0.25M 3-methyl-2-pyridylmagnesium bromide. Yield: 22 mg of a white solid. LC-MSD, m/z for $C_{22}H_{16}BrN_3O_2$ $[M+H]^+ = 434.0, 436.0$; HPLC retention time: 1.8 min.

10

Example 111


[0395] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methyl-pyridine-2-carbonyl)-1H-quinolin-4-one



15 **[0396]** Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 1.96 mL 0.25M 4-methyl-2-pyridylmagnesium bromide. Yield: 17 mg of a white solid. LC-MSD, m/z for $C_{22}H_{16}BrN_3O_2$ $[M+H]^+ = 434.0, 436.0$; HPLC retention time: 1.8 min.

Example 112


20 **[0397] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(5-methyl-pyridine-2-carbonyl)-1H-quinolin-4-one**



- [0398] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 1.96 mL 0.25M 5-methyl-2-pyridylmagnesium bromide. Yield: 33 mg of a white solid. LC-MSD, m/z for $C_{22}H_{16}BrN_3O_2$ [M+H]⁺ = 434.0, 436.0; HPLC retention time: 2.0 min.

Example 113


[0399] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2,3-dimethyl-3H-imidazole-4-carbonyl)-1H-quinolin-4-one



- [0400] Experimental conditions analogous to those described for Step 6 of Example 60 from 120 mg (0.30 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 3 mL DCM and 146 mg (0.66 mmol) of 5-iodo-1,2-dimethyl-1H-imidazole in 1 mL DCM with 0.34 mL 2M isopropylmagnesium chloride. Yield: 36 mg of a white powder. LC-MSD, m/z for $C_{21}H_{17}BrN_4O_2$ [M+H]⁺ = 437.0, 439.0; HPLC retention time: 0.4 min.

Example 114


[0401] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(6-ethyl-pyridine-3-carbonyl)-1H-quinolin-4-one



- [0402] Experimental conditions analogous to those described for Step 6 of Example 60 from 120 mg (0.30 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 153 mg (0.66 mmol) of 2-ethyl-5-iodo-pyridine in 1 mL THF with 0.34 mL 2M isopropylmagnesium chloride. Yield: 62 mg of a white powder. LC-MSD, m/z for $C_{23}H_{18}BrN_3O_2$ [M+H]⁺ = 448.0, 450.0; HPLC retention time: 1.6 min.

Example 115

[0403] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methoxy-2-methyl-benzoyl)-1H-quinolin-4-one




5 **[0404]** Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1.5 mL THF and 0.98 mL 0.5M 4-methoxy-2-methylphenylmagnesium bromide. Yield: 41 mg of a white solid. LC-MSD, m/z for $C_{24}H_{19}BrN_2O_3$ $[M+H]^+ = 463.0, 465.0$; HPLC retention time: 2.4 min.

10

Example 116


[0405] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-chloro-3-fluoro-benzoyl)-1H-quinolin-4-one



15 **[0406]** Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1.5 mL THF and 0.98 mL 0.5M 4-chloro-3-fluorophenylmagnesium bromide. Yield: 52 mg of a white solid. LC-MSD, m/z for $C_{22}H_{13}BrClFN_2O_2$ $[M+H]^+ = 471.0, 473.0$; HPLC retention time: 2.6 min.

Example 117

20 **[0407] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2,6-dimethyl-pyridine-3-carbonyl)-1H-quinolin-4-one**




[0408] Experimental conditions analogous to those described for Step 6 of Example 60 from 105 mg (0.26 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 134 mg (0.58 mmol) of 2,6-dimethyl-5-iodo-pyridine in 1 mL THF with 0.30 mL 2M isopropylmagnesium chloride.

5 Yield: 19 mg of a white powder. LC-MSD, m/z for $C_{23}H_{18}BrN_3O_2$ $[M+H]^+ = 448.0, 450.0$; HPLC retention time: 1.2 min.

Example 118


[0409] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-chloro-3-methyl-benzoyl)-1H-quinolin-4-one



10 [0410] Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 0.98 mL 0.5M 4-chloro-3-methylphenylmagnesium bromide. Yield: 54 mg of a white solid. LC-MSD, m/z for $C_{23}H_{16}BrClN_2O_2$ $[M+H]^+ = 467.0, 469.0$; HPLC retention time: 2.6 min.

Example 119


[0411] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methylsulfanyl-benzoyl)-1H-quinolin-4-one



20 [0412] Experimental conditions analogous to those described for Step 6 of Example 60 from 210 mg (0.52 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 3 mL THF and 2.3 mL 0.5M 4-thioanisolemagnesium bromide. Yield: 111 mg of a white solid. LC-MSD, m/z for $C_{23}H_{17}BrN_2O_2S$ $[M+H]^+ = 465.0, 467.0$; HPLC retention time: 2.4 min.

Example 120

[0413] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(5-chloro-thiophene-2-carbonyl)-1H-quinolin-4-one




5 **[0414]** Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 0.5 mL THF and 2.0 mL 0.25M 5-chloro-2-thienylmagnesium bromide. Yield: 56 mg of a white solid. LC-MSD, m/z for $C_{20}H_{12}BrClN_2O_2S$ $[M+H]^+ = 458.9, 460.9, 462.9$; HPLC retention time: 2.5 min.

10

Example 121


[0415] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(6-chloro-pyridine-3-carbonyl)-1H-quinolin-4-one



15 **[0416]** Experimental conditions analogous to those described for Step 6 of Example 60 from 275 mg (0.68 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 3 mL THF and 360 mg (1.51 mmol) of 2-chloro-5-iodo-pyridine in 2 mL THF with 0.79 mL 2M isopropylmagnesium chloride. Yield: 187 mg of a white powder. LC-MSD, m/z for $C_{21}H_{13}BrClN_3O_2$ $[M+H]^+ = 454.0, 456.0$; HPLC retention time: 2.2 min.

Example 122


[0417] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(6-methoxy-5-methyl-pyridine-3-carbonyl)-1H-quinolin-4-one



- 5 **[0418]** Experimental conditions analogous to those described for Step 6 of Example 60 from 120 mg (0.30 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 164 mg (0.66 mmol) of 5-iodo-2-methoxy-3-methyl-pyridine in 1 mL THF with 0.34 mL 2M isopropylmagnesium chloride. Yield: 40 mg of a white powder. LC-MSD, m/z for $C_{23}H_{18}BrN_3O_3$ $[M+H]^+ = 464.0, 466.0$;
- 10 HPLC retention time: 2.4 min:

Example 123


[0419] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-fluoro-3-methyl-benzoyl)-1H-quinolin-4-one



- 15 **[0420]** Experimental conditions analogous to those described for Step 6 of Example 60 from 90 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 2 mL THF and 0.49 mL 1M 4-fluoro-3-methylphenylmagnesium bromide. Yield: 40 mg of a white solid. LC-MSD, m/z for $C_{23}H_{16}BrFN_2O_2$ $[M+H]^+ = 451.0, 453.0$; HPLC retention time: 2.5 min.

Example 124

[0421] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-chloro-3-methoxy-benzoyl)-1H-quinolin-4-one




5 **[0422]** Experimental conditions analogous to those described for Step 6 of Example 60 from 92 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 2.01 mL 0.25M 4-chloro-3-methoxyphenylmagnesium bromide. Yield: 40 mg of a white solid. LC-MSD, m/z for $C_{23}H_{16}BrClN_2O_3$ $[M+H]^+ = 483.0, 485.0$; HPLC retention time: 2.5 min.

10

Example 125


[0423] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-chloro-benzoyl)-1H-quinolin-4-one



15 **[0424]** Experimental conditions analogous to those described for Step 6 of Example 60 from 150 mg (0.37 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 3 mL THF and 0.82 mL 1M 4-chlorophenylmagnesium bromide. Yield: 73 mg of a white solid. LC-MSD, m/z for $C_{22}H_{14}BrClN_2O_2$ $[M+H]^+ = 453.0, 455.0$; HPLC retention time: 2.6 min.

Example 126

20 **[0425] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(5-methoxy-6-methyl-pyridine-2-carbonyl)-1H-quinolin-4-one**




[0426] Experimental conditions analogous to those described for Step 6 of Example 60 from 120 mg (0.30 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 164 mg (0.66 mmol) of 6-iodo-3-methoxy-2-methyl-pyridine in 1 mL THF with 0.34 mL 2M isopropylmagnesium chloride.

5 Yield: 60 mg of a white powder. LC-MSD, m/z for $C_{23}H_{18}BrN_3O_3$ $[M+H]^+ = 464.0, 466.0$; HPLC retention time: 1.9 min.

Example 127

[0427] Preparation of 3-(4-Methoxy-3-methyl-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one



10 **Step 1:** 1-(6-Methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester

[0428] Experimental conditions analogous to those described for Step 3 of Example 1, from 2.87 g (13.2 mmol) of 4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester, 0.64 g (15.9 mmol) of 60% sodium hydride, 2.95 g (15.9 mmol) of 2-bromomethyl-6-methyl-pyridine in 30 mL DMF to give 3.18 g of the product as an off-white solid.

Step 2: 1-(6-Methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid

[0429] Experimental conditions analogous to those described for Step 4 of Example 60, from 3.15 g (9.77 mmol) of 1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester, 80 mL of 1:1 methanol-water mixture and 0.28 g (11.7 mmol) of lithium hydroxide with a work-up consisting only of thorough evaporation of solvents.

Step 3: 1-(6-Methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide

[0430] Experimental conditions analogous to those described for Step 5 of Example 60, from crude 1-(6-Methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid,


1.27 g (12.7 mmol) of *N,O*-dimethylhydroxylamine hydrochloride, 9 mL (6.5 g, 64.7 mmol) of triethylamine and 9.2 mL (9.83 g, 15.5 mmol) of 50% 1-propanephosphonic acid cyclic anhydride in 50 mL acetonitrile to give 2.30 g of the product as an off-white solid.

Step 4: 3-(4-Methoxy-3-methyl-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one

[0431] Experimental conditions analogous to those described for Step 6 of Example 60, from 168 mg (0.50 mmol) of 1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 2.5 mL THF and 2.5 mL 0.5M 4-methoxy-3-methylphenylmagnesium bromide. Yield: 107 mg of a white solid. LC-MSD, *m/z* for $C_{25}H_{22}N_2O_3$ $[M+H]^+ = 399.1$; HPLC retention time: 2.1 min.

Example 128


[0432] Preparation of 3-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one



[0433] Experimental conditions analogous to those described for Step 6 of Example 60, from 161 mg (0.48 mmol) of 1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 2.5 mL THF and 2.4 mL 0.5M 3,4-(ethylenedioxy)phenylmagnesium bromide. Yield: 65 mg of a white solid. LC-MSD, *m/z* for $C_{25}H_{20}N_2O_4$ $[M+H]^+ = 413.1$; HPLC retention time: 1.8 min.

Example 129

[0434] Preparation of 3-(4-Dimethylamino-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one




[0435] Experimental conditions analogous to those described for Step 6 of Example 60, from 138 mg (0.41 mmol) of 1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-

3-carboxylic acid methoxy-methyl-amide in 2 mL THF and 2 mL 0.5M 4-*N,N*-dimethylanilinemagnesium bromide. Yield: 17 mg of a white solid. LC-MSD, *m/z* for $C_{25}H_{23}N_3O_2$ $[M+H]^+ = 398.1$; HPLC retention time: 1.9 min.

Example 130


- 5 [0436] Preparation of 1-(6-Methyl-pyridin-2-ylmethyl)-3-(6-trifluoromethyl-pyridine-3-carbonyl)-1H-quinolin-4-one



- 10 [0437] Experimental conditions analogous to those described for Step 6 of Example 60, from 120 mg (0.36 mmol) of 1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 214 mg (0.78 mmol) of 5-iodo-2-trifluoromethyl-pyridine in 1.5 mL THF with 0.41 mL 2M isopropylmagnesium chloride. Yield: 81 mg of a white powder. LC-MSD, *m/z* for $C_{23}H_{16}F_3N_3O_2$ $[M+H]^+ = 424.1$; HPLC retention time: 2.2 min.

Example 131


- 15 [0438] Preparation of 3-(3-Fluoro-4-methoxy-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one



- 20 [0439] Experimental conditions analogous to those described for Step 6 of Example 60, from 120 mg (0.36 mmol) of 1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 2 mL THF and 1.6 mL 0.5M 3-fluoro-4-methoxyphenylmagnesium bromide. Yield: 95 mg of a white solid. LC-MSD, *m/z* for $C_{24}H_{19}FN_2O_3$ $[M+H]^+ = 403.1$; HPLC retention time: 1.9 min.

Example 132


[0440] Preparation of 3-(6-Ethyl-pyridine-3-carbonyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one




- 5 **[0441]** Experimental conditions analogous to those described for Step 6 of Example 60, from 85 mg (0.25 mmol) of 1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 2.5 mL THF and 129 mg (0.56 mmol) of 2-ethyl-5-iodo-pyridine in 1 mL THF with 0.29 mL 2M isopropylmagnesium chloride. Yield: 41 mg of a white powder. LC-MSD, m/z for $C_{24}H_{21}N_3O_2$ $[M+H]^+ = 384.1$; HPLC retention time: 10 0.7 min.

Example 133

[0442] Preparation of 3-(6-Chloro-pyridine-3-carbonyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one



- 15 **[0443]** Experimental conditions analogous to those described for Step 6 of Example 60, from 800 mg (2.37 mmol) of 1-(6-methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 25 mL THF and 1.25 g (5.22 mmol) of 2-chloro-5-iodo-pyridine in 7 mL THF with 2.73 mL 2M isopropylmagnesium chloride. Yield: 635 mg of a white powder. LC-MSD, m/z for $C_{22}H_{16}ClN_3O_2$ $[M+H]^+ = 390.1, 392.0$; HPLC retention time: 20 2.0 min.

Example 134**[0444] Preparation of 1-(3-Chloro-benzyl)-3-(6-chloro-pyridine-3-carbonyl)-1H-quinolin-4-one**

5 **Step 1:** 1-(3-Chloro-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester

[0445] Experimental conditions analogous to those described for Step 1 of Example 3, from 5.08 g (23.4 mmol) of 4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester, 1.12 g (28.1 mmol) of 60% sodium hydride, 4.52 g (28.1 mmol) of 3-chlorobenzyl chloride in 60 mL DMF at 60°C to give 7.01 g of the product as an off-white solid.

10 **Step 2:** 1-(3-Chloro-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid

[0446] Experimental conditions analogous to those described for Step 4 of Example 60, from 7.00 g (20.5 mmol) of 1-(3-chloro-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester, 200 mL of 1:1 methanol-water mixture and 0.98 g (41.0 mmol) of lithium hydroxide with a work-up consisting only of thorough evaporation of solvents. The residue was directly taken to step 3.

Step 3: 1-(3-Chloro-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide


20 **[0447]** Experimental conditions analogous to those described for Step 5 of Example 60, from crude 1-(3-Chloro-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid, 2.21 g (22.6 mmol) of *N,O*-dimethylhydroxylamine hydrochloride, 14.3 mL (10.4 g, 103 mmol) of triethylamine and 14.6 mL (15.6 g, 24.5 mmol) of 50% 1-propanephosphonic acid cyclic anhydride in 100 mL acetonitrile to give 3.10 g of the product as an off-white solid.

Step 4: Preparation of 1-(3-Chloro-benzyl)-3-(6-chloro-pyridine-3-carbonyl)-1H-quinolin-4-one

[0448] Experimental conditions analogous to those described for Step 6 of Example 60, from 600 mg (1.68 mmol) of 1-(3-chloro-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 4 mL THF and 887 mg (3.70 mmol) of 2-chloro-5-iodo-pyridine in 4 mL THF with 1.93 mL 2M isopropylmagnesium chloride. Yield: 418 mg of a white powder. LC-MSD, m/z for $C_{22}H_{14}Cl_2N_2O_2$ $[M+H]^+ = 409.0, 411.0$; HPLC retention time: 3.3 min.

Example 135

[0449] Preparation of 1-(3-Chloro-benzyl)-3-(6-methoxy-5-methyl-pyridine-3-carbonyl)-1H-quinolin-4-one




10

[0450] Experimental conditions analogous to those described for Step 6 of Example 60, from 119 mg (0.33 mmol) of 1-(3-chloro-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 1 mL THF and 183 mg (0.73 mmol) of 5-iodo-2-methoxy-3-methyl-pyridine in 1 mL THF with 0.38 mL 2M isopropylmagnesium chloride. Yield: 86 mg of a white powder. LC-MSD, m/z for $C_{24}H_{19}ClN_2O_3$ $[M+H]^+ = 419.1, 421.1$; HPLC retention time: 3.1 min.

15


Example 136

[0451] Preparation of 1-(3-Chloro-benzyl)-3-(4-methoxy-benzoyl)-1H-quinolin-4-one




[0452] Experimental conditions analogous to those described for Step 6 of Example 60, from 300 mg (0.84 mmol) of 1-(3-chloro-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 3 mL THF and 3.7 mL 0.5M 4-methoxyphenylmagnesium bromide. Yield: 168 mg of a white solid. LC-MSD, m/z for $C_{24}H_{18}ClNO_3$ $[M+H]^+ = 404.1, 406.0$; HPLC retention time: 2.4 min.

20


Example 137**[0453] Preparation of 1-(3-Chloro-benzyl)-3-(6-ethyl-pyridine-3-carbonyl)-1H-quinolin-4-one**

- 5 [0454] Experimental conditions analogous to those described for Step 6 of Example 60, from 300 mg (0.84 mmol) of 1-(3-chloro-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 2 mL THF and 433 mg (1.86 mmol) of 2-ethyl-5-iodo-pyridine in 2 mL THF with 0.97 mL 2M isopropylmagnesium chloride. Yield: 127 mg of a white powder. LC-MSD, m/z for $C_{24}H_{19}ClN_2O_2$ $[M+H]^+ = 403.1, 405.1$; HPLC retention
- 10 time: 1.8 min.

Example 138**[0455] Preparation of 1-(3-Chloro-benzyl)-3-(6-methoxy-pyridine-3-carbonyl)-1H-quinolin-4-one**

- 15 [0456] Experimental conditions analogous to those described for Step 6 of Example 60, from 151 mg (0.37 mmol) of 1-(3-chloro-benzyl)-3-(6-chloro-pyridine-3-carbonyl)-1H-quinolin-4-one and 170 mg (3.15 mmol) of sodium methoxide were stirred in 2 mL of dry methanol in a sealed vessel at 75°C for 2 h. The reaction mixture was evaporated and purified by flash chromatography to give 134 mg of a white powder. LC-MSD, m/z for
- 20 $C_{23}H_{17}ClN_2O_3$ $[M+H]^+ = 405.1, 407.1$; HPLC retention time: 2.3 min.

Example 139

[0457] Preparation of 1-(4-Methoxy-benzyl)-3-(6-trifluoromethyl-pyridine-3-carbonyl)-1H-quinolin-4-one

5 **Step 1:** 1-(4-Methoxy-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester

[0458] Experimental conditions analogous to those described for Step 3 of Example 1, from 03.00 g (13.8 mmol) of 4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester, 0.66 g (16.6 mmol) of 60% sodium hydride, 2.60 g (16.6 mmol) of 4-methoxybenzyl chloride in 30 mL DMF to give 3.10 g of the product as an off-white solid.

10 **Step 2:** 1-(4-Methoxy-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid

[0459] Experimental conditions analogous to those described for Step 4 of Example 60, from 3.10 g (8.80 mmol) of 1-(4-methoxy-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester, 40 mL of 1:1 methanol-water mixture and 0.44 g (18.3 mmol) of lithium hydroxide with a work-up consisting only of thorough evaporation of solvents.

15 **Step 3:** 1-(4-Methoxy-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide

[0460] Experimental conditions analogous to those described for Step 5 of Example 60, from crude 1-(4-Methoxy-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid, 1.03 g (10.6 mmol) of *N,O*-dimethylhydroxylamine hydrochloride, 6.1 mL (4.43 g, 43.8 mmol) of triethylamine and 6.3 mL (6.80 g, 10.7 mmol) of 50% 1-propanephosphonic acid cyclic anhydride in 30 mL acetonitrile to give 1.90 g of the product as an off-white solid.


Step 4: 1-(4-Methoxy-benzyl)-3-(6-trifluoromethyl-pyridine-3-carbonyl)-1H-quinolin-4-one

[0461] Experimental conditions analogous to those described for Step 6 of Example 60, from 864 mg (2.45 mmol) of 1-(4-methoxy-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide in 8 mL THF and 1.47 g (5.40 mmol) of 2-ethyl-5-

iodo-pyridine in 8 mL THF with 2.82 mL 2M isopropylmagnesium chloride. Yield: 800 mg of a white powder. LC-MSD, m/z for $C_{24}H_{17}F_3N_2O_3$ $[M+H]^+ = 439.1$; HPLC retention time: 2.6 min.

Example 140

5 [0462] Preparation of 1-(3-Bromo-benzyl)-3-(6-trifluoromethyl-pyridine-3-carbonyl)-1H-quinolin-4-one



Step 1: 3-(6-Trifluoromethyl-pyridine-3-carbonyl)-1H-quinolin-4-one


10 [0463] 800 mg (1.83 mmol) of 1-(4-methoxy-benzyl)-3-(6-trifluoromethyl-pyridine-3-carbonyl)-1H-quinolin-4-one was heated in a sealed tube to 120°C in 15 mL of 4 M HCl in dioxane for 20 h. The solution was evaporated and the residue ultrasonicated in 20 mL saturated aqueous $NaHCO_3$. Filtration of the solid followed by aqueous wash, DCM wash and drying gave 340 mg of a light-brown powder. LC-MSD, m/z for $C_{16}H_9F_3N_2O_2$ $[M+H]^+ = 319.0$; HPLC retention time: 1.8 min.

15 Step2: 1-(3-Bromo-benzyl)-3-(6-trifluoromethyl-pyridine-3-carbonyl)-1H-quinolin-4-one

[0464] Experimental conditions analogous to those described for Step 6 of Example 60, from 71 mg (0.22 mmol) of 3-(6-trifluoromethyl-pyridine-3-carbonyl)-1H-quinolin-4-one, 11 mg (0.27 mmol) of 60% sodium hydride, 67 mg (0.27 mmol) of 3-bromobenzyl bromide and 1 mL of *N,N*-dimethylformamide. Yield: 85 mg of a white solid: LC-MSD, m/z for $C_{23}H_{14}BrF_3N_2O_2$ $[M+H]^+ = 487.0, 489.0$; HPLC retention time: 2.7 min.

Example 141

[0465] Preparation of 3-(6-Dimethylamino-pyridine-3-carbonyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one




25 [0466] 95 mg (0.37 mmol) of 3-(6-chloro-pyridine-3-carbonyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one was heated with 3 mL of 2 M solution of dimethylamine in

THF in a sealed vessel at 70°C for 2 h. The reaction mixture was evaporated and purified by flash chromatography to give 88 mg of a yellow powder. LC-MSD, m/z for C₂₄H₂₂N₄O₂ [M+H]⁺ = 399.1; HPLC retention time: 0.5 min.

Example 142


- 5 [0467] Preparation of 1-(3-Chloro-benzyl)-3-(6-dimethylamino-pyridine-3-carbonyl)-1H-quinolin-4-one



- 10 [0468] Experimental conditions analogous to those described for Example 141, from 151 mg (0.37 mmol) of 1-(3-chloro-benzyl)-3-(6-chloro-pyridine-3-carbonyl)-1H-quinolin-4-one and 2 mL 2 M dimethylamine solution. Yield: 127 mg of a yellow powder. LC-MSD, m/z for C₂₄H₂₀ClN₃O₂ [M+H]⁺ = 418.1, 420.1; HPLC retention time: 1.6 min.

Example 143


- [0469] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(6-dimethylamino-pyridine-3-carbonyl)-1H-quinolin-4-one



- 15 [0470] Experimental conditions analogous to those described for Example 141, from 42 mg (0.092 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-3-(6-chloro-pyridine-3-carbonyl)-1H-quinolin-4-one and 1 mL 2 M dimethylamine solution. Yield: 17 mg of a yellow powder. LC-MSD, m/z for C₂₃H₁₉BrN₄O₂ [M+H]⁺ = 463.0, 465.0; HPLC retention time: 0.6 min.

Example 144

- 20 [0471] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(6-pyrrolidin-1-yl-pyridine-3-carbonyl)-1H-quinolin-4-one




[0472] Experimental conditions analogous to those described for Example 141, from 103 mg (0.23 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-3-(6-chloro-pyridine-3-carbonyl)-1H-quinolin-4-one and 0.5 mL pyrrolidine in 2 mL THF. Yield: 50 mg of a yellow powder. LC-MSD, m/z for $C_{25}H_{21}BrN_4O_2$ $[M+H]^+ = 489.0, 491.0$; HPLC retention time: 1.1 min.

5

Example 145

[0473] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(6-diethylamino-pyridine-3-carbonyl)-1H-quinolin-4-one




[0474] Experimental conditions analogous to those described for Example 141, from 97 mg (0.21 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-3-(6-chloro-pyridine-3-carbonyl)-1H-quinolin-4-one and 3 mL diethylamine in 7 mL THF. Yield: 50 mg of a yellow powder. LC-MSD, m/z for $C_{25}H_{23}BrN_4O_2$ $[M+H]^+ = 491.0, 493.0$; HPLC retention time: 2.9 min.

Example 146

[0475] Preparation of 3-(6-Amino-pyridine-3-carbonyl)-1-(6-bromo-pyridin-2-ylmethyl)-1H-quinolin-4-one

15




[0476] 100 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-3-(6-chloro-pyridine-3-carbonyl)-1H-quinolin-4-one and 72 mg (1.1 mmol) of sodium azide were heated at 100°C in 1 mL of DMF for 1 h. The temperature of the solution was lowered to 70°C and 1 mL of water was added, followed by 214 uL (155 mg, 1.54 mmol) of triethylamine and 378 mg (1.32 mmol) of tris(2-carboxyethyl)phosphine hydrochloride. After 1 h of reaction time the mixture was purified on reverse-phase HPLC, followed by flash chromatography to give 60 mg of a yellow powder. LC-MSD, m/z for $C_{21}H_{15}BrN_4O_2$ $[M+H]^+ = 435.0, 437.0$; HPLC retention time: 0.6 min.

20

Example 147

[0477] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(6-methoxy-pyridine-3-carbonyl)-1H-quinolin-4-one




5 **[0478]** Experimental conditions analogous to those described for Example 141, from 38 mg (0.084 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-3-(6-chloro-pyridine-3-carbonyl)-1H-quinolin-4-one, 90 mg (1.67 mmol) of sodium methoxide and 1 mL dry methanol. Yield: 19 mg of a white powder. LC-MSD, m/z for $C_{22}H_{16}BrN_3O_3$ $[M+H]^+ = 450.0, 452.0$; HPLC retention time: 2.3 min.


10

Example 148

[0479] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(6-oxo-1,6-dihydro-pyridine-3-carbonyl)-1H-quinolin-4-one



15 **[0480]** 70 mg (0.22 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-3-(6-chloro-pyridine-3-carbonyl)-1H-quinolin-4-one was heated at 100°C in 2 mL of concentrated aqueous hydrobromic acid in a sealed tube for 20 h. The solution was evaporated and purified on reverse-phase HPLC and free-based to give 36 mg of a yellow powder. LC-MSD, m/z for $C_{21}H_{14}BrN_3O_3$ $[M+H]^+ = 436.0, 438.0$; HPLC retention time: 1.4 min.

Example 149**[0481] Preparation of 7-(3,4-dimethyl-benzoyl)-5-pyridin-2-ylmethyl-5H-[1,3]dioxolo[4,5-g]quinolin-8-one**

- 5 **Step 1:** Synthesis of 3-(benzo[1,3]dioxol-5-ylamino)-2-(3,4-dimethyl-benzoyl)-acrylic acid methyl ester

[0482] Experimental conditions analogous to those described for Step 1 of Example 1, from crude 2-(3,4-dimethyl-benzoyl)-3-methoxy-acrylic acid methyl ester (4.03 g, 16.3 mmol) and benzo[1,3]dioxol-5-ylamine (2.45 g, 17.9 mmol). Yield: 3.14 g of a yellow crystalline solid:
 10 LC-MSD, m/z for $C_{20}H_{20}NO_5$ $[M+H]^+ = 354.4$; HPLC retention time: 2.8 min.

Step 2: Synthesis of 7-(3,4-dimethyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one


[0483] Experimental conditions analogous to those described for Step 2 of Example 1, from 3-(benzo[1,3]dioxol-5-ylamino)-2-(3,4-dimethyl-benzoyl)-acrylic acid methyl ester (1.69 g, 4.78 mmol). Yield: 0.95 g of off-white crystals: LC-MSD, m/z for $C_{19}H_{15}NO_4$ $[M+H]^+ =$
 15 322.4; HPLC retention time: 1.7 min.

Step 3: Synthesis of 7-(3,4-dimethyl-benzoyl)-5-pyridin-2-ylmethyl-5H-[1,3]dioxolo[4,5-g]quinolin-8-one

[0484] Experimental conditions analogous to those described for Step 3 of Example 1, from 71 mg (0.22 mmol) of 7-(3,4-dimethyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one, 23 mg of 60% sodium hydride, 72 mg of 2-bromomethylpyridine hydrobromide and 1.3 mL of *N,N*-dimethylformamide. Yield: 75 mg of a white solid: LC-MSD, m/z for $C_{25}H_{20}N_2O_4$ $[M+H]^+ = 413.5$; HPLC retention time: 2.1 min.
 20

Example 150


[0485] Preparation of 7-(3,4-Dimethyl-benzoyl)-5-pyridin-3-ylmethyl-5H-[1,3]dioxolo[4,5-g]quinolin-8-one



[0486] Experimental conditions analogous to those described for Step 3 of Example 1, from 71 mg (0.22 mmol) of 7-(3,4-dimethyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one, 23 mg of 60% sodium hydride, 72 mg of 3-bromomethylpyridine hydrobromide and 1.3 mL of *N,N*-dimethylformamide. Yield: 45 mg of a white solid: LC-MSD, *m/z* for $C_{25}H_{20}N_2O_4$ $[M+H]^+ = 413.5$; HPLC retention time: 1.5 min.

Example 151


[0487] Preparation of 7-(3,4-Dimethyl-benzoyl)-5-pyridin-4-ylmethyl-5H-[1,3]dioxolo[4,5-g]quinolin-8-one



[0488] Experimental conditions analogous to those described for Step 3 of Example 1, from 71 mg (0.22 mmol) of 7-(3,4-dimethyl-benzoyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one, 23 mg of 60% sodium hydride, 72 mg of 4-bromomethylpyridine hydrobromide and 1.3 mL of *N,N*-dimethylformamide. Yield: 61 mg of a white solid: LC-MSD, *m/z* for $C_{25}H_{20}N_2O_4$ $[M+H]^+ = 413.5$; HPLC retention time: 1.2 min.

Example 152

[0489] Preparation of 8-(3,4-Dimethyl-benzoyl)-6-pyridin-2-ylmethyl-2,3-dihydro-6H-[1,4]dioxino[2,3-g]quinolin-9-one




[0490] Experimental conditions analogous to those described for Step 3 of Example 1, from 58 mg (0.17 mmol) of 8-(3,4-dimethyl-benzoyl)-2,3-dihydro-6H-[1,4]dioxino[2,3-g]quinolin-

9-one, 18 mg of 60% sodium hydride, 57 mg of 2-bromomethylpyridine hydrobromide and 1.2 mL of *N,N*-dimethylformamide. Yield: 63 mg of a white solid: LC-MSD, *m/z* for $C_{26}H_{22}N_2O_4$ $[M+H]^+ = 427.5$; HPLC retention time: 2.1 min.

Example 153


5 [0491] Preparation of 8-(3,4-Dimethyl-benzoyl)-6-pyridin-3-ylmethyl-2,3-dihydro-6H-[1,4]dioxino[2,3-g]quinolin-9-one




10 [0492] Experimental conditions analogous to those described for Step 3 of Example 1, from 58 mg (0.17 mmol) of 8-(3,4-dimethyl-benzoyl)-2,3-dihydro-6H-[1,4]dioxino[2,3-g]quinolin-9-one, 18 mg of 60% sodium hydride, 57 mg of 3-bromomethylpyridine hydrobromide and 1.2 mL of *N,N*-dimethylformamide. Yield: 55 mg of a white solid: LC-MSD, *m/z* for $C_{26}H_{22}N_2O_4$ $[M+H]^+ = 427.5$; HPLC retention time: 1.6 min.

Example 154

15 [0493] Preparation of 8-(3,4-Dimethyl-benzoyl)-6-pyridin-4-ylmethyl-2,3-dihydro-6H-[1,4]dioxino[2,3-g]quinolin-9-one



20 [0494] Experimental conditions analogous to those described for Step 3 of Example 1, from 58 mg (0.17 mmol) of 8-(3,4-dimethyl-benzoyl)-2,3-dihydro-6H-[1,4]dioxino[2,3-g]quinolin-9-one, 18 mg of 60% sodium hydride, 57 mg of 4-bromomethylpyridine hydrobromide and 1.2 mL of *N,N*-dimethylformamide. Yield: 52 mg of a white solid: LC-MSD, *m/z* for $C_{26}H_{22}N_2O_4$ $[M+H]^+ = 427.5$; HPLC retention time: 1.4 min.

Example 156**[0495] Preparation of 1-(6-bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-2-methyl-1H-quinolin-4-one**

5 **Step 1:** Synthesis of 2-(3,4-dimethyl-benzoyl)-3-phenylamino-but-2-enoic acid methyl ester

[0496] 10.6 g (51.4 mmol) of 3-(3,4-dimethyl-phenyl)-3-oxo-propionic acid methyl ester was heated with 12.4 g (103 mmol) of trimethyl orthoacetate and 5.51 g (54.0 mmol) of acetic anhydride at 115°C for 3 days. The mixture was evaporated and combined with 4.69 mL (51.4 mmol) of aniline. Yield: 8.60 g of a yellow solid (after flash chromatography contains inseparable 3-(3,4-dimethyl-phenyl)-3-oxo-propionic acid methyl ester): LC-MSD, m/z for C₂₀H₂₁NO₃ [M+H]⁺ = 324.2; HPLC retention time: 2.1 min.

Step 2: Synthesis of 3-(3,4-Dimethyl-benzoyl)-2-methyl-1H-quinolin-4-one

[0497] Experimental conditions analogous to those described for Step 2 of Example 1, from 2-(3,4-dimethyl-benzoyl)-3-phenylamino-but-2-enoic acid methyl ester (8.60 g, 26.6 mmol).


15 Yield: 0.92 g of off-white crystals after recrystallization from hot methanol: LC-MSD, m/z for C₁₉H₁₇NO₂ [M+H]⁺ = 292.1; HPLC retention time: 1.7 min.

Step 3: Synthesis of 1-(6-bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-2-methyl-1H-quinolin-4-one

[0498] Experimental conditions analogous to those described for Step 3 of Example 1, from 57 mg (0.20 mmol) of 3-(3,4-dimethyl-benzoyl)-2-methyl-1H-quinolin-4-one, 9 mg (0.24 mmol) of 60% sodium hydride, 59 mg of 2-bromo-6-bromomethyl-pyridine and 0.7 mL of N,N-dimethylformamide. Yield: 44 mg of a white solid: LC-MSD, m/z for C₂₅H₂₁BrN₂O₂ [M+H]⁺ = 461.1, 463.1; HPLC retention time: 2.7 min.

Example 157


[0499] Preparation of 1-(6-bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-6,7-difluoro-1H-quinolin-4-one



[0500] Experimental conditions analogous to those described for Step 3 of Example 1, from 74 mg (0.24 mmol) of 3-(3,4-dimethyl-benzoyl)-6,7-difluoro-1H-quinolin-4-one, 71 mg (0.28 mmol) of 2-bromo-6-bromomethyl-pyridine, 0.57 mL of 0.5M toluene solution of potassium bis(trimethylsilyl)amide and 2 mL of THF. Yield: 73 mg of a white solid: LC-MSD, m/z for $C_{24}H_{17}BrF_2N_2O_2$ $[M+H]^+ = 483.4, 485.4$; HPLC retention time: 2.6 min.

Example 158


[0501] Preparation of 1-(6-bromo-pyridin-2-ylmethyl)-3-(5,6-dimethyl-pyridine-3-carbonyl)-6-fluoro-1H-quinolin-4-one



[0502] Experimental conditions analogous to those described for Step 3 of Example 1, from 50 mg (0.17 mmol) of 3-(5,6-dimethyl-pyridine-3-carbonyl)-6-fluoro-1H-quinolin-4-one, 8 mg (0.20 mmol) of 60% sodium hydride and 51 mg (0.20 mmol) of 2-bromo-6-bromomethyl-pyridine and 0.7 mL of *N,N*-dimethylformamide. Yield: 38 mg of a white solid: LC-MSD, m/z for $C_{23}H_{17}BrFN_3O_2$ $[M+H]^+ = 466.2, 468.1$; HPLC retention time: 2.1 min.

Example 159


[0503] Preparation of 3-(5,6-Dimethyl-pyridine-3-carbonyl)-6-fluoro-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one



[0504] Experimental conditions analogous to those described for Step 3 of Example 1, from 71 mg (0.24 mmol) 3-(5,6-dimethyl-pyridine-3-carbonyl)-6-fluoro-1H-quinolin-4-one, 12 mg (0.29 mmol) of 60% sodium hydride, 53 mg (0.29 mmol) of 2-bromomethyl-6-methyl-pyridine and 1 mL of *N,N*-dimethylformamide. Yield: 67 mg of a white solid: LC-MSD, *m/z* for $C_{24}H_{20}FN_3O_2$ $[M+H]^+ = 402.1$; HPLC retention time: 0.7 min.

Example 160


[0505] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-pyridin-2-ylmethyl-6-trifluoromethyl-1H-quinolin-4-one



[0506] Experimental conditions analogous to those described for Step 3 of Example 1, from 55 mg (0.16 mmol) of 3-(3,4-dimethyl-benzoyl)-6-trifluoromethyl-1H-quinolin-4-one, 18 mg of 60% sodium hydride, 52 mg of 2-bromomethylpyridine hydrobromide and 1 mL of *N,N*-dimethylformamide. Yield: 49 mg of a white solid: LC-MSD, *m/z* for $C_{25}H_{19}F_2N_2O_2$ $[M+H]^+ = 437.5$; HPLC retention time: 2.6 min.

Example 161


[0507] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(5-trifluoromethyl-furan-2-ylmethyl)-1H-quinolin-4-one



[0508] Experimental conditions analogous to those described for Step 3 of Example 1, from 55 mg (0.20 mmol) of 3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one, 10 mg of 60% sodium hydride, 55 mg (0.24 mmol) 2-bromomethyl-5-trifluoromethyl-furan and 0.7 mL of *N,N*-dimethylformamide. Yield: 70 mg of a white solid: LC-MSD, *m/z* for $C_{24}H_{18}F_3NO_3$ $[M+H]^+ = 426.4$; HPLC retention time: 2.7 min.

Example 162

[0509] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(6-methoxy-pyridin-2-ylmethyl)-1H-quinolin-4-one




5 **[0510]** Experimental conditions analogous to those described for Step 3 of Example 1, from 50 mg (0.18 mmol) of 3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one, 9 mg (0.21 mmol) of 60% sodium hydride, 44 mg (0.22 mmol) 2-bromomethyl-6-methoxy-pyridine and 0.8 mL of *N,N*-dimethylformamide. Yield: 45 mg of a white solid: LC-MSD, *m/z* for $C_{25}H_{22}N_2O_3$ $[M+H]^+ = 399.3$; HPLC retention time: 2.8 min.

10

Example 163


[0511] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(6-fluoro-pyridin-2-ylmethyl)-1H-quinolin-4-one



15 **[0512]** Experimental conditions analogous to those described for Step 3 of Example 1, from 49 mg (0.18 mmol) of 3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one, 8 mg (0.21 mmol) of 60% sodium hydride, 40 mg (0.21 mmol) 2-bromomethyl-6-fluoro-pyridine and 0.8 mL of *N,N*-dimethylformamide. Yield: 28 mg of a white solid: LC-MSD, *m/z* for $C_{24}H_{19}FN_2O_2$ $[M+H]^+ = 387.3$; HPLC retention time: 2.6 min.

Example 164


20 **[0513] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(6-oxo-1,6-dihydro-pyridin-2-ylmethyl)-1H-quinolin-4-one**



[0514] 182 mg (0.41 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one in a solution of 3 mL acetic acid and 3 mL concentrated aqueous hydrochloric acid was heated in a sealed tube at 150°C for 24 h. Purification on reverse-phase HPLC and free-basing gave 95 mg of a white solid: LC-MSD, m/z for C₂₄H₂₀N₂O₃ [M+H]⁺ = 385.1; HPLC retention time: 0.4 min.

Example 165


[0515] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methanesulfinyl-benzoyl)-1H-quinolin-4-one



[0516] 42 mg (0.09 mmol) of 1-(6-bromo-pyridin-2-ylmethyl)-3-(4-methylsulfanyl-benzoyl)-1H-quinolin-4-one was dissolved in 1 mL acetic acid followed by the addition of 16 µL of 35% aqueous hydrogen peroxide. The reaction was stirred at r.t for 20 h and evaporated. Purification using flash chromatography gave 33 mg of a white solid. LC-MSD, m/z for C₂₃H₁₇BrN₂O₃S [M+H]⁺ = 481.0, 483.0; HPLC retention time: 1.8 min.

Example 166


[0517] Preparation of 1-(6-Amino-pyridin-2-ylmethyl)-3-(5,6-dimethyl-pyridine-2-carbonyl)-1H-quinolin-4-one



[0518] Experimental conditions analogous to those described for Step 3 of Example 1, from 127 mg (0.46 mmol) of 3-(5,6-dimethyl-pyridine-2-carbonyl)-1H-quinolin-4-one, 22 mg (0.55 mmol) of 60% sodium hydride, 155 mg (0.55 mmol) of N-(6-bromomethyl-pyridin-2-yl)-2,2,2-trifluoro-acetamide and 1 mL of N,N-dimethylformamide. The 130 mg of trifluoroacetamide product were heated to 60°C in a mixture of 1 mL of methanol and 4 mL of diethylamine for 3 h, then overnight at 45°C. The product was filtered off and washed with a small amount of DCM. Yield: 36 mg of a white solid: LC-MSD, m/z for C₂₃H₂₀N₄O₂ [M+H]⁺ = 385.2; HPLC retention time: 0.8 min.

Example 167

[0519] Preparation of 1-(6-Amino-pyridin-2-ylmethyl)-3-(5,6-dimethyl-pyridine-3-carbonyl)-1H-quinolin-4-one




5 **[0520]** Experimental conditions analogous to those described for Step 3 of Example 1, from 75 mg (0.27 mmol) of 3-(5,6-dimethyl-pyridine-3-carbonyl)-1H-quinolin-4-one, 13 mg (0.32 mmol) of 60% sodium hydride, 92 mg (0.32 mmol) of *N*-(6-bromomethyl-pyridin-2-yl)-2,2,2-trifluoro-acetamide and 0.7 mL of *N,N*-dimethylformamide. Yield: 20 mg of a white solid: LC-MSD, m/z for $C_{23}H_{20}N_4O_2$ $[M+H]^+ = 385.1$; HPLC retention time: 0.3 min.

10

Example 168


[0521] Preparation of 3-(5,6-Dimethyl-pyridine-2-carbonyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one



15 **[0522]** Experimental conditions analogous to those described for Step 3 of Example 1, from 95 mg (0.34 mmol) of 3-(5,6-dimethyl-pyridine-2-carbonyl)-1H-quinolin-4-one, 16 mg (0.41 mmol) of 60% sodium hydride, 77 mg (0.41 mmol) of 2-bromomethyl-6-methyl-pyridine and 1 mL of *N,N*-dimethylformamide. Yield: 14 mg of a white solid: LC-MSD, m/z for $C_{24}H_{21}N_3O_2$ $[M+H]^+ = 384.1$; HPLC retention time: 1.9 min.

Example 169


20 **[0523] Preparation of 1-[1-(6-Bromo-pyridin-2-yl)-ethyl]-3-(5,6-dimethyl-pyridine-3-carbonyl)-1H-quinolin-4-one**



[0524] Experimental conditions analogous to those described for Step 3 of Example 1, from 55 mg (0.20 mmol) of 3-(5,6-dimethyl-pyridine-3-carbonyl)-1H-quinolin-4-one, 10 mg (0.26 mmol) of 60% sodium hydride, 68 mg (0.26 mmol) of 2-bromo-6-(1-bromo-ethyl)-pyridine and 0.7 mL of *N,N*-dimethylformamide. Yield: 24 mg of a white solid: LC-MSD, *m/z* for $C_{24}H_{20}BrN_3O_2$ $[M+H]^+ = 462.0, 464.0$; HPLC retention time: 1.4 min.

Example 170


[0525] Preparation of 1-[1-(6-Bromo-pyridin-2-yl)-ethyl]-3-(5,6-dimethyl-pyridine-2-carbonyl)-1H-quinolin-4-one



[0526] Experimental conditions analogous to those described for Step 3 of Example 1, from 50 mg (0.18 mmol) of 3-(5,6-dimethyl-pyridine-2-carbonyl)-1H-quinolin-4-one, 9 mg (0.22 mmol) of 60% sodium hydride, 57 mg (0.22 mmol) of 2-bromo-6-(1-bromo-ethyl)-pyridine and 0.7 mL of *N,N*-dimethylformamide. Yield: 4.4 mg of a white solid: LC-MSD, *m/z* for $C_{24}H_{20}BrN_3O_2$ $[M+H]^+ = 462.0, 464.0$; HPLC retention time: 2.0 min.

Example 171


[0527] Preparation of 1-[1-(6-Bromo-pyridin-2-yl)-ethyl]-3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one



[0528] Experimental conditions analogous to those described for Step 3 of Example 1, from 52 mg (0.19 mmol) of 3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one, 9 mg (0.23 mmol) of 60% sodium hydride, 60 mg (0.23 mmol) of 2-bromo-6-(1-bromo-ethyl)-pyridine and 0.7 mL of *N,N*-dimethylformamide. Yield: 32 mg of a white solid: LC-MSD, *m/z* for $C_{25}H_{21}BrN_2O_2$ $[M+H]^+ = 461.0, 463.0$; HPLC retention time: 2.6 min.

Example 172

[0529] Preparation of 3-(5,6-Dimethyl-pyridine-3-carbonyl)-1-(6-trifluoromethyl-pyridin-2-ylmethyl)-1H-quinolin-4-one




- 5 **[0530]** Experimental conditions analogous to those described for Step 3 of Example 1, from 60 mg (0.22 mmol) of 3-(5,6-dimethyl-pyridine-3-carbonyl)-1H-quinolin-4-one, 10 mg (0.26 mmol) of 60% sodium hydride, 62 mg (0.26 mmol) of 2-bromomethyl-6-trifluoromethyl-pyridine and 0.7 mL of *N,N*-dimethylformamide. Yield: 29 mg of a white solid: LC-MSD, m/z for $C_{24}H_{18}F_3N_3O_2$ $[M+H]^+ = 438.1$; HPLC retention time: 1.4 min.

10

Example 173


[0531] Preparation of 3-(5,6-Dimethyl-pyridine-2-carbonyl)-1-(6-trifluoromethyl-pyridin-2-ylmethyl)-1H-quinolin-4-one



- 15 **[0532]** Experimental conditions analogous to those described for Step 3 of Example 1, from 63 mg (0.23 mmol) of 3-(5,6-dimethyl-pyridine-2-carbonyl)-1H-quinolin-4-one, 11 mg (0.27 mmol) of 60% sodium hydride, 65 mg (0.27 mmol) of 2-bromomethyl-6-trifluoromethyl-pyridine and 0.7 mL of *N,N*-dimethylformamide. Yield: 31 mg of a white solid: LC-MSD, m/z for $C_{24}H_{18}F_3N_3O_2$ $[M+H]^+ = 438.1$; HPLC retention time: 1.6 min.

Example 174


- 20 **[0533] Preparation of 6-[3-(5,6-Dimethyl-pyridine-2-carbonyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridine-2-carbonitrile**



- [0534] Experimental conditions analogous to those described for Step 3 of Example 1, from 67 mg (0.24 mmol) of 3-(5,6-dimethyl-pyridine-2-carbonyl)-1H-quinolin-4-one, 12 mg (0.29 mmol) of 60% sodium hydride, 57 mg (0.29 mmol) of 6-bromomethyl-pyridine-2-carbonitrile and 0.7 mL of *N,N*-dimethylformamide. Yield: 34 mg of a white solid: LC-MSD, *m/z* for $C_{24}H_{18}N_4O_2$ $[M+H]^+ = 395.1$; HPLC retention time: 1.0 min.

Example 175


[0535] Preparation of 6-[3-(3,4-Dimethyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridine-2-carbonitrile



- [0536] Experimental conditions analogous to those described for Step 3 of Example 1, from 51 mg (0.18 mmol) of 3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one, 9 mg (0.22 mmol) of 60% sodium hydride, 44 mg (0.22 mmol) of 6-bromomethyl-pyridine-2-carbonitrile and 0.7 mL of *N,N*-dimethylformamide. Yield: 27 mg of a white solid: LC-MSD, *m/z* for $C_{25}H_{19}N_3O_2$ $[M+H]^+ = 394.1$; HPLC retention time: 2.1 min.

Example 176


[0537] Preparation of 6-[3-(3,4-Dimethyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridine-2-carboxylic acid



- [0538] 49 mg (0.12 mmol) of 6-[3-(3,4-dimethyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridine-2-carbonitrile was heated to 100°C for 1 h in 3 g of 70% aqueous sulfuric acid. The solution was then cooled down, diluted with 20 mL of water and filtered. The residue was purified on reverse-phase HPLC and converted to HCl salt to give 28 mg of a white solid. LC-MSD, *m/z* for $C_{25}H_{21}N_2O_4$ $[M+H]^+ = 413.1$; HPLC retention time: 1.7 min.

Example 177


[0539] Preparation of 6-[3-(3,4-Dimethyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridine-2-carboxylic acid amide



- 5 **[0540]** 27 mg (0.06 mmol) of 6-[3-(3,4-dimethyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridine-2-carboxylic acid hydrochloride was dissolved in a mixture of 2 mL DMSO and 0.2 mL 2 M methanolic ammonia followed by the addition of 100 mg (0.36 mmol) of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride. The mixture was stirred for 1 h at r.t. followed by purification on reverse-phase HPLC and flash chromatography to give 17 mg of a white solid. LC-MSD, m/z for $C_{25}H_{21}N_3O_3$ $[M+H]^+ = 412.2$; HPLC retention time: 1.7 min.

Example 178

[0541] Preparation of 1-(2-Fluoro-benzyl)-3-(pyrazine-2-carbonyl)-1H-quinolin-4-one



- 15 **[0542]** Experimental conditions analogous to those described for Step 3 of Example 1, from 15.6 mg (0.39 mmol) of NaH (60%), 75 mg (0.30 mmol) of 3-(Pyrazine-2-carbonyl)-1H-quinolin-4-one, 3 mL of anhydrous DMF, 78 mg (0.4 mmol) of 2-fluorobenzylbromide. The crude product was purified by flash chromatography to yield 37 mg of colorless solid. LC-MSD, m/z for $C_{21}H_{14}FN_3O_2$ $[M+H]^+ : 360.5$, $[M+2H]^+ : 361.5$. Reverse phase HPLC
20 gradient acetonitrile 0.1% TFA 20-95% in 4 min: 2.287 min.

Example 179

[0543] Preparation of 1-(3-methyl-benzyl)-3-(pyrazine-2-carbonyl)-1H-quinolin-4-one




[0544] Experimental conditions analogous to those described for Step 3 of Example 1, from 15.6 mg (0.39 mmol) of NaH (60%), 75 mg (0.30 mmol) of 3-(Pyrazine-2-carbonyl)-1H-quinolin-4-one, 3 mL of anhydrous DMF, 76 mg (0.4 mmol) of 3-methylbenzylbromide. The crude product was purified by flash chromatograph to yield 35 mg of colorless solid.

5 LC-MSD, m/z for $C_{22}H_{17}N_3O_2$ $[M+H]^+$: 356.5, $[M+2H]^+$: 357.5. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 2.394 min.

Example 180

[0545] Preparation of 1-(2-methyl-benzyl)-3-(pyrazine-2-carbonyl)-1H-quinolin-4-one




10 [0546] Experimental conditions analogous to those described for Step 3 of Example 1, from 15.6 mg (0.39 mmol) of NaH (60%), 75 mg (0.30 mmol) of 3-(Pyrazine-2-carbonyl)-1H-quinolin-4-one, 3 mL of anhydrous DMF, 76 mg (0.4 mmol) of 2-methylbenzylbromide. The crude product was purified by flash chromatograph to yield 41 mg of colorless solid.

15 LC-MSD, m/z for $C_{21}H_{16}N_4O_2$ $[M+H]^+$: 357.5, $[M+2H]^+$: 358.5. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 1.895 min

Example 181

[0547] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(6-hydroxymethyl-pyridin-2-ylmethyl)-1H-quinolin-4-one




20 [0548] Experimental conditions analogous to those described for Step 3 of Example 1, from 104 mg (2.6 mmol) of NaH (60%), 470 mg (1.70 mmol) of 3-(3,4-Dimethyl-benzoyl)-1H-quinolin-4-one, 12 mL of anhydrous DMF, 470 mg (2.33 mmol) of (3-Bromomethyl-phenyl)-methanol. The crude product was purified by flash chromatograph to yield 350 mg of colorless solid. LC-MSD, m/z for $C_{25}H_{22}N_2O_3$ $[M+H]^+$: 399.5, $[M+2H]^+$: 400.5. Reverse
25 phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 2.226 min.

Example 182**[0549] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(6-methoxymethyl-pyridin-2-ylmethyl)-1H-quinolin-4-one**

- 5 **[0550]** 50 mg (0.13 mmol) of 3-(3,4-Dimethyl-benzoyl)-1-(6-hydroxymethyl-pyridin-2-ylmethyl)-1H-quinolin-4-one was dissolved in 3 mL of DMSO. 28 mg (0.5 mmol) of potassium hydroxide was added into the solution and the mixture was stirred at 50 °C overnight. The reaction mixture was poured into 20 mL of ice-water. The mixture was extracted with 30 mL of ethyl acetate. The organic layer was concentrated to dryness. The
- 10 crude product was purified by preparatory HPLC to yield 30 mg of colorless solid. LC-MSD, m/z for $C_{26}H_{24}N_2O_3$ $[M+H]^+$: 413.5, $[M+2H]^+$: 414.5. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 2.492 min.

Example 183

15 **[0551] Preparation of 3-(3,4-Dimethyl-benzoyl)-1-(3-methylaminomethyl-benzyl)-1H-quinolin-4-one**




- [0552]** 80 mg (0.2 mmol) of 3-(3,4-Dimethyl-benzoyl)-1-(6-hydroxymethyl-pyridin-2-ylmethyl)-1H-quinolin-4-one was dissolved in 6 mL of dichloromethane. 200 mg (0.5 mmol) Dess-Martin reagent was added into the solution and the mixture was stirred at rt for 4 hours.
- 20 The reaction was quenched by adding 20 mL of water, 4 mL of sat. aqueous sodium bicarbonate solution and 200 mg of sodium thiosulfate. The mixture was extracted with 20 mL of ethyl acetate and the organic layer was separated and dried over magnesium sulfate. The solid was filtered and the filtrate was concentrated to dryness. The obtained crude product was used directly for the next step.

[0553] 40 mg (0.1 mmol) of crude 6-[3-(3,4-Dimethyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridine-2-carbaldehyde, 0.06 mL (2.0 M, 0.12 mmol) of methylamine in THF and 44 mg (0.2 mmol) of sodium triacetoxyborohydride were mixed in 3 mL of dichloromethane and the mixture was stirred at rt for 2 hours. The reaction was quenched by adding 20 mL of sat. aqueous sodium bicarbonate. The mixture was extracted with 30 mL of ethyl acetate. The organic layer was concentrated to dryness. The crude product was purified by preparatory HPLC to yield 22 mg of colorless solid. LC-MSD, m/z for $C_{26}H_{25}N_3O_2$ [M+H]⁺: 412.5, [M+2H]⁺: 413.5. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 1.963 min.

Example 184


[0554] Preparation of 1-(6-Dimethylaminomethyl-pyridin-2-ylmethyl)-3-(3,4-dimethyl-benzoyl)-1H-quinolin-4-one



[0555] Experimental conditions analogous to those described for Example 183, from 140 mg (0.1 mmol) of crude 6-[3-(3,4-Dimethyl-benzoyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridine-2-carbaldehyde, 0.06 mL (2.0 M, 0.12 mmol) of dimethylamine in THF and 44 mg (0.2 mmol) of sodium triacetoxyborohydride in 3 mL of dichloromethane. The crude product was purified by preparatory HPLC to yield 19 mg of colorless solid. LC-MSD, m/z for $C_{27}H_{27}N_3O_2$ [M+H]⁺: 426.5, [M+2H]⁺: 427.5. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 1.826 min.

Example 185

[0556] Preparation of 3-(5,6-Dimethyl-pyridine-3-carbonyl)-1-(6-hydroxymethyl-pyridin-2-ylmethyl)-1H-quinolin-4-one




[0557] Experimental conditions analogous to those described for Step 3 of Example 1, from 104 mg (2.6 mmol) of NaH (60%), 470 mg (1.7 mmol) of 3-(Pyrazine-2-carbonyl)-1H-

quinolin-4-one, 12 mL of anhydrous DMF, 470 mg (2.33 mmol) of (6-Bromomethyl-pyridin-2-yl)-methanol. The crude product was purified by flash chromatograph to yield 350 mg of colorless solid. LC-MSD, m/z for $C_{24}H_{21}N_3O_3$ $[M+H]^+$: 400.5, $[M+2H]^+$: 401.5. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 0.517 min

5

Example 186

[0558] Preparation 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2-[1,3]dioxan-2-yl-benzoyl)-1H-quinolin-4-one




[0559] Experimental conditions analogous to those described for Step 6 of Example 60, from 1.01 g (2.5 mmol) of 1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide was dissolved in 10 mL of anhydrous THF. 22 mL (0.25 M, 5.5 mmol) of 2-(1, 3-dioxan-2-yl)-phenylmagnesium bromide solution in THF was added slowly at 0 °C. The mixture was stirred at rt for 2 hours. 20 mL of sat. aqueous ammonium chloride was added and the mixture was extracted with 30 mL of ethyl acetate 2 times. The combined organic layer was collected and combined, dried over $MgSO_4$ overnight. $MgSO_4$ solid was filtered and the filtrate was concentrated to dryness. The crude was purified by flash chromatograph to yield 1.1 g of product as colorless solid. LC-MSD, m/z for $C_{26}H_{21}N_2O_4Br$ $[M+H]^+$: 505.5, $[M+2H]^+$: 506.5. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 2.337 min.

20

Example 187


[0560] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2-dimethylaminomethyl-benzoyl)-1H-quinolin-4-one




[0561] 1.01 g of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2-[1,3]dioxan-2-yl-benzoyl)-1H-quinolin-4-one was dissolved in 10 mL of 4 N HCl in Dioxane and the mixture was stirred at rt for 2 hours. The mixture was concentrated to dryness, re-dissolved in 50 mL of ethyl acetate and washed with sat. aqueous NaHCO₃ (50 mL, 2 times), sat. aqueous NaCl (50 mL, 2 times), then concentrated to dryness. The crude was used directly for the next step reaction. 92 mg (0.2 mmol) of the crude 2-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-benzaldehyde was dissolved in 3 mL of dichloromethane. 150 μ L (2.0 M, 0.3 mmol) of N, N-dimethylamine, 221 mg (1.0 mmol) of sodium triacetoxyborohydride were added into the solution and the mixture was stirred at rt for 2 hours. 5 mL of sat. aqueous sodium bicarbonate was added to quench the reaction. The mixture was extracted with ethyl acetate (10 mL, 2 times). The organic layer was combined and concentrated to dryness. The crude product was purified by preparatory HPLC to yield 51 mg of product as colorless solid. LC-MSD, m/z for C₂₅H₂₂N₃O₂Br [M+H]⁺: 476.4, [M+2H]⁺: 477.4. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 1.796 min

Example 188


[0562] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-[1,3]dioxan-2-yl-benzoyl)-1H-quinolin-4-one




[0563] Experimental conditions analogous to those described for Step 6 of Example 60, from 143 mg (0.33 mmol) of 1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide, 4 mL (0.25 M, 1 mmol) of 3-(1,3-dioxan-2-yl)-phenylmagnesium bromide in THF solution, 4 mL of THF. The crude product was purified by flash chromatograph to yield 110 mg of colorless solid. LC-MSD, m/z for C₂₆H₂₁N₂O₄Br [M+H]⁺: 505.5, [M+2H]⁺: 506.5. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 2.317 min.

Example 189**[0564] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-[1,3]dioxan-2-yl-4-methoxy-benzoyl)-1H-quinolin-4-one**

- 5 **[0565]** Experimental conditions analogous to those described for Step 6 of Example 60, from 143 mg (0.33 mmol) of 1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide, 4 mL (0.25 M, 1 mmol) of 3-(1, 3-dioxan-2-yl)-4-methoxyphenylmagnesium bromide in THF solution, 4 mL of THF. The crude product was purified by flash chromatograph to yield 120 mg of colorless solid. LC-MSD, m/z for
- 10 $C_{27}H_{23}N_2O_5Br$ $[M+H]^+$: 535.5, $[M+2H]^+$: 536.5. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 2.254 min


Example 190**[0566] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-[1,3]dioxan-2-yl-benzoyl)-1H-quinolin-4-one**

- 15 **[0567]** Experimental conditions analogous to those described for Step 6 of Example 60, from 143 mg (0.33 mmol) of 1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide, 4 mL (0.25 M, 1 mmol) of 3-(1, 3-dioxan-2-yl)-phenylmagnesium bromide solution in THF, 4 mL of THF. The crude product was purified
- 20 by flash chromatograph to yield 110 mg of colorless solid. LC-MSD, m/z for $C_{26}H_{21}N_2O_4Br$ $[M+H]^+$: 505.5, $[M+2H]^+$: 506.5. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 2.308 min.

Example 191**[0568] Preparation of 2-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-benzoic acid**

5 **[0569]** 720 mg (1.6 mmol) of 2-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-benzaldehyde was dissolved in 30 mL of acetone. 316 mg (2 mmol) of potassium permanganate was added and the mixture was stirred at rt for 2 hours. The reaction was quenched by adding 300 mg of solid sodium thiosulfate and 50 mL of water. The mixture was extracted with dichloromethane (50 mL, 2 times). The organic layer was
 10 combined and dried over anhydrous magnesium sulfate overnight. Magnesium sulfate was filtered and the filtrate was concentrated to dryness. The crude was purified by flash chromatograph to yield 360 mg of product as colorless solid. LC-MSD, m/z for $C_{23}H_{15}N_2O_4Br$ $[M+H]^+$: 463.3, $[M+2H]^+$: 464.3. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 1.973 min.

15


Example 192**[0570] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methylaminomethyl-benzoyl)-1H-quinolin-4-one**

20 **[0571]** 4-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-benzaldehyde was synthesized analogous to example 10 with 90 mg (0.18 mmol) of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-[1,3]dioxan-2-yl-benzoyl)-1H-quinolin-4-one, 4 mL of 4 N HCl in dioxane. The crude product obtained was used directly for next step with 84 mg (0.4 mmol) of sodium triacetoxyborohydride, 0.2 mL (2.0 M, 0.4 mmol) of methylamine in THF, 2 mL of DCM. The crude product was purified by flash chromatograph to yield 35 mg of

colorless solid. LC-MSD, m/z for $C_{24}H_{20}N_3O_2Br$ $[M+H]^+$: 462.3, $[M+2H]^+$: 463.3. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 0.581 min.

Example 193


[0572] Preparation of 2-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-benzoic acid methyl ester



[0573] 93 mg (0.2 mmol) of 2-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-benzoic acid was dissolved in 4 mL of methanol. 0.1 mL of concentrated sulfuric acid was added into the solution and the mixture was heated at 80 °C in the sealed tube for 6 hours. The solution was diluted with 50 mL of ethyl acetate, washed with sat. aqueous sodium bicarbonate (50 mL, 2 times), sat. aqueous sodium chloride (50 mL, 2 times). The organic layer was concentrated to dryness. The crude product was purified by flash chromatograph to yield 50 mg of colorless solid. LC-MSD, m/z for $C_{24}H_{17}N_2O_4Br$ $[M+H]^+$: 477.3, $[M+2H]^+$: 478.3. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 2.252 min

Example 194

[0574] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(2-oxazol-2-yl-benzoyl)-1H-quinolin-4-one




[0575] 108 mg (0.24 mmol) of 2-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-benzaldehyde 47 mg (0.24 mmol) of toluenesulfonylmethyl isocyanate, 20 mg (0.29 mmol) of sodium ethoxide were dissolved in 5 mL of THF and the mixture was stirred at rt for 3 h. The reaction was quenched with 50 mL of water and the mixture was extracted with 50 mL of ethyl acetate. The organic layer was separated and concentrated to dryness. The crude product purified by flash chromatograph to yield 30 mg

of colorless solid. LC-MSD, m/z for $C_{25}H_{16}N_3O_3Br$ $[M+H]^+$: 486.4, $[M+2H]^+$: 487.4. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 3.091 min.

Example 196

[0576] Preparation of 2-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-N,N-dimethyl-benzamide




[0577] 93 mg (0.2 mmol) of 2-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-benzoic acid was dissolved in 5 mL of THF. 0.2 mL (2 M, 0.4 mmol) of dimethylamine, 0.636 mg (50%, 1 mmol) of propylphosphonic anhydride in ethyl acetate solution, 129 mg (1 mmol) of diisopropylethylamine were added into the solution and the mixture was stirred at rt for 2 hours. The reaction was quenched by adding 50 mL of water and the mixture was extracted with 50 mL of ethyl acetate. The organic layer was separated and concentrated to dryness. The crude was purified by flash chromatograph to yield 55 mg of colorless solid. LC-MSD, m/z for $C_{25}H_{20}N_3O_3Br$ $[M+H]^+$: 490.3, $[M+2H]^+$: 491.3.


Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 1.922 min

Example 197


[0578] Preparation of 2-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-N-methyl-benzamide




[0579] Experimental conditions analogous to those described for Example 196, from 93 mg (0.2 mmol) of 2-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-benzoic acid, 5 mL of THF, 0.2 mL (2 M, 0.4 mmol) of methylamine, 0.636 mg (50%, 1 mmol) of propylphosphonic anhydride in ethyl acetate solution, 129 mg (1 mmol) of diisopropylethylamine. The crude was purified by flash chromatograph to yield 34 mg of colorless solid. LC-MSD, m/z for $C_{24}H_{18}N_3O_3Br$ $[M+H]^+$: 476.3, $[M+2H]^+$: 477.3. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 1.980 min.

Example 198**[0580] Preparation of 2-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-N-cyclopropyl-benzamide**


- 5 **[0581]** Experimental conditions analogous to those described for Example 196, from 93 mg (0.2 mmol) of 2-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-benzoic acid, 5 mL of THF, 0.2 mL (2 M, 0.4 mmol) of cyclopropylamine, 0.636 mg (50%, 1 mmol) of propylphosphonic anhydride in ethyl acetate solution, 129 mg (1 mmol) of diisopropylethylamine. The crude was purified by flash chromatograph to yield 40
- 10 mg of colorless solid. LC-MSD, m/z for $C_{26}H_{20}N_3O_3Br$ $[M+H]^+$: 502.4, $[M+2H]^+$: 503.4. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 2.107 min

Example 199**[0582] Preparation of 3-[2-(Azetidine-1-carbonyl)-benzoyl]-1-(6-bromo-pyridin-2-ylmethyl)-1H-quinolin-4-one**

- 15 **[0583]** Experimental conditions analogous to those described for Example 196, from 93 mg (0.2 mmol) of 2-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-benzoic acid, 5 mL of THF, 22.8 mg (0.4 mmol) of azetidine in THF, 0.636 mg (50%, 1 mmol) of propylphosphonic anhydride in ethyl acetate solution, 129 mg (1 mmol) of diisopropylethylamine. The crude was purified by flash chromatograph to yield 50 mg of
- 20 colorless solid. LC-MSD, m/z for $C_{26}H_{20}N_3O_3Br$ $[M+H]^+$: 502.4, $[M+2H]^+$: 503.4. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 1.997 min

Example 200**[0584] Preparation of 3-(2-Bromo-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one**

5 **[0585]** Experimental conditions analogous to those described for Step 6 of Example 60, from 1.41 g (5 mmol) of 2-bromo-iodobenzene was dissolved 10 mL of anhydrous THF. 2.5 mL (2.0 M, 5 mmol) of isopropylmagnesium chloride was added into the solution at -10 °C. The mixture was stirred at -10 °C for 1 hour then added slowly into a prepared solution of 674 mg (2 mmol) of 1-(6-Methyl-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-
 10 carboxylic acid methoxy-methyl-amide in 10 mL of anhydrous THF at -10 °C. The mixture was stirred at 0 °C for 2 hours. 50 mL of sat. aqueous ammonium chloride was added to quenched the reaction. The mixture was extracted with 50 mL of ethyl acetate. The organic layer was dried over magnesium sulfate overnight. The solid was filtered and the filtrate was concentrated to dryness. The crude product was purified by flash chromatograph to yield 850
 15 mg of colorless solid. LC-MSD, m/z for C₂₃H₁₇N₂O₂Br [M+H]⁺: 433.5, [M+2H]⁺: 434.5. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 2.076 min.

Example 201**[0586] Preparation of 3-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-N,N-dimethyl-benzamide**

20


[0587] Experimental conditions analogous to those described for Example 196, from 93 mg (0.2 mmol) of 3-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-benzoic acid was dissolved in 5 mL of THF. 0.2 mL (2 M, 0.4 mmol) of dimethylamine, 0.636 mg (50%, 1 mmol) of propylphosphonic anhydride in ethyl acetate solution, 129 mg (1
 25 mmol) of diisopropylethylamine were added into the solution and the mixture was stirred at rt for 2 hours. The reaction was quenched by adding 50 mL of water and the mixture was

extracted with 50 mL of ethyl acetate. The organic layer was separated and concentrated to dryness. The crude was purified by flash chromatograph to yield 50 mg of colorless solid. LC-MSD, m/z for $C_{25}H_{20}N_3O_3Br$ $[M+H]^+$: 490.3, $[M+2H]^+$: 491.3. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 1.990 min.

5

Example 202


[0588] Preparation of 3-(2-Bromo-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one



[0589] Experimental conditions analogous to those described for Example 196, from 96 mg (0.2 mmol) of 2-methoxyl-3-[1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-quinoline-3-carbonyl]-benzoic acid was dissolved in 5 mL of THF. 0.2 mL (2 M, 0.4 mmol) of dimethylamine, 0.636 mg (50%, 1 mmol) of propylphosphonic anhydride in ethyl acetate solution, 129 mg (1 mmol) of diisopropylethylamine were added into the solution and the mixture was stirred at rt for 2 hours. The reaction was quenched by adding 50 mL of water and the mixture was extracted with 50 mL of ethyl acetate. The organic layer was separated and concentrated to dryness. The crude product was purified by flash chromatography to yield 51 mg of colorless solid. LC-MSD, m/z for $C_{26}H_{22}N_3O_4Br$ $[M+H]^+$: 520.5, $[M+2H]^+$: 521.5. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 2.010 min.

Example 203

[0590] Preparation of 1-(6-Methyl-pyridin-2-ylmethyl)-3-(2-morpholin-4-yl-benzoyl)-1H-quinolin-4-one



Step 1: 3-(2-Iodo-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one

[0591] 443 mg (1 mmol) of 3-(2-Bromo-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one, 9.5 mg (0.05 mmol) of copper iodide, 14.2 mg (0.1 mmol) (1S,2S)-1-


hydroxy-2-methylaminocyclohexane and 300 mg (2 mmol) of sodium iodide were mixed in 5 mL of dioxane. The mixture was stirred at 110 °C in a sealed tube for 18 hours. The reaction was quenched by adding 50 mL of water. The mixture was extracted with 50 mL of ethyl acetate. The organic layer was washed with 50 mL of water, 50 mL of sat. brine, dried over magnesium sulfate overnight. The solid was filtered and the filtrate was concentrated to dryness. The crude product was purified with flash chromatography to yield 270 mg of 3-(2-Iodo-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one as colorless solid.

Step 2: 1-(6-Methyl-pyridin-2-ylmethyl)-3-(2-morpholin-4-yl-benzoyl)-1H-quinolin-4-one

[0592] 200 mg (0.4 mmol) of 3-(2-Iodo-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one The obtained compound was mixed with 87 mg (1.0 mmol) of morpholine, 96 mg (1.0 mmol) of sodium butoxide, 13 mg (0.05 mmol) of 18-C-6 crown ether, 9 mg (0.01 mmol) of Tris(dibenzylideneacetone)dipalladium(0) and 18 mg of 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl in 5 mL of THF. The mixture was stirred at 70 °C overnight. The mixture was diluted with 20 mL of ethyl acetate and washed with 20 mL of water. The organic layer was concentrated to dryness and purified by preparatory HPLC to yield 12 mg of product as colorless solid. LC-MSD, m/z for C₂₇H₂₅N₃O₃ [M+H]⁺: 440.5, [M+2H]⁺: 441.5. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 1.858 min.

Example 204


[0593] Preparation of 3-(3-Fluoro-4-methoxy-benzoyl)-1-(6-cyano-pyridin-2-ylmethyl)-1H-quinolin-4-one



[0594] Experimental conditions analogous to those described for Step 3 of Example 1, from 10.4 mg (0.26 mmol) of NaH (60%), 60 mg (0.20 mmol) of 3-(3-Fluoro-4-methoxy-benzoyl)-1H-quinolin-4-one, 2 mL of anhydrous DMF, 60 mg (0.32 mmol) of 2-bromomethyl-6-cyanopyridine. The crude product was purified by flash chromatography to yield 28 mg of colorless solid. LC-MSD, m/z for C₂₄H₁₆FN₃O₃ [M+H]⁺: 414.3, [M+2H]⁺: 415.3. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 2.191 min

Example 205


[0595] Preparation of 3-(3-Fluoro-4-methoxy-benzoyl)-1-(6-methyl-pyrazin-2-ylmethyl)-1H-quinolin-4-one




- 5 **[0596]** Experimental conditions analogous to those described for Step 3 of Example 1, from 10.4 mg (0.26 mmol) of NaH (60%), 60 mg (0.20 mmol) of 3-(3-Fluoro-4-methoxy-benzoyl)-1H-quinolin-4-one, 2 mL of anhydrous DMF, 60 mg (0.32 mmol) of 2-bromomethyl-6-methylpyrazine. The crude product was purified by flash chromatography to yield 27 mg of colorless solid. LC-MSD, m/z for $C_{23}H_{18}FN_3O_3$ $[M+H]^+$: 404.4, $[M+2H]^+$: 405.4 Reverse
10 phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 1.961 min.

Example 206

[0597] Preparation of 1-(3-Bromo-benzyl)-3-(6-methoxy-pyridine-3-carbonyl)-1H-quinolin-4-one



- 15 **[0598]** Experimental conditions analogous to those described for Step 3 of Example 1, from 201 mg (0.5 mmol) of 1-(3-Bromo-benzyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methoxy-methyl-amide, 237 mg (1 mmol) of 2-Chloro-5-iodo-pyridine, 0.55 mL (2M, 1.1 mmol) of isopropylmagnesium bromide in THF solution, 8 mL of anhydrous THF. The crude 1-(3-Bromo-benzyl)-3-(6-chloro-pyridine-3-carbonyl)-1H-quinolin-4-one was
20 dissolved in 10 mL of methanol, 450 mg of sodium methoxide was added and the mixture was stirred at 75°C for 2 hours. The solvent was removed under vacuum and the crude product was purified by flash chromatography to yield 103 mg of colorless solid. LC-MSD, m/z for $C_{23}H_{17}N_2O_3Br$ $[M+H]^+$: 449.4, $[M+2H]^+$: 450.4. Reverse phase HPLC gradient acetonitrile 0.1% TFA 20-95% in 4 min: 2.988 min.


Example 207**[0599] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-fluoro-4-methoxy-benzoyl)-7-trifluoromethyl-1H-[1,8]naphthyridin-4-one**

5 **Step 1:** 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-7-trifluoromethyl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid methoxy-methyl-amide

10 **[0600]** A mixture of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-7-trifluoromethyl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester (0.72 g, 1.6 mmol, 1 equiv) and methylmethoxyamine hydrochloride (0.16 g, 1 equiv) in 2 mL of toluene was treated with AlMe₃ (0.5 M in toluene, 3.5 mL, 1.1 equiv) at rt for 1 h. The reaction was quenched by slow addition of saturated aqueous solution of sodium potassium tartrate. The organic layer was dried over sodium sulfate, filtered and evaporated to give crude 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-7-trifluoromethyl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid methoxy-methyl-amide.

15 **Step 2:** 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-fluoro-4-methoxy-benzoyl)-7-trifluoromethyl-1H-[1,8]naphthyridin-4-one

20 **[0601]** Experimental conditions analogous to those described for Step 6 of Example 60, from 80 mg of 1-(6-bromo-pyridin-2-ylmethyl)-4-oxo-7-trifluoromethyl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid methoxy-methyl-amide, 2 mL of THF was treated with 3-fluoro-4-methoxyphenyl magnesium chloride (0.5 M in THF, 1.3 mL, 2 equiv) at rt for 2h. The reaction was quenched by slow addition of saturated aqueous ammonium chloride. The mixture was subjected to HPLC and then preparative TLC purification to give 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3-fluoro-4-methoxy-benzoyl)-7-trifluoromethyl-1H-[1,8]naphthyridin-4-one. LCMS (ES) M+H 536.0.

Example 208**[0602] Preparation of 3-(4-Chloro-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one****5 Step 1: 3-Iodo-1H-quinolin-4-one**


[0603] 1H-Quinolin-4-one (2.90 g, 20 mmol, 1 equiv) in 5 mL of DMF was treated with 1.12 g of KOH (2 equiv) and 5.30 g of iodine (1.05 equiv) for 2 hours. The reaction was quenched by slow addition of saturated aqueous solution of Na₂S₂O₃. Filtration gave 3-iodo-1H-quinolin-4-one as an off-white solid.

10 Step 2: 3-iodo-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one


[0604] 3-iodo-1H-quinolin-4-one (1.36 g, 5 mmol, 1 equiv) in 5 mL of DMF was treated with 0.22 g of NaH (1.1 equiv) for 10 min. 2-Bromomethyl-6-methylpyridine (1.11 g, 1.2 equiv) was then added and stirring continued for 3 h. The reaction was quenched by slow addition of saturated aqueous solution of NH₄Cl. Standard workup followed by flash chromatography gave 3-iodo-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one as a white solid.

Step 3: Preparation of 3-(4-Chloro-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one

[0605] A -78 °C solution of 3-iodo-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one (113 mg, 0.3 mmol, 1 equiv) in 3 mL of THF was treated with 1.65 mL of isopropyl magnesium chloride (1.1 equiv) for 2 hours. Then 4-chloro-N-methoxy-N-methylbenzamide (46 µL, 1.2 equiv) was added and stirring continued at rt for 2 hours. The reaction was quenched by slow addition of saturated aqueous solution of NH₄Cl. Standard workup followed by HPLC purification gave 3-(4-chloro-benzoyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one. LCMS (ES) M+H 389.1

Example 209**[0606] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(3,4-dimethoxy-benzoyl)-1H-[1,8]naphthyridin-4-one**


- 5 [0607] Experimental conditions analogous to those described for Step 6 of Example 60, from 100 mg (0.248 mmol) of 1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid methoxy-methyl-amide in THF 2 ml, was added 1.09 ml (0.545 mmol) 3,4-dimethoxyphenylmagnesium bromide. The reaction mixture was stirred at room temperature for 30 min, then quenched with saturated solution of NH_4Cl , extracted with ethyl acetate and purified with flash chromatography to give the desired product 22 mg. LCMS observed for $(\text{M}+\text{H})^+$: 480.

Example 210**[0608] Preparation of 6-[3-(4-Methoxy-3-methyl-benzoyl)-4-oxo-4H-[1,8]naphthyridin-1-ylmethyl]-pyridine-2-carbonitrile**

- 15 [0609] Experimental conditions analogous to those described for Step 3 of Example 1, from 50 mg (0.17 mmol) of 3-(4-Methoxy-3-methyl-benzoyl)-1H-[1,8]naphthyridin-4-one in THF 2 ml, was added KHMDS in THF 0.4 ml (0.2 mmol) slowly. The reaction mixture was stirred at room temperature for 60 min, followed by the addition of 40 mg (0.2 mmol) of 6-Bromomethyl-pyridine-2-carbonitrile. The mixture was heated to 60 °C for 60 min, then quenched with water and purified with HPLC to give the desired product (15 mg). LCMS $(\text{M}+\text{H})^+$: 411.1.

Example 211


[0610] Preparation of 3-(4-Methoxy-3-methyl-benzoyl)-1-(6-trifluoromethyl-pyridin-2-ylmethyl)-1H-[1,8]naphthyridin-4-one



5 **[0611]** Experimental conditions analogous to those described for Step 3 of Example 1, from 50 mg (0.17 mmol) of 3-(4-Methoxy-3-methyl-benzoyl)-1H-[1,8]naphthyridin-4-one, and 2-Bromomethyl-6-trifluoromethyl-pyridine 53 mg (0.22 mmol), to give 14 mg of desired compound. LCMS (M+H)⁺: 454.1.

Example 212


10 **[0612] Preparation of 3-(4-Methoxy-3-methyl-benzoyl)-1-(3-trifluoromethyl-benzyl)-1H-[1,8]naphthyridin-4-one**



15 **[0613]** Experimental conditions analogous to those described for Step 3 of Example 1, from 50 mg (0.17 mmol) of 3-(4-Methoxy-3-methyl-benzoyl)-1H-[1,8]naphthyridin-4-one, and 1-Bromomethyl-3-trifluoromethyl-benzene 53 mg (0.22 mmol), to give 12 mg of desired compound. LCMS (M+H)⁺: 453.1.

Example 213

[0614] Preparation of 1-(3-Bromo-benzyl)-3-(4-methoxy-3-methyl-benzoyl)-1H-[1,8]naphthyridin-4-one




[0615] Experimental conditions analogous to those described for Step 3 of Example 1, from 50 mg (0.17 mmol) of 3-(4-Methoxy-3-methyl-benzoyl)-1H-[1,8]naphthyridin-4-one, and 1-Bromo-3-bromomethyl-benzene 55mg (0.22 mmol), to give 17 mg of desired compound. LCMS (M+H)⁺: 463.1.

5

Example 214


[0616] Preparation of 3-(5-Methyl-isoxazole-3-carbonyl)-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one



[0617] To the solution of 3-Iodo-1-(6-methyl-pyridin-2-ylmethyl)-1H-quinolin-4-one (300 mg, 0.82 mmol, 1.2 eq) in THF(2 ml), was added isopropylmagnesium chloride in THF(0.88 mL, 1.76 mmol, 2.1 eq) slowly at -40 °C. The reaction mixture was warmed to room temperature and stirred for 60 min, followed by the addition of 5-Methyl-isoxazole-3-carboxylic acid methoxy-methyl-amide (116 mg, 0.068 mmol, 1 eq). The mixture was stirred overnight, quenched with water and purified with HPLC to give the desired product (25 mg). LCMS observed for (M+H)⁺: 360.1.

Example 216

[0618] Preparation of 6-[3-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-4-oxo-4H-quinolin-1-ylmethyl]-pyridine-2-carbonitrile




[0619] The mixture of 3-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-1H-quinolin-4-one(70 mg, 0.228 mmol, 1 eq) in DMF (1 ml) and sodium hydride (11.8 mg, 0.296 mmol, 1.3 eq) was stirred at room temperature for 60 min, followed by the addition of 6-Bromomethyl-pyridine-2-carbonitrile (74.1 mg, 0.296 mmol, 1.3 eq). The mixture was stirred for 60 min, quenched with water, taken up with ethyl acetate, dried over sodium sulfate and purified with

flash chromatography to give the desired product (17 mg). LCMS observed for (M+H)⁺: 424.1.

Example 217


[0620] Preparation of 3-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-1-(6-trifluoromethyl-pyridin-2-ylmethyl)-1H-quinolin-4-one



[0621] Experimental conditions analogous to those described for Step 3 of Example 1, from 3-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-1H-quinolin-4-one 70 mg (0.228 mmol) and 71.1 mg (0.296 mmol) of 2-Bromomethyl-6-trifluoromethyl-pyridine, to give 20 mg of desired compound. LCMS (M+H)⁺: 467.1.

Example 218


[0622] Preparation of 1-(6-Amino-pyridin-2-ylmethyl)-3-(2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-1H-quinolin-4-one



[0623] The mixture of 3-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-1H-quinolin-4-one 70 mg (0.228 mmol) in DMF (1 mL) and sodium hydride 11.8 mg (0.296 mmol) was stirred at room temperature for 60 min, followed by the addition of N-[1-(2-Bromo-1-methyl-ethylideneamino)-vinyl]-2,2,2-trifluoro-acetamide 83.8 mg (0.296 mmol). The mixture was stirred for 60 min, quenched with water, taken up with ethyl acetate, dried over sodium sulfate and purified with flash chromatography. The purified product was treated with Diethylamine in methanol over weekend, filtered to give the desired product 10 mg. LCMS observed for (M+H)⁺: 414.

Example 219


[0624] Preparation of 1-(3-Bromo-benzyl)-3-(2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-1H-quinolin-4-one



5 **[0625]** Experimental conditions analogous to those described for Step 3 of Example 1, from 3-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-1H-quinolin-4-one (70 mg, 0.228 mmol) and 74 mg (0.296 mmol) of 1-Bromo-3-bromomethyl-benzene, to give 25 mg of desired compound. LCMS (M+H)⁺: 476.

Example 220


10 **[0626] Preparation of 3-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-1-(3-trifluoromethyl-benzyl)-1H-quinolin-4-one**



15 **[0627]** Experimental conditions analogous to those described for Step 3 of Example 1, from 3-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-1H-quinolin-4-one 70.7 mg (0.296 mmol) and 71.1 mg (0.296 mmol) of 1-Bromomethyl-3-trifluoromethyl-benzene, to give 21mg of desired compound. LCMS (M+H)⁺: 466.

Example 221

[0628] Preparation of 1-(3-Chloro-benzyl)-3-(2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-1H-quinolin-4-one




[0629] Experimental conditions analogous to those described for Step 3 of Example 1, from 3-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-1H-quinolin-4-one 70 mg (0.228 mmol) and 71.1 mg (0.296 mmol) 1-Chloro-3-chloromethyl-benzene, to give 24mg of desired compound. LCMS (M+H)⁺: 432.

5

Example 222

[0630] Preparation of 1-(6-Bromo-pyridin-2-ylmethyl)-3-(4-methoxy-3-methyl-benzoyl)-1H-[1,8]naphthyridin-4-one



[0631] Experimental conditions analogous to those described for Step 6 of Example 60, from 55 mg (0.136 mmol) of 1-(6-Bromo-pyridin-2-ylmethyl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid methoxy-methyl-amide, and 0.5 ml (0.285 mmol) of 4-methoxy-3-methylphenyl magnesium chloride, to give desired compound as a white solid. LCMS (M+H)⁺: 464.





















Biological Example 1























[0632] To demonstrate that the compounds described above are useful modulators for chemokine binding to CCXCKR2, the compounds were screened *in vitro* to determine their ability to displace SDF-1 from the CCXCKR2 receptor at multiple concentrations. The compounds were combined with mammary gland cells expressing the CCXCKR2 receptor in the presence of the ¹²⁵I-labeled chemokine as detailed in *Determination of IC₅₀ values, Reagents and Cells* (see below). The ability of the compounds to displace the labeled chemokine from the CCXCKR2 receptor sites at multiple concentrations was then determined with the screening process.





















[0633] Compounds that were deemed effective modulators were able to displace at least 50% of the SDF-1 from the CCXCKR2 receptor at concentrations at or below 20 micromolar (μM) but > 500 nM (+); and more preferably at concentrations from > 100 nM to ≤ 500 nM (++). At present, especially preferred compounds can displace at least 50% of the SDF-1 from the CCXCKR2 receptor at concentrations at or below 100 nM (+++). Exemplary compounds that met these criteria are reproduced in Table 4 below. All compounds were





















prepared as described in the Examples above, or by related methods substituting readily available starting materials.






















Table 4





















No	Structure	Activity	No	Structure	Activity
1		++	2		+
3		+	4		+++
5		+	6		+
7		+	8		+++
9		+++	10		+
11		+	12		+
13		+	14		+
15		+	16		+
17		+	18		++
19		+	20		+++























21		+++	22		+++
23		+++	24		+
25		+	26		+
27		+	28		+++
29		+++	30		++
31		+++	32		+++
33		+	34		+
35		+	36		+
37		+++	38		+
39		+++	40		+++
41		++	42		++























43		++	44		+++
45		+++	46		+
47		++	48		++
49		+++	50		+++
51		+++	52		++
53		+++	54		+++
55		+++	56		+++
57		+++	58		+
59		+++	60		++
61		+	62		+

























63		+	64		+++
65		+++	66		+++
67		+++	68		+++
69		+++	70		+++
71		++	72		+
73		+++	74		+++
75		+++	76		+++
77		+++	78		++
79		+++	80		+++
81		+++	82		+++























83		+	84		+
85		+++	86		+
87		+++	88		++
89		+++	90		+++
91		+++	92		+
93		+++	94		+++
95		+	96		+++
97		+++	98		+++
99		++	100		+++
101		+++	102		+++
103		+++	104		+++

105		+++	106		+++
107		+++	108		+++
109		+	110		+
111		++	112		++
113		+++	114		+++
115		+++	116		+
117		+	118		+
119		+++	120		+++
121		+++	122		++
123		+	124		+++











125		++	126		+++
127		++	128		+
129		+++	130		+++
131		+++	132		+++
133		+++	134		+++
135		+	136		+++
137		++	138		+++
139		+	140		+++
141		+++	142		+++
143		+++	144		+++
145		+++	146		++

147		+++	148		+++
149		++	150		++
151		+++	152		+
153		++	154		+++
155		+++	156		+++
157		+++	158		+++
159		+++	160		+++
161		+++	162		+++
163		+++	164		+++
165		+++	166		+++
167		+	168		+++

169		+	170		+
171		+++	172		+++
173		+++	174		+++
175		+++	176		+++
177		++	178		+++
179		+++	180		+++
181		+	182		+++
183		+++	184		+++
185		+++	186		+++
187		+++	188		+++
189		+++	190		++
191		++	192		++

193		+++	194		+++
195		+++	196		+++
197		+++	198		+++
199		+	200		+++
201		+	202		+++
203		+++	204		+++
205		+++	206		+
207		+++	208		+
209		++	210		+
211		+++	212		+++
213		+	214		++

215		+++	216		+
217		+++	218		++
219		++	220		+++
221		+	222		+++
223		+	224		+
225		+++	226		+
227		+++	228		+++
229		++	230		++
231		+++	232		++
233		+++	234		++
235		+++	236		+

237		+	238		+
239		++	240		+++
241		++	242		+++
243		+++	244		++
245		+++	246		+++

1. Determination of IC₅₀ values.

[0634] *Reagents and Cells.* ¹²⁵I-labeled SDF-1 was purchased from Perkin-Elmer Life Sciences, Inc. (Boston, MA). The MCF-7 (adenocarcinoma; mammary gland) cell line was obtained from the American Type Culture Collection (Manassas, VA) or and was cultured in DMEM (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (FBS) (HyClone Logan, UT) and bovine insulin (0.01 mg/mL) (Sigma, St. Louis, MO) at 37° C in a humidified incubator at a 5% CO₂/air mixture. CCXCKR2 transfected MDA-MB-435S were produced as described below. MDA-MB-435S human breast cancer line, was purchased from ATCC, and cultured in DMEM/10% FBS medium. The complete coding sequence of the gene encoding CCXCKR2 (a.k.a.CXCR7, hRDC1), was isolated from MCF-7 cells using μ MACs mRNA isolation kit (Miltényi Biotec, Auburn, CA). DNA contamination was removed by DNase digestion via RNeasy columns (Qiagen, Inc., Valencia, CA) and cDNA was generated using GeneAmp RNA PCR Core Kit (Applied Biosystems, Foster City, CA). PCR of cDNA samples was performed using Taq PCR Master Mix kit (Qiagen, Inc.) and hRDC1 primers harboring 5' and 3' Not I sites (hRDC1F 5'-GAATGCGGCCGCTATGGATCTGCATCTCTTCGACT-3' (SEQ ID NO:11), hRDC1R 5'-GAATGCGGCCGCTCATTGTTGGTGCTCTGCTCCAAG-3' (SEQ ID NO:12)) Not I digested PCR product was ligated into Not I digested pcDNA3.1(+)(Invitrogen, Carlsbad, CA) and screened for

orientation and sequence confirmed. Plasmid DNA was then isolated from overnight bacterial cultures by Maxiprep (Qiagen, Inc.). Plasmid DNA (10µg was added to MDA-MB-435s cells and cells were electroporated (0.22kV, 960uF) via Gene Pulser (Biorad laboratories, Hercules, CA). 48 hr post-electroporation, cells were transferred to selection medium (1000ug/ml G418).

5

[0635] *Binding Analysis.* Target compounds were tested to determine their ability to bind with CCXCKR2 sites on MCF-7 and/or MDA-MB-435S cells. Efficiency-maximized radioligand binding using filtration protocols as described in Dairaghi DJ, et al., *HHV8-encoded vMIP-I selectively engages chemokine receptor CCR5. Agonist and antagonist profiles of viral chemokines.*, J. Biol. Chem. 1999 Jul 30; 274(31): 21569-74 and Gosling J, et al., *Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK.*, J. Immunol. 2000 Mar 15; 164(6):2851-6 was used.

10

[0636] In these assays, MCF-7 and/or MDA-MB-435S cells were interrogated with the target compounds and the ability of these compounds to displace ¹²⁵I radiolabeled SDF-1 was assessed using the protocol described in *Dairaghi* and *Gosling*. The target compounds were added to the plate to the indicated concentration and were then incubated with cells followed by the addition of radiolabeled chemokine (¹²⁵I SDF-1) for 3 hr at 4°C in the following binding medium (25 mM HEPES, 140 mM NaCl, 1 mM CaCl₂, 5 mM MgCl₂ and 0.2% bovine serum albumin, adjusted to pH 7.1). All assays were then incubated for 3 hrs at 4° C with gentle agitation. Following incubation in all binding assays, reactions were aspirated onto PEI-treated GF/B glass filters (Packard) using a cell harvester (Packard) and washed twice (25 mM HEPES, 500 mM NaCl, 1 mM CaCl₂, 5 mM MgCl₂, adjusted to pH 7.1). Scintillant (MicroScint 10, Packard) was added to the wells, and the filters were counted in a Packard Topcount scintillation counter. Data were analyzed and plotted using Prism (GraphPad Prism™ version 3.0a for Macintosh™, GraphPad Software, www.graphpad.com).

15

20

25

SEQUENCE TABLE

SEQ ID NO:1 CCXCKR2 coding sequence

ATGGATCTGCATCTCTTCGACTACTCAGAGCCAGGGAACCTTCTCGGACATCAGCT
 GGCCATGCAACAGCAGCGACTGCATCGTGGTGGACACGGTGATGTGTCCCAACA
 5 TGCCCAACAAAAGCGTCCTGCTCTACACGCTCTCCTTCATTTACATTTTCATCTTC
 GTCATCGGCATGATTGCCAACTCCGTGGTGGTCTGGGTGAATATCCAGGCCAAGA
 CCACAGGCTATGACACGCACTGCTACATCTTGAACCTGGCCATTGCCGACCTGTG
 GGTGTCTCTACCATCCCAGTCTGGGTGGTCACTCTCGTGCAGCACAACCAGTGG
 CCCATGGGCGAGCTCACGTGCAAAGTCACACACCTCATCTTCTCCATCAACCTCT
 10 TCGGCAGCAATTTCTTCCTCACGTGCATGAGCGTGGACCGCTACCTCTCCATCACC
 TACTTCACCAACACCCCCAGCAGCAGGAAGAAGATGGTACGCCCGTGTCGTCTGC
 ATCCTGGTGTGGCTGCTGGCCTTCTGCGTGTCTCTGCCTGACACCTACTACCTGAA
 GACCGTCACGTCTGCGTCCAACAATGAGACCTACTGCCGGTCTTCTACCCCGAG
 CACAGCATCAAGGAGTGGCTGATCGGCATGGAGCTGGTCTCCGTTGTCTTGGGCT
 15 TTGCCGTTCCCTTCTCCATTATCGCTGTCTTCTACTTCTGCTGGCCAGAGCCATC
 TCGGCGTCCAGTGACCAGGAGAAGCACAGCAGCCGGAAGATCATCTTCTCCTAC
 GTGGTGGTCTTCTTGTCTGCTGGCTGCCCTACCACGTGGCGGTGCTGCTGGACA
 TCTTCTCCATCCTGCACTACATCCCTTTACCTGCCGGCTGGAGCACGCCCTCTTC
 ACGGCCCTGCATGTCACACAGTGCCTGTCGCTGGTGCACCTGCTGCGTCAACCTG
 20 TCCTCTACAGCTTCATCAATCGCAACTACAGGTACGAGCTGATGAAGGCCTTCAT
 CTTCAAGTACTCGGCCAAAACAGGGCTACCAAGCTCATCGATGCCTCCAGAGTC
 TCAGAGACGGAGTACTCTGCCTTGGAGCAGAGCACCAAATGA

25 SEQ ID NO:2 CCXCKR2 amino acid sequence

MDLHLFDYSEPGNFSDISWPCNSSDCIVVDTVMCPNMPNKSULLYTLSTFYIFIFVIGM
 IANSVVVWVNIQAKTTGYDTHCYILNLALADLWVVLTPVWVVSLLVQHNQWPMGEL
 TCKVTHLIFSINLFGSIFELTCMSVDRYLSITYFINTPSSRKKMVRRVVCILVWLLAFC
 VSLPDTYYLKTVTSASNNETYCRSFYPEHSIKEWLIGMELVSVVLGFAVPFSILAVFYF
 30 LLARASASSDQEKHSSRKIIFSYYVVFVLCWLPYHVAVLLDIFSILHYIPFTCRLEHAL
 FTALHVTQCLSLVHCCVNPVLYSPINRNYRYELMKAFIFKYSAGTGLTKLIDASRVSE
 TEYSALEQSTK

SEQ ID NO:3 CCXCKR2.2 coding sequence

35 ATGGATCTGCACCTCTTCGACTACGCCGAGCCAGGCAACTTCTCGGACATCAGCT
 GGCCATGCAACAGCAGCGACTGCATCGTGGTGGACACGGTGATGTGTCCCAACA
 TGCCCAACAAAAGCGTCCTGCTCTACACGCTCTCCTTCATTTACATTTTCATCTTC
 GTCATCGGCATGATTGCCAACTCCGTGGTGGTCTGGGTGAATATCCAGGCCAAGA
 40 CCACAGGCTATGACACGCACTGCTACATCTTGAACCTGGCCATTGCCGACCTGTG
 GGTGTCTCTACCATCCCAGTCTGGGTGGTCACTCTCGTGCAGCACAACCAGTGG
 CCCATGGGCGAGCTCACGTGCAAAGTCACACACCTCATCTTCTCCATCAACCTCT
 TCAGCGGCATTTCTTCCTCACGTGCATGAGCGTGGACCGCTACCTCTCCATCACC
 TACTTCACCAACACCCCCAGCAGCAGGAAGAAGATGGTACGCCCGTGTCGTCTGC
 45 ATCCTGGTGTGGCTGCTGGCCTTCTGCGTGTCTCTGCCTGACACCTACTACCTGAA
 GACCGTCACGTCTGCGTCCAACAATGAGACCTACTGCCGGTCTTCTACCCCGAG
 CACAGCATCAAGGAGTGGCTGATCGGCATGGAGCTGGTCTCCGTTGTCTTGGGCT

TTGCCGTTCCCTTCTCCATTATCGCTGTCTTCTACTTCCTGCTGGCCAGAGCCATC
 TCGGCGTCCAGTGACCAGGAGAAGCACAGCAGCCGGAAGATCATCTTCTCCTAC
 GTGGTGGTCTTCCTTGTCTGCTGGCTGCCCTACCACGTGGCGGTGCTGCTGGACA
 TCTTCTCCATCCTGCACTACATCCCTTTCACCTGCCGGCTGGAGCACGCCCTCTTC
 5 ACGGCCCTGCATGTCACACAGTGCCTGTCGCTGGTGCCTGCTGCGTCAACCCTG
 TCCTCTACAGCTTCATCAATCGCAACTACAGGTACGAGCTGATGAAGGCCTTCAT
 CTTCAAGTACTCGGCCAAAACAGGGCTCACCAAGCTCATCGATGCCTCCAGAGTG
 TCGGAGACGGAGTACTCCGCCTTGGAGCAAAACGCCAAGTGA

10 SEQ ID NO:4 CCXCKR2.2 amino acid sequence

MDLHLFDYAEPGNFSDISWPCNSSDCIVVDTVMCPNMPNKSVELLYTSLFIYIFIFVIGM
 IANSVVVWVNIQAKTTGYDTHCYILNLAIADLWVVLTPVWVVSLLVQHNQWPMGEL
 TCKVTHLIFSINLFSGIFFLTCMSVDRYLSITYFTNTPSSRKKMVRVRVCILVWLLAFC
 VSLPDTYYLKTVTSASNNETYCRSFYPEHSIKEWLIGMELVSVVLGFAVPFSIIAVFYF
 15 LLARAISSSDQEKHSSRKIIFSYYVVVFLVCWLPYHVAVLLDIFSILHYIPFTCRLEHAL
 FTALHVTQCLSLVHCCVNPVLYSFINRNYRYELMKAFIFKYSAKTGLTKLIDASRVSE
 TEYSALEQNAK

SEQ ID NO:5 CCXCKR2.3 coding sequence

20 ATGGATCTGCATCTCTTCGACTACTCAGAGCCAGGGAACCTTCTCGGACATCAGCT
 GGCCATGCAACAGCAGCGACTGCATCGTGGTGGACACGGTGATGTGTCCCAACA
 TGCCCAACAAAAGCGTCCTGCTCTACACGCTCTCCTTCATTTACATTTTCATCTTC
 GTCATCGGCATGATTGCCAACTCCGTGGTGGTCTGGGTGAATATCCAGGCCAAGA
 25 CCACAGGCTATGACACGCACTGCTACATCTTGAACCTGGCCATTGCCGACCTGTG
 GGTTGTCCTCACCATCCCAGTCTGGGTGGTCAGTCTCGTGCAGCACAACCAGTGG
 CCCATGGGCGAGCTCACGTGCAAAGTCACACACCTCATCTTCTCCATCAACCTCT
 TCGGCAGCATTTTCTTCCTCACGTGCATGAGCGTGGACCGCTACCTCTCCATCACC
 TACTTCACCAACACCCCCAGCAGCAGGAAGAAGATGGTACGCCGTGTCGTCTGC
 30 ATCCTGGTGTGGCTGCTGGCCTTCTGCGTGTCTCTGCCTGACACCTACTACCTGAA
 GACCGTCACGTCTGCGTCCAACAATGAGACCTACTGCCGGTCCTTCTACCCCGAG
 CACAGCATCAAGGAGTGGCTGATCGGCATGGAGCTGGTCTCCGTTGTCTTGGGCT
 TTGCCGTTCCCTTCTCCATTGTCGCTGTCTTCTACTTCCTGCTGGCCAGAGCCATC
 TCGGCGTCCAGTGACCAGGAGAAGCACAGCAGCCGGAAGATCATCTTCTCCTAC
 35 GTGGTGGTCTTCCTTGTCTGCTGGTTGCCCTACCACGTGGCGGTGCTGCTGGACAT
 CTTCTCCATCCTGCACTACATCCCTTTCACCTGCCGGCTGGAGCACGCCCTCTTCA
 CGGCCCTGCATGTCACACAGTGCCTGTCGCTGGTGCCTGCTGCGTCAACCCTGT
 CCTCTACAGCTTCATCAATCGCAACTACAGGTACGAGCTGATGAAGGCCTTCATC
 TTCAAGTACTCGGCCAAAACAGGGCTCACCAAGCTCATCGATGCCTCCAGAGTCT
 40 CAGAGACGGAGTACTCTGCCTTGGAGCAGAGCACCAAATGA

SEQ ID NO:6 CCXCKR2.3 amino acid sequence

MDLHLFDYSEPGNFSDISWPCNSSDCIVVDTVMCPNMPNKSVLLYTLSFIYIFIFVIGM
 IANSVVVWVNIQAKTTGYDTHCYILNLAIADLWVVLTPVWVVS LVQHNQWPMGEL
 TCKVTHLIFSINLFGSIFFLT CMSVDRYLSITYFTNTPSSRKKMVRRVVCILVWLLAFC
 5 VSLPDTYYLKT VTSASNNETYCRSFYPEHSIKEWLIGMELVS VVLGFAVPFSIVAVFY
 FLLARAISSSDQEKHSSRKIIFS YVVVFLVCWLPYHVAVLLDIFSILHYIPFTCRLEHA
 LFTALHVTQCLSLVHCCVNPVLYSFINRNYRYELMKAFIFKYS AKTGLTKLIDASRVSE
 ETEYSALEQSTK

10 SEQ ID NO:7 CCXCKR2.4 coding sequence

ATGGATCTGCATCTCTTCGACTACTCAGAGCCAGGGAACTTCTCGGACATCAGCT
 GGCCATGCAACAGCAGCGACTGCATCGTGGTGGACACGGTGATGTGTCCCAACA
 TGCCCAACAAAAGCGTCCTGCTCTACACGCTCTCCTTCATTTACATTTTCATCTTC
 15 GTCATCGGCATGATTGCCAACTCCGTGGTGGTCTGGGTGAATATCCAGGCCAAGA
 CCACAGGCTATGACACGCACTGCTACATCTTGAACCTGGCCATTGCCGACCTGTG
 GGTTGTCCTCACCATCCCAGTCTGGGTGGTCAGTCTCGTGCAGCACAACCAGTGG
 CCCATGGGCGAGCTCACGTGCAAAGTCACACACCTCATCTTCTCCATCAACCTCT
 TCGGCAGCATTTTCTTCTCCTCACGTGCATGAGCGTGGACCGCTACCTCTCCATCACC
 20 TACTTCACCAACACCCCCAGCAGCAGGAAGAAGATGGTACGCCGTGTCGTCTGC
 ATCCTGGTGTGGCTGCTGGCCTTCTGCGTGTCTCTGCCTGACACCTACTACCTGAA
 GACCGTCACGTCTGCGTCCAACAATGAGACCTACTGCCGGTCCTTCTACCCCGAG
 CACAGCATCAAGGAGTGGCTGATCGGCATGGAGCTGGTCTCCGTTGTCTTGGGCT
 TTGCCGTTCCCTTCTCCATTATCGCTGTCTTCTACTTCTGCTGGCCAGAGCCATC
 25 TCGGCGTCCAGTGACCAGGAGAAGCACAGCAGCCGGAAGATCATCTTCTCCTAC
 GTGGTGGTCTTCTTGTCTGCTGGCTGCCCTACCACGTGGCGGTGCTGCTGGACA
 TCTTCTCCATCCTGCACTACATCCCTTTCACCTGCCGGCTGGAGCACGCCCTCTTC
 ACGGCCCTGCATGTCACACAGTGCCTGTCGCTGGTGCCTGCTGCGTCAACCCTG
 TCCTCTACAGCTTCATCAATCGCAACTACAGGTACGAGCTGATGAAGGCCTTCAT
 30 CTTCAAGTACTCGGCCAAAACAGGGCTCACCAAGCTCATCGATGCCTCCAGAGTC
 TCAGAGACGGAGTACTCTGCCTTGGAGCAGAGCACCAAATGA

SEQ ID NO:8 CCXCKR2.4 amino acid sequence

MDLHLFDYSEPGNFSDISWPCNSSDCIVVDTVMCPNMPNKSVLLYTLSFIYIFIFVIGM
 35 IANSVVVWVNIQAKTTGYDTHCYILNLAIADLWVVLTPVWVVS LVQHNQWPMGEL
 TCKVTHLIFSINLFGSIFFLT CMSVDRYLSITYFTNTPSSRKKMVRRVVCILVWLLAFC
 VSLPDTYYLKT VTSASNNETYCRSFYPEHSIKEWLIGMELVS VVLGFAVPFSIIAVFYF
 LLARAISSSDQEKHSSRKIIFS YVVVFLVCWLPYHVAVLLDIFSILHYIPFTCRLEHAL
 FTALHVTQCLSLVHCCVNPVLYSFINRNYRYELMKAFIFKYS AKTGLTKLIDASRVSE
 40 TEYSALEQSTK

SEQ ID NO:9 CCXCKR2.5 coding sequence

ATGGATCTGCATCTCTTCGACTACTCAGAGCCAGGGAACTTCTCGGACATCAGCT
 45 GGCCGTGCAACAGCAGCGACTGCATCGTGGTGGACACGGTGATGTGTCCCAACA
 TGCCCAACAAAAGCGTCCTGCTCTACACGCTCTCCTTCATTTACATTTTCATCTTC
 GTCATCGGCATGATTGCCAACTCCGTGGTGGTCTGGGTGAATATCCAGGCCAAGA
 CCACAGGCTATGACACGCACTGCTACATCTTGAACCTGGCCATTGCCGACCTGTG

GGTTGTCCTCACCATCCCAGTCTGGGTGGTCAGTCTCGTGCAGCACAACCAGTGG
 CCCATGGGCGAGCTCACGTGCAAAGTCACACACCTCATCTTCTCCATCAACCTCT
 TCAGCAGCATTTTCTTCCTCACGTGCATGAGCGTGGACCGCTACCTCTCCATCACC
 TACTTCACCAACACCCCCAGCAGCAGGAAGAAGATGGTACGCCGTGTCGTCTGC
 5 ATCCTGGTGTGGCTGCTGGCCTTCTGCGTGTCTCTGCCTGACACCTACTACCTGAA
 GACCGTCACGTCTGCGTCCAACAATGAGACCTACTGCCGGTCCTTCTACCCCGAG
 CACAGCATCAAGGAGTGGCTGATCGGCATGGAGCTGGTCTCCGTTGTCTTGGGCT
 TTGCCGTTCCCTTCTCCATTATCGCTGTCTTCTACTTCCTGCTGGCCAGAGCCATC
 TCGGCGTCCAGTGACCAGGAGAAGCACAGCAGCCGGAAGATCATCTTCTCCTAC
 10 GTGGTGGTCTTCCTTGTCTGCTGGTTGCCCTACCACGTGGCGGTGCTGCTGGACAT
 CTTCTCCATCCTGCACTACATCCCTTTCACCTGCCGGCTGGAGCACGCCCTCTTCA
 CGGCCCTGCATGTCACACAGTGCCTGTCGCTGGTGCCTGCTGCGTCAACCCTGT
 CCTCTACAGCTTCATCAATCGCAACTACAGGTACGAGCTGATGAAGGCCTTCATC
 TTCAAGTACTCGGCCAAAACAGGGCTCACCAAGCTCATCGATGCCTCCAGAGTCT
 15 CAGAGACGGAGTACTCCGCCTTGGAGCAGAGCACCAAATGA

SEQ ID NO:10 CCXCKR2.5 amino acid sequence

MDLHLFDYSEPGNFSDISWPCNSSDCIVVDTVMCPNMPNKSVELLYTSLFIYIFIFVIGM
 IANSVVVWVNIQAKTTGYDTHCYILNLAIADLWVVLTPVWVVSLSVQHNQWPMGEL
 20 TCKVTHLIFSINLFSSIFFLTCMSVDRYLSITYFTNTPSSRKKMVRRVVCILVWLLAFC
 VSLPDTYYLKTVTSASNNETYCRSFYPEHSIKEWLIGMELVSVVLGFAVPFSIIAVFYF
 LLARAISSDQEKHSSRKIIFS YVVVFLVCWLPYHVAVLLDIFSILHYIPFTCRLEHAL
 FTALHVTQCLSLVHCCVNPVLYSFINRNYRYELMKAFIFKYS AKTGLTKLIDASRVSE
 TEYSALEQSTK


25 [0637] One of ordinary skill in the art will recognize from the provided description, figures, and examples, that modifications and changes can be made to the various embodiments of the invention without departing from the scope of the invention.

[0638]

30 Any conflict between any reference cited herein and the teaching of this specification is to be resolved in favor of the latter. Similarly, any conflict between an art-recognized definition of a word or phrase and a definition of the word or phrase as provided in this specification is to be resolved in favor of the latter.

WHAT IS CLAIMED IS:

1. A compound having formula I



and pharmaceutically acceptable salts and N-oxides thereof; wherein

- 5 --- is a double bond;

A is N or CH;

R¹ is absent;

L¹ is -C(O)-;

R² is -R^e;

- 10 R³ is -CH₂-R^e;


R^e in R² is a 5-6 membered aryl or heteroaryl group that is optionally substituted with 1-5 substituents selected from the group consisting of halogen, -CN, -NO₂, -CO₂R^f, -OC(O)R^f, -C(O)NR^fR^s, -C(O)R^f, -S(O)R^f, -S(O)₂R^f, -R^f, -C(NOR^f)R^s, -NR^f-C(O)NR^fR^s, -NH-C(NH₂)=NH, -NR^fC(NH₂)=NH, -NH-C(NH₂)=NR^f, -NH-C(NHR^f)=NH, -NR^fS(O)₂R^f,
 15 -NR^fS(O)₂R^f, -NR^fS(O)₂NR^fR^s, -N₃, -C(NR^fV)=NV, -N(V)C(R^f)=NV, -X²C(NOR^f)R^s, -X²C(NR^fV)=NV, -X²N(V)C(R^f)=NV, -X²NR^fR^s, -X²SR^f, -X²CN, -X²NO₂, -X²CO₂R^f, -X²OC(O)R^f, -X²CONR^fR^s, -X²C(O)R^f, -X²OC(O)NR^fR^s, -X²NR^sC(O)R^f, -X²NR^sC(O)₂R^f, -X²NR^fC(O)NR^fR^s, -X²NH-C(NH₂)=NH, -X²NR^fC(NH₂)=NH, -X²NH-C(NH₂)=NR^f, -X²NH-C(NHR^f)=NH, -X²S(O)R^f, -X²S(O)₂R^f, -X²NR^fS(O)₂R^f, -X²S(O)₂NR^fR^s, -X²N₃, -OR^f, -SR^f,
 20 -NR^fR^s, -NR^sC(O)R^f, -NR^sC(O)₂R^f, -S(O)₂R^f, -S(O)₂NR^fR^s, -X²OR^f, -O-X²OR^f, -X²NR^fR^s, -O-X²NR^fR^s and -NR^s-X²CO₂R^f, wherein any two substituents located on adjacent atoms in R^e are optionally combined to form a 5- to 7- membered ring optionally having from 1-3


heteroatoms selected from N, O and S; X^2 is C_{1-8} alkylene, C_{1-8} heteroalkylene, C_{2-8} alkenylene, C_{2-8} alkynylene, arylene or heteroarylene; and each R^f and R^s is independently selected from hydrogen, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl and heteroaryl, or optionally, R^f and R^s when attached to the same nitrogen atom are combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O and S, and wherein each R^t is independently selected from the group consisting of C_{1-8} alkyl, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl and heteroaryl, V is independently selected from the group consisting of $-R^t$, $-CN$, $-CO_2R^f$ and $-NO_2$, and each of X^2 , R^f , R^s and R^t is optionally further substituted with from one to three members selected from the group consisting of $-OH$, $-OR^u$, $-OC(O)NHR^u$, $-OC(O)N(R^u)_2$, $-SH$, $-SR^u$, $-S(O)R^u$, $-S(O)_2R^u$, $-SO_2NH_2$, $-S(O)_2NHR^u$, $-S(O)_2N(R^u)_2$, $-NHS(O)_2R^u$, $-NR^uS(O)_2R^u$, $-C(O)NH_2$, $-C(O)NHR^u$, $-C(O)N(R^u)_2$, $-C(O)R^u$, $-NHC(O)R^u$, $-NR^uC(O)R^u$, $-NHC(O)NH_2$, $-NR^uC(O)NH_2$, $-NR^uC(O)NHR^u$, $-NHC(O)NHR^u$, $-NR^uC(O)N(R^u)_2$, $-NHC(O)N(R^u)_2$, $-CO_2H$, $-CO_2R^u$, $-NHCO_2R^u$, $-NR^uCO_2R^u$, $-CN$, $-NO_2$, $-NH_2$, $-NHR^u$, $-N(R^u)_2$, $-NR^uS(O)NH_2$ and $-NR^uS(O)_2NHR^u$, wherein each R^u is independently an unsubstituted C_{1-6} alkyl;

R^e in R^3 is a 5-6 membered heteroaryl group that is optionally substituted with 1-5 substituents selected from the group consisting of halogen, $-CN$, $-NO_2$, $-CO_2R^f$, $-OC(O)R^f$, $-C(O)NR^fR^s$, $-C(O)R^f$, $-S(O)R^t$, $-S(O)_2R^t$, $-R^t$, $-C(NOR^f)R^s$, $-NR^f-C(O)NR^fR^s$, $-NH-C(NH_2)=NH$, $-NR^tC(NH_2)=NH$, $-NH-C(NH_2)=NR^t$, $-NH-C(NHR^t)=NH$, $-NR^fS(O)_2R^t$, $-NR^fS(O)_2R^t$, $-NR^fS(O)_2NR^fR^s$, $-N_3$, $-C(NR^fV)=NV$, $-N(V)C(R^f)=NV$, $-X^2C(NOR^f)R^s$, $-X^2C(NR^fV)=NV$, $-X^2N(V)C(R^f)=NV$, $-X^2NR^fR^s$, $-X^2SR^f$, $-X^2CN$, $-X^2NO_2$, $-X^2CO_2R^f$, $-X^2OC(O)R^f$, $-X^2CONR^fR^s$, $-X^2C(O)R^f$, $-X^2OC(O)NR^fR^s$, $-X^2NR^sC(O)R^f$, $-X^2NR^sC(O)_2R^t$, $-X^2NR^fC(O)NR^fR^s$, $-X^2NH-C(NH_2)=NH$, $-X^2NR^tC(NH_2)=NH$, $-X^2NH-C(NH_2)=NR^t$, $-X^2NH-C(NHR^t)=NH$, $-X^2S(O)R^t$, $-X^2S(O)_2R^t$, $-X^2NR^fS(O)_2R^t$, $-X^2S(O)_2NR^fR^s$, $-X^2N_3$, $-OR^f$, $-SR^f$, $-NR^fR^s$, $-NR^sC(O)R^f$, $-NR^sC(O)_2R^t$, $-S(O)_2R^t$, $-S(O)_2NR^fR^s$, $-X^2OR^f$, $-O-X^2OR^f$, $-X^2NR^fR^s$, $-O-X^2NR^fR^s$ and $-NR^s-X^2CO_2R^f$, wherein any two substituents located on adjacent atoms in R^e are optionally combined to form a 5- to 7- membered ring optionally having from 1-3 heteroatoms selected from N, O and S; X^2 is C_{1-8} alkylene, C_{1-8} heteroalkylene, C_{2-8} alkenylene, C_{2-8} alkynylene, arylene or heteroarylene; and each R^f and R^s is independently

- selected from hydrogen, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₃₋₆ cycloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, aryl and heteroaryl, or optionally, R^r and R^s when attached to the same nitrogen atom are combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O and S, and wherein each R^t is
- 5 independently selected from the group consisting of C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₃₋₆ cycloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, aryl and heteroaryl, V is independently selected from the group consisting of -R^t, -CN, -CO₂R^r and -NO₂, and each of X², R^r, R^s and R^t is optionally further substituted with from one to three members selected from the group consisting of -OH, -OR^u, -OC(O)NHR^u, -OC(O)N(R^u)₂, -SH, -SR^u, -S(O)R^u, -S(O)₂R^u, -SO₂NH₂, -S(O)₂NHR^u,
- 10 -S(O)₂N(R^u)₂, -NHS(O)₂R^u, -NR^uS(O)₂R^u, -C(O)NH₂, -C(O)NHR^u, -C(O)N(R^u)₂, -C(O)R^u, -NHC(O)R^u, -NR^uC(O)R^u, -NHC(O)NH₂, -NR^uC(O)NH₂, -NR^uC(O)NHR^u, -NHC(O)NHR^u, -NR^uC(O)N(R^u)₂, -NHC(O)N(R^u)₂, -CO₂H, -CO₂R^u, -NHCO₂R^u, -NR^uCO₂R^u, -CN, -NO₂, -NH₂, -NHR^u, -N(R^u)₂, -NR^uS(O)NH₂ and -NR^uS(O)₂NHR^u, wherein each R^u is independently an unsubstituted C₁₋₆ alkyl; and
- 15 each of the ring vertices a, b, c and d in formula I is N, C(H) or C(R⁴), wherein R⁴ at each occurrence is independently selected from the group consisting of halogen, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₁₋₈ alkoxy and C₁₋₈ haloalkoxy, and optionally any two R⁴ substituents located on adjacent ring vertices are combined to form a 5- to 6-membered ring having from 0 to 2 heteroatom ring members selected from the group consisting of N, O and S.


- 20 2. The compound, salt or N-oxide of claim 1, wherein A is CH.
3. The compound, salt or N-oxide of claim 1 or 2, wherein R^e in R² is a pyridyl ring, optionally substituted as defined in claim 1.
4. The compound, salt or N-oxide of claim 1 or 2, wherein R^e in R² is:






5. The compound, salt or N-oxide of claim 1 or 2, wherein R^e in R^2 is a phenyl ring, optionally substituted as defined in claim 1.

6. The compound, salt or N-oxide of claim 1 or 2, wherein R^e in R^2 is:




wherein R^{2a} , R^{2b} , R^{2c} , R^{2d} and R^{2e} are each independently selected from the group consisting of hydrogen, halogen, -CN, -NO₂, OR^f, -SR^f, -NR^fR^s, -CO₂R^f, -C(O)NR^fR^s, optionally substituted C₁₋₈ alkyl, optionally substituted C₁₋₈ haloalkyl and optionally substituted C₃₋₆ cycloalkyl; and R^f and R^s are each independently selected from the group consisting of hydrogen, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₃₋₆ cycloalkyl, C₂₋₈ alkenyl and C₂₋₈ alkynyl.

7. The compound, salt or N-oxide of claim 1 or 2, wherein R^e in R^2 is:




8. The compound, salt or N-oxide of any one of claims 1 to 7, wherein R^e in R^3 is a pyridyl group, optionally substituted as defined in claim 1.

9. The compound, salt or N-oxide of any one of claims 1 to 7, wherein R^e in R^3 is:



wherein R^{3a} is selected from the group consisting of halogen, -CN, -NO₂, -R^t, -CO₂R^r,
 -CONR^rR^s, -N₃, -X²NR^rR^s, -X²SR^r, -X²CN, -X²NO₂, -X²CO₂R^r, -X²CONR^rR^s, -X²C(O)R^r,
 -X²NR^sC(O)R^r, -X²NR^sC(O)₂R^t, -X²N₃, -OR^r, -SR^r, -NR^rR^s, -NR^sC(O)R^r, -NR^sC(O)₂R^t,
 5 -X²OR^r and -NR^s-X²CO₂R^r.

10. The compound, salt or N-oxide of any one of claims 1 to 7, wherein R^e in R³ is:



10 11. The compound, salt or N-oxide of any one of claims 1 to 10, wherein the ring vertices a, b, c and d are each CH.

12. The compound, salt or N-oxide of any one of claims 1 to 10, wherein the ring vertices a, b, c and d are each independently selected from the group consisting of CH and C(R⁴), wherein each R⁴ is independently selected from the group consisting of halogen,

C₁₋₈ alkyl, C₁₋₈ haloalkyl and C₁₋₈ alkoxy; or any two R⁴ substituents located on adjacent ring vertices are combined to form a 5- to 6-membered ring having 1 to 2 heteroatoms selected from the group consisting of N and O.

13. The compound, salt or N-oxide of any one of claims 1 to 10, wherein
5 the ring vertices a, c and d are each CH; and the ring vertex b is CR⁴, wherein R⁴ is a C₁₋₄ haloalkyl.

14. The compound, salt or N-oxide of any one of claims 1 to 10, wherein
the ring vertices a and d are each CH and the ring vertices b and c are each C(R⁴) wherein the R⁴ substituents are combined to form a 5- or 6-membered ring having two oxygen atoms.

10 15. The compound, salt or N-oxide of claim 1, wherein A, a, b, c and d are
each CH; R² is phenyl, substituted with one or two groups selected from the group consisting
of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, or are combined to form a fused 6-member ring having
two oxygen atom ring members; R³ is a pyridylmethyl group optionally substituted with one
or two groups selected from the group consisting of halogen and cyano.

15 16. The compound, salt or N-oxide of claim 1, wherein A, a, b, c and d are
each CH; R² is pyridyl, substituted with one or two groups selected from the group consisting
of halogen, C₁₋₄ alkyl and C₁₋₄ alkoxy; R³ is a pyridylmethyl group optionally substituted with
one or two groups selected from the group consisting of halogen and cyano.

20 17. The compound, salt or N-oxide of claim 1, wherein A, b and c are each
CH; one of a or d is CH and the other is N; R² is phenyl, substituted with one or two groups
selected from the group consisting of halogen, C₁₋₄ alkyl and C₁₋₄ alkoxy; R³ is a
pyridylmethyl or benzyl group optionally substituted with one or two groups selected from the
group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy and cyano.

25 18. The compound, salt or N-oxide of any one of claims 1 to 10, wherein at
least one of ring vertices a, b, c or d is N.

19. The compound, salt or N-oxide of any one of claims 1 to 10, wherein

the ring vertices a, c and d are each C(H) or C(R⁴) and the ring vertex b is N.


20. The compound, salt or N-oxide of any one of claims 1 to 10, wherein the ring vertices a, b and d are each C(H) or C(R⁴) and the ring vertex c is N.

21. The compound, salt or N-oxide of any one of claims 1 to 10, wherein
5 the ring vertices a, b and c are each C(H) or C(R⁴) and the ring vertex d is N.


22. The compound, salt or N-oxide of any one of claims 1 to 10, wherein the ring vertices b, c and d are each C(H) or C(R⁴) and the ring vertex a is N.






















23. The compound, salt or N-oxide of any one of claims 1 to 10, wherein two ring vertices are N.

10 24. A compound or N-oxide thereof or a pharmaceutically acceptable salt thereof, wherein said compound is:




























CA2629461



25. A compound or N-oxide thereof or a pharmaceutically acceptable salt thereof, wherein said compound is:



5

26. A pharmaceutical composition comprising a compound, N-oxide or salt as defined in any one of claims 1 to 25 and a pharmaceutically acceptable excipient.

27. Use of a compound, N-oxide or salt as defined in any one of claims 1 to 25 for treating a disease or disorder in a mammal.

10 28. The use of claim 27, wherein said disease or disorder is cancer, inflammation, HIV infectivity or a progenitor/stem cell disorder.

29. Use of a compound, N-oxide or salt as defined in any one of claims 1 to 25 for inhibiting binding of chemokine I-TAC or SDF-1 to a CCXCKR2 receptor.

15 30. The use of claim 29, wherein the inhibiting is in a cell that expresses the CCXCKR2 receptor.